An investigation into the relationships between telomere length and cardiac function and geometry by Raymond, Adrew Ryan
AN INVESTIGATION INTO THE RELATIONSHIPS 
BETWEEN TELOMERE LENGTH AND CARDIAC 
FUNCTION AND GEOMETRY 
 
 
 
 
 
ANDREW RYAN RAYMOND 
 
 
 
 
A thesis submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree 
of Doctor of Philosophy. 
 
 
 
 
South Africa, Johannesburg, 2014 
 
 
ii 
 
DECLARATION 
This thesis is being submitted for the Degree of Doctor of Philosophy at the 
University of the Witwatersrand, Johannesburg. It has not been submitted before for any 
degree or examination at any other University.  
I declare that this thesis is my own. Data that was not obtained by me includes the 
multiple gated equilibrium cardiac blood pool scintigraphic scans to determine left 
ventricular ejection fraction, as this had to be performed by a qualified professional. 
Furthermore, echocardiography data was obtained by a single experienced observer to negate 
inter-observer variation and ensure blinding to the designation of control and experimental 
groups during echocardiography measurements.       
I certify that all human and animal studies in this thesis had approval from the 
Committee for Research in Human Studies and the Animal Ethics Screening Committee of 
the University of the Witwatersrand respectively.  
 
 
Andrew R. Raymond  
___________ day of ___________ 2014 
 
  
Dr R.Brooksbank (Supervisor)   Prof A. Woodiwiss (Supervisor)   
___________ day of ___________  2014  ___________ day of ___________  2014 
 
iii 
 
ABSTRACT 
Telomere length is inversely associated with the presence of heart failure. However, it 
is uncertain whether a reduced telomere length has pathophysiological consequences in the 
heart or is merely an epiphenomenon. The relationship between telomere length and heart 
failure may be causal, or it may reflect an association with inflammation or with risk factors 
for coronary artery disease, in which case it would be specific to ischaemic heart disease. 
Therefore, the main aim of this thesis was to determine whether telomere attrition is a cause 
of heart failure or a consequence of ongoing processes (eg. cardiomyocyte apoptosis, 
senescence, or mitochondrial dysfunction) in heart failure. Hence, I investigated the 
relationships between telomere length and a non-ischaemic form of heart disease (excludes 
oxidative stress and inflammation associated with coronary artery disease and its risk factors) 
and between telomere length and measurements of cardiac remodelling and systolic function 
prior to the development of heart failure.  
Hence, in my first study I evaluated associations between leukocyte telomere length 
and the presence or severity of a non-ischaemic form of heart failure, namely idiopathic 
dilated cardiomyopathy (IDC). Relative telomere length (log T/S), measured using a 
quantitative real-time polymerase chain reaction assay, was correlated with age in patients 
with IDC (p=0.002, n=223) and in control participants (p=0.023, n=227). However, no 
differences in leukocyte log T/S were noted between IDC patients and healthy controls both 
prior to (p=0.16) and after (log T/S: IDC=-0.22±0.022 vs. control=-0.22±0.024, p=0.114) 
adjustments for confounders. Moreover, with adjustments for age, sex, regular alcohol 
consumption and smoking, log T/S was not associated with echocardiographic left ventricular 
(LV) ejection fraction (EF) or LV end diastolic diameter (EDD) in patients with IDC. In 
conclusion, relative leukocyte telomere length is not associated with the presence of IDC or 
the severity of heart failure in IDC (as indexed by LVEF and LVEDD). These data suggest 
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that telomere attrition is unlikely to be a cause of IDC (non-ischaemic heart disease) or a 
consequence of heart failure in general. 
To further explore whether telomere shortening is a cause of cardiac remodelling and 
systolic dysfunction, I investigated the relationships between telomere length and an animal 
model of alcoholic cardiomyopathy (a form of dilated cardiomyopathy). Sprague-Dawley 
(SD) rats received either drinking water with (ethanol: n=19) or without (control: n=19) 5% 
(v/v) ethanol ad libitum, for four months. Echocardiography was performed to determine LV 
dimensions and function in vivo and isolated perfused heart preparations (ethanol n=10, 
control n=10) were performed to obtain ex vivo load-independent measurements of LV 
chamber geometry and function. Ethanol consumption resulted in LV dilatation (LVEDD: 
ethanol=8.20±0.14mm vs. control=7.56±0.11mm, p=0.0014; the volume intercept at 0mmHg 
(V0) of the LV end diastolic pressure-volume relationship: ethanol=0.40±0.03ml vs. 
control=0.31±0.02ml, p=0.020), and a reduced LV relative wall thickness 
(ethanol=0.50±0.08mm vs. control=0.60±0.09mm, p=0.0011); but no changes in LV systolic 
chamber function as indexed by endocardial fractional shortening (FSend) or the slope of the 
LV systolic pressure-volume relation (end systolic elastance-Ees). Ethanol administration 
resulted in a marked increase in cardiomyocyte apoptosis (ethanol=0.85±0.13% vs. 
control=0.36±0.06%, p=0.0021), and % apoptosis was correlated with LVEDD (r=0.39, 
n=38, p=0.021) and V0 (r=0.44, n=19, p=0.046). However, no differences in leukocyte, 
cardiac, liver, or kidney telomere length were noted between ethanol and control groups; and 
cardiac telomere length was not associated with indices of LV dilatation or apoptosis. In 
conclusion, chronic alcohol-induced cardiac remodelling and apoptosis in the absence of 
systolic dysfunction are independent of changes in telomere length.  
Having shown in two studies that telomere attrition is unlikely to be a 
pathophysiological cause of heart failure, I then explored whether telomere shortening in 
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heart failure is due to processes such as β-adrenergic receptor activation and inflammation, 
which occur in heart failure. I first evaluated whether LV dilatation and systolic chamber 
dysfunction produced by chronic β-adrenergic receptor (β-AR) activation are associated with 
leukocyte or cardiac telomere shortening. Six months of daily injections of the β-AR agonist, 
isoproterenol (0.02 mg.kg
-1
.day
-1
) (ISO: n=16), or the saline vehicle (control: n=15) to SD 
rats, resulted in LV dilatation (LVEDD: ISO=9.18±0.60mm vs. control=8.41±0.90mm, 
p=0.010; V0: ISO=0.45±0.06ml vs. control=0.37±0.08ml, p=0.03) and LV systolic chamber 
dysfunction (FSend: ISO=39.88±5.18% vs. control=45.14±5.64%, p=0.01; Ees: 
ISO=608.60±175.40 vs. control=901.10±229.60, p=0.01). Although leukocyte log T/S 
decreased over six months in rats receiving either the β-AR agonist or the saline vehicle 
(p<0.05); neither cardiac (ISO=-0.10±0.14 vs. control=-0.15±0.12, p=0.35) nor leukocyte log 
T/S (ISO=-0.11±0.19 vs. control=-0.15±0.18, p=0.52) were altered by chronic β-AR 
activation. Moreover, cardiac telomere length was not associated with indices of LV 
dilatation or systolic chamber function. In conclusion, chronic β-AR activation that is 
sufficient to produce LV dilatation and systolic chamber dysfunction was not associated with 
alterations in leukocyte or cardiac telomere length. Hence, telomere shortening in chronic 
heart failure is unlikely to be attributed to chronic β-AR activation. 
I then evaluated the impact of chronic inflammation on telomere length, LV 
remodelling and systolic function in an animal model. After 12 months of fortnightly 
intraperitoneal injections of 2.5x10
7 
Staphylococcus aureus cell walls (S. aureus: n=30) or 
saline vehicle (control: n=30) in SD rats, there were no differences in LV dimensions (EDD, 
V0) or systolic chamber function (FSend, Ees) between the two groups. In the control group no 
differences in plasma C-reactive protein concentrations (a marker of inflammation) were 
noted at 3 or 11 months compared to the baseline concentrations at 1 month. However, in the 
S. aureus group there was an increase in CRP concentrations at both 3 months (S. aureus: 3 
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months=435.40±89.95µl.ml
-1
 vs. 1 month=347.80±101.90µl.ml
-1
, p<0.0001) and 11 months 
(S. aureus: 11 months=511.40±93.34µl.ml
-1
 vs. 1 month=347.80±101.90µl.ml
-1
, p<0.0001), 
and CRP concentrations were increased in the S. aureus group compared to the control group 
at 11 months (S. aureus=511.40±93.30µl.ml
-1
 vs. control=391.20±122.10µl.ml
-1
, p<0.01). 
Leukocyte log T/S (at 11 months) (S. aureus =-0.21±0.15 vs. control=-0.053±0.11, p = 0.002) 
and cardiac log T/S (S. aureus=-0.20±0.10 vs. control=-0.11±0.084, p= 0.0021) were reduced 
in the S. aureus group. However cardiac log T/S was not associated with LVEDD, V0, FSend, 
or Ees. In conclusion, a chronic inflammatory stimulus that produced reductions in leukocyte 
and cardiac telomere length did not induce LV dilatation and a reduction in systolic chamber 
function. Hence, the negative association between telomere length and heart failure may be 
due to the impact of inflammatory processes on telomere length rather than signifying a cause 
of heart failure.    
Having shown that telomere length may be reduced as an epiphenomenon due to 
ongoing inflammatory processes with no pathophysiological consequences on cardiac 
geometry or function in rats, I attempted to validate these findings in humans. Hence, I 
evaluated the relationship between leukocyte telomere length, indices of inflammation, LV 
remodelling, and systolic function in a cross-sectional human study. Leukocyte telomere 
length was determined in 622 participants from a randomly selected community based cohort. 
There was a negative bivariate relationship between T/S ratio and age in the group 
(p<0.0001) and telomere length was reduced in participants that regularly consumed alcohol 
compared to those who did not (p=0.01). No relationships between log T/S and smoking, sex, 
BMI, or blood pressure were noted. However, there was a negative relationship between 
leukocyte telomere length and C-reactive protein concentrations after multivariate 
adjustments for confounders (r=-0.11; p=0.0039; n=662). There were no associations 
between log T/S and echocardiographic indices of LV dilatation (LVEDD) or systolic 
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dysfunction (FSend, FSmid) in the participants. In conclusion, leukocyte telomere length was 
inversely associated with indices of inflammation. However, leukocyte telomere length was 
not associated with indices of LV remodelling and systolic function. These findings are 
consistent with the previous findings that chronic inflammation in rats capable of producing a 
marked decrease in cardiac telomere length has no pathophysiological consequence on 
cardiac dimensions or systolic function. Hence, inflammation may be an important 
determinant of leukocyte telomere length in humans, but leukocyte telomere length is not a 
bio-marker of adverse cardiac geometry or function. 
The main findings from my thesis are as follows; a reduced telomere length was not 
associated with IDC (a non-ischaemic form of heart disease) nor with a model of alcoholic 
cardiomyopathy, which demonstrates that reduced telomere length may not be associated 
with all types of cardiomyopathy. Although chronic β-AR activation and ethanol 
consumption induced cardiac remodelling and β-AR activation induced systolic dysfunction, 
cardiac telomere length was not altered. Moreover, in IDC, alcoholic cardiomyopathy, 
chronic β-AR stimulation, chronic inflammation, and in a random, community-based 
population a reduced telomere length was not associated with features of heart failure such as 
LV dilatation (LVEDD and V0), reduced systolic chamber function (FSend and Ees), reduced 
intrinsic myocardial function (FSmid and Een), and myocardial apoptosis. However, chronic 
inflammation resulted in reductions in leukocyte and cardiac telomere length in the absence 
of changes in cardiac geometry and systolic function. These data indicate that the 
pathophysiological processes of heart failure, namely LV dilatation and reduced systolic 
function, may be independent of changes in telomere length and that telomere length may 
only be reduced as an epiphenomenon due to inflammatory processes in heart failure.   
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1.1 OVERVIEW 
It is predicted that by the year 2020 cardiovascular disease will be responsible for 
approximately 25 million deaths per year and will be a leading cause of death worldwide 
(Yusuf et al., 2001). One of the reasons for the increased prevalence in cardiovascular disease 
is the ongoing epidemiological shifts, especially in developing countries (Levenson et al., 
2002). These epidemiological shifts affect improvements in healthcare, which subsequently 
decrease the number of deaths due to infectious diseases and malnutrition and increase the 
prevalence of age and lifestyle associated diseases such as cardiovascular diseases (Levenson 
et al., 2002). In order to treat and manage cardiovascular diseases a comprehensive 
understanding of the risk factors associated with cardiovascular disease is required.     
A prominent risk factor for heart failure is advancing age. Heart failure can be defined 
as an inability of the heart to pump sufficient blood to meet the body's metabolic 
requirements (Mann, 1999). Despite a good characterisation of risk factors for cardiovascular 
diseases, the age of onset and disease progression are still highly variable between individuals 
(Wong
b
 et al., 2010). The variations in the onset and progression of heart failure may be due 
to discrepancies between chronological and biological age (Huzen et al., 2010). 
Chronological age is merely the number of years from birth, whereas biological age 
represents the cumulative effect of various stresses on tissues throughout life. It has been 
proposed that telomere length could serve as a possible marker of biological age (Zglinicki 
and Martin-Ruiz, 2005).  
 Telomeres are specialized structures that cap the end of chromosomes whose main 
function is to maintain chromosomal integrity. As telomere length decreases progressively 
with each cell division; telomere length is thought to represent the replication history of the 
cell (Aubert and Lansdorp, 2008), and by inference the age of the cell. Moreover, telomere 
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length is also influenced by important features associated with the pathophysiology of 
diseases, such as oxidative stress and inflammation (Houben et al., 2008; Zglinicki and 
Martin-Ruiz, 2005). Hence, telomere length is a possible biomarker of aging. Further 
credence to the tenet of telomere length as a marker of biological age can be found in human 
disorders of premature aging. In this regard, telomere length has been associated with 
disorders such as Werner syndrome (Schulz et al., 1996), Bloom syndrome (Yankiwski et al., 
2000), Hutchinson-Gilford progeria (Allsopp et al., 1992), Down syndrome (Vaziri et al., 
1993), and dyskeratosis congenita  (Mitchell et al., 1999) in which age related pathologies 
such as; atherosclerosis, osteoporosis, cataracts, and immune deficiency occur. The 
association between telomere length and human disorders of aging demonstrates a link 
between telomere length and the biological changes associated with the aging phenotype. 
This is consistent with the notion of telomere length as a bio-marker of aging that provides a 
surrogate marker of the cumulative effects of various stresses on the body throughout life.    
Given the importance of advancing age in cardiovascular disease, it has emerged that 
telomere biology could play a role as a risk factor in the pathophysiology of cardiovascular 
diseases.  In this regard, cross-sectional studies have shown that telomere length is inversely 
associated with heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 
2012). These associations may indicate that reduced telomere length is either a causal factor 
or alternatively an epiphenomenon of heart failure. Hence, the main aim of my thesis was to 
further investigate the relationships between telomere length and cardiac remodelling, 
systolic function, and heart failure to determine whether telomere attrition is a cause of heart 
failure or a consequence of ongoing processes in heart failure. As an introduction to my thesis 
the sections to follow will elaborate on the structure and function of telomeres and outline the 
evidence demonstrating a link between telomere biology and cardiovascular disease, which 
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encompasses; diseases of the heart and blood vessels, adverse cardiac remodelling that 
precedes heart failure, and heart failure itself. 
 
1.2 WHAT ARE TELOMERES?  
Telomeres consist of non-coding repeats of 5'-TTAGGG-3'/5'-CCCTAA-3' located at 
the end of chromosomes. In humans the telomere sequence can extend from 5 to 15 000 base 
pairs (Aubert and Lansdorp, 2008). Telomeres function to protect against chromosomal 
degradation, fusion and the recognition of chromosomal ends as double-stranded breaks 
(Aubert and Lansdorp, 2008). Telomere length shortens progressively with each cell division 
(Aubert and Lansdorp, 2008), and when telomere length reaches a threshold level, cellular 
senescence and apoptotic pathways are activated (Aubert and Lansdorp, 2008; Artandi 
andAttardi, 2005). Hence, telomere length is important in maintaining normal cellular 
activity.      
Telomere length is maintained by the enzyme telomerase, which consists of an RNA 
component (Terc) and a reverse transcriptase component (Tert). The Terc component of 
telomerase provides an RNA template for the Tert enzyme, which then facilitates the addition 
of new telomeric sequences from the RNA template and hence the elongation of telomeres 
(Aubert and Lansdorp, 2008). In addition to telomerase, two important proteins associated 
with telomeres are telomere repeat binding factors (TRF) 1 and 2 (Aubert and Lansdorp, 
2008; Artandi and Attardi, 2005). TRF1 regulates access of telomerase to the telomere 
complex and thus is crucial in the regulation of telomere length (Artandi and Attardi, 2005). 
TRF2 is responsible for maintaining the protective ends of telomeres and is important in the 
suppression of DNA damage pathways (Artandi and Attardi, 2005). In this regard, telomeres 
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are characterised by a single stranded guanine rich 3' overhang that folds back on itself to 
form a protective structure known as the telomere-loop (t-loop) (FIGURE1.1).  
 
FIGURE 1.1 Representation of the telomere sequence found at the end of the chromosome 
with the guanine rich overhang at the 3' end, which forms the protective telomere-loop 
structure (Wong et al., 2008). 
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This protective t-loop, which is maintained by TRF2, prevents the recognition of DNA ends 
as breaks and in doing so prevents the activation of cellular senescence and apoptotic 
pathways (Aubert and Lansdorp, 2008; Artandi and Attardi, 2005). 
The maintenance of telomere length is crucial in the prevention of cellular senescence 
and activation of apoptotic pathways (FIGURE1.2) (Artandi and Attardi, 2005; Wong et al., 
2009). Senescence is characterised by full cessation of normal cellular activity and apoptosis 
is a mechanism of regulated cellular death. The activation of these pathways is associated 
with ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia- and Rad3-related (ATR) 
kinases. These kinases (ATM/ATR) phosphorylate DNA checkpoint kinase (Chk) 1 and 2 
(Artandi and Attardi, 2005; Wong et al., 2009). Chk 1 and 2 activation lead to senescence via 
the inhibition cell division cycle 25 (Cdc25). Furthermore, Chk 1 and 2 phosphorylate p53, 
which induces senescence via increased p21 expression, which is linked to p16 whose 
mechanism of increased expression during DNA damage signalling is currently unknown 
(Artandi and Attardi, 2005; Wong et al., 2009). In terms of apoptosis, p53 activation results 
in the increased expression of genes involved in apoptosis such as; bax, noxa, Perp, and 
puma. The driving factors that result in either senescence or apoptosis once telomere induced 
DNA damage signaling has been activated are currently unknown (Artandi and Attardi, 2005; 
Wong et al., 2009).  
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FIGURE 1.2 Diagram representing the pathway of telomere shortening resulting in the 
activation of cellular senescence and apoptosis. ATM, ataxia-telangiectasia mutated; ATR, 
ataxia-telangiectasia - and Rad3 - related kinases; Chk, DNA checkpoint kinase; Cdc25, cell 
division cycle 25;  -  denotes an inhibitory pathway. (Figure modified from Artandi and 
Attardi, 2005 and Wong et al., 2009).    
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As telomere biology plays a crucial role in maintaining genomic stability via the 
regulation of apoptotic pathways and cellular senescence, it is reasonable to expect that 
telomeres may have an important role in the pathophysiology of diseases associated with 
aging such as cardiovascular diseases. In this regard, the evidence demonstrating a 
relationship between telomere biology and cardiovascular disease, which includes diseases of 
the heart and blood vessels, adverse cardiac remodelling, and heart failure, will be discussed 
in the sections to follow.  
 
1.3 WHAT IS THE EVIDENCE TO INDICATE A RELATIONSHIP BETWEEN TELOMERE LENGTH 
AND CARDIOVASCULAR DISEASE?   
Studies conducted on cardiac tissue have provided evidence that telomere length may 
be associated with cardiovascular disease (TABLE 1.1). It has been demonstrated in the 5th 
generation offspring of Terc knockout mice that telomere length was reduced in 
cardiomyocytes. Later generations of these Terc knockout mice presented with cardiac 
characteristics similar to that of a dilated cardiomyopathy in humans (Leri et al., 2003). 
Moreover, cardiomyocyte replication was reduced and accompanied by an increased 
expression of p53 and apoptosis in these animals. The data from Terc knockout mice suggest 
that critically short telomere length could have a role in the pathophysiological processes 
present in heart failure. In this regard, in a model of cardiac hypertrophy caused by aortic 
constriction in rats, telomere length was reduced, apoptosis was increased, p53 expression 
was up-regulated, and TRF2 was down-regulated (Sheng et al., 2013). In diseased human 
hearts, it was found that telomere length in cardiomyocytes was reduced and was associated 
with an increased expression of p16 and senescent cardiomyocytes.  
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TABLE 1.1 Studies demonstrating a link between telomere length and cardiovascular disease. 
 
TL, telomere length; Terc 
-
/
-
, telomerase reverse transcriptase knockout; TRF2, telomere repeat binding factor 2; Chk 2, DNA checkpoint kinase 
2; AOC, aortic constriction; Q-FISH, qualitative fluorescence in situ hybridisation; TRF, terminal restriction fragment; qRT-PCR, quantitative 
real time polymerase reverse chain reaction.     
Main findings Cell type Human/animal Methodology Reference 
TL was reduced and resulted in a dilated cardiomyopathy Cardiomyocyte Terc 
-
/
-
 mice Q-FISH Leri et al.,2003 
Pressure overload increased TL attrition Cardiomyocyte AOC rat TRF Sheng et al., 2013 
TL was reduced in diseased hearts Cardiomyocyte Human Q-FISH Chimenti et al., 2003 
TL reduced in heart failure (with reduced TRF2 and Chk2 activation) Cardiomyocyte Human TRF Oh et al., 2003 
Severe cardiac loading reduced TL and TRF2 Cardiomyocyte Mice TRF Oh et al., 2003 
TL reduced in degenerative aortic valve stenosis Leukocyte Human qRT-PCR Kurz et al., 2006 
TL is reduced in patients with heart failure Leukocyte Human qRT-PCR Starr et al., 2007; van der Harst et al., 2007; 
Weischer et al., 2012 
Reduced TL in participants with coronary artery disease Endothelial, leukocyte Human Slot blot, qRT-PCR Ogami et al., 2004; Brouilette et al., 2007; 
 
Reduced TL associated with increased risk for myocardial infarction 
 
Leukocyte 
 
Human 
 
TRF, qRT-PCR 
Brouilette et al., 2003 
Zee et al., 2009; Weischer et al., 2012 
 
Offspring from parents who suffered cardiac events inherited shorter TL 
 
Leukocyte 
 
Human 
 
TRF, qRT-PCR 
Brouilette et al., 2008;  Fitzpatrick et al., 2007  
Wong et al., 2011 
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Furthermore, the cardiomyocytes with reduced telomere length were also associated with 
apoptosis (Chimenti et al., 2003). Similarly, Oh et al. (2003) demonstrated that reduced 
telomere length and apoptosis in cardiomyocytes was present in heart failure. Oh et al. (2003) 
discovered that this reduction in telomere length was also accompanied by a decreased 
expression of TRF2, which is consistent with the results from the aortic constriction rat 
model conducted by Sheng et al. (2013). Further investigations by Oh et al. (2003) showed 
that reductions in TRF2 expression could be a determining factor behind telomere attrition 
and cardiomyocyte apoptosis in diseased hearts. 
In summary, these data suggest that there is an association between reduced telomere 
length and dysfunctional cardiac tissue. Importantly, the reductions in cardiomyocyte 
telomere length are associated with adverse changes in cardiomyocytes such as senescence 
(Chimenti et al., 2003) and apoptosis (Chimenti et al., 2003; Oh et al., 2003; Leri et al., 
2003; Sheng et al., 2011), which are pathways known to be regulated by telomere length 
(Artandi and Attardi, 2005). Furthermore, the Terc knockout model (Leri et al., 2003) 
provides evidence to suggest that reduced telomere length has a causal role in heart failure. In 
this regard, later generations of these mice with the shortest cardiomyocyte telomeres 
developed heart failure. However, the studies linking cardiomyocyte telomere length to 
diseased heart tissue are limited. Moreover, the two investigations conducted by Chimenti et 
al. (2003) and Oh et al. (2003) that have investigated human heart tissue samples have 
limited sample sizes of 19 and 14 respectively. Thus, in order to firmly establish a link 
between telomere length and cardiovascular disease in humans, further evidence is required 
and is discussed in the sections to follow.  
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1.3.1 IS TELOMERE LENGTH ASSOCIATED WITH THE PRESENCE OF CARDIOVASCULAR 
DISEASE IN HUMANS? 
Supporting evidence for a negative relationship between telomere length and 
cardiovascular disease in humans has been demonstrated by numerous large cross-sectional 
studies (TABLE 1.1), that have found an association between reduced leukocyte telomere 
length and cardiovascular disease. In this regard, leukocyte telomere length is negatively 
associated with ventricular function in the elderly (Collerton et al., 2007); is reduced in 
patients with degenerative aortic valve stenosis compared to healthy participants (Kurz et al., 
2006); is associated with increased risk for myocardial infarctions (Brouilette et al., 2003; 
Fitzpatrick et al., 2007; Weischer et al., 2012; Zee et al., 2009); and is reduced in patients 
with heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 2012). 
Moreover, it has been demonstrated that leukocyte telomere length is associated with the 
severity of heart failure (van der Harst et al., 2007). 
There is therefore significant evidence demonstrating that reduced leukocyte telomere 
length is associated with the presence of cardiovascular disease (Brouilette et al., 2003; 
Fitzpatrick et al., 2007; Kurz et al., 2006; Starr et al., 2007; van der Harst et al., 2007; 
Weischer et al., 2012; Zee et al., 2009). However, these studies fail to elucidate the cause and 
effect relationships between reduced leukocyte telomere length and heart failure. From the 
available data it is uncertain if reduced telomere length is a causal factor heralding the onset 
of heart failure. In this regard, the relationships between leukocyte telomere length and 
cardiovascular disease have only been determined using outcome based studies and not using 
measurements of cardiac function. Although Collerton et al. (2007) did show that leukocyte 
telomere length was negatively associated with left ventricular ejection fraction, an important 
consideration is that this study consisted of individuals older than 85 years. Given the strong 
negative relationship between telomere length and age and between ejection fraction and age 
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the association between telomere length and ejection fraction in this study is to be expected. 
Hence, telomere length may have no impact on cardiac structure and function and may 
merely be reduced as a consequence of the pathophysiological processes of cardiovascular 
diseases. Furthermore, there are numerous risk factors for cardiovascular disease that could 
also contribute to the increased telomere attrition evident in cardiovascular disease.      
 
1.3.2 IS TELOMERE LENGTH ASSOCIATED WITH RISK FACTORS FOR CARDIOVASCULAR 
DISEASE IN HUMANS? 
Negative associations between leukocyte telomere length and numerous risk factors 
for cardiovascular disease have been found. These factors include; coronary artery disease 
(Brouilette et al., 2007; Ogami et al., 2004), homocysteine  concentrations (Richards et al., 
2008), intima-media thickness (O’Donnell et al., 2008), physical fitness (Krauss et al., 2011), 
hypertension (Fuster et al., 2007; Weischer et al., 2012), atherosclerosis (Huzen et al., 2011; 
Samani et al., 2001), anaemia (Wong et al., 2010), left ventricular mass (Kuznetsova et al., 
2010; Vasan et al., 2009), type 2 diabetes mellitus (Salpea et al., 2010; Weischer et al., 
2012), obesity (Valdes  et al., 2005; Weischer et al., 2012), smoking (Valdes  et al., 2005; 
Weischer et al., 2012), total cholesterol, high-density lipoprotein cholesterol, and C-reactive 
protein concentrations (Weischer et al., 2012). Moreover, reduced leukocyte telomere length 
has also been associated with a family history of ischaemic heart disease (Brouilette et al., 
2008; Wong et al., 2011). It is well established that a previous family history of 
cardiovascular disease is a risk factor for heart failure. In this regard, the healthy offspring of 
individuals with cardiovascular disease had reduced telomere length compared to age-
matched controls whose parents did not suffer from cardiovascular disease (Brouilette et al., 
2008; Wong et al., 2011). These results demonstrate an inheritance of shorter telomere length 
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from parents with ischaemic heart disease and by inference a possible inherited risk for 
ischaemic heart disease in these individuals (Brouilette et al., 2008; Wong et al., 2011).  
It should be noted that there are numerous inconsistencies within the literature 
regarding associations between leukocyte telomere length and risk factors for cardiovascular 
disease (Bekaert et al., 2007). Some studies have demonstrated associations whereas others 
have not. In this regard, differences in methodologies and study populations need to be taken 
into consideration (Bekaert et al., 2007). The measurement of mean telomere length is 
traditionally determined via Southern blot analysis (Cawthon, 2002; O’Donnell et al., 2008; 
Richards et al., 2008; Samani et al., 2001; Valdes  et al., 2005; Vasan et al., 2009). However, 
this protocol is labour intensive and has a low throughput and hence Southern blotting is not 
an ideal methodolgy for large-scale epidemiological studies (Cawthon, 2002). In this regard, 
Cawthon (2002) developed a high throughput quantitative real-time polymerase chain 
reaction (qRT-PCR) protocol that determines relative telomere length. This real-time PCR 
method has been validated and shown to give a measure of relative telomere length, which is 
proportional to mean telomere length as determined by Southern blotting (Brouilette et al., 
2007; Cawthon, 2002). Modified versions of the qRT-PCR protocol developed by Cawthon 
have been adopted in many investigations between telomere length and risk factors for 
cardiovascular disease (Brouilette et al., 2007; Brouilette et al., 2008; Huzen et al., 2011; 
Krauss et al., 2011; Kuznetsova et al., 2010; Salpea et al., 2010; Weischer et al., 2012; Wong 
et al., 2010; Wong et al., 2011). Hence, differences in the approach taken to measure 
leukocyte telomere length could account for the inconsistencies within the literature 
regarding associations between leukocyte telomere length and risk factors for cardiovascular 
disease. However, it is more likely that differences in the age range and the characteristics of 
the cohorts under investigation that could account for these inconsistencies.  
 INTRODUCTION Page 14 
The association between telomere length and both cardiovascular disease and risk 
factors for cardiovascular diseases further complicates the cause and effect relationships 
between reduced telomere length and cardiovascular disease. In this regard, it is uncertain if 
reduced telomere length is a causal factor heralding the onset of heart failure or if telomere 
length is reduced as a consequence of the pathophysiological processes of heart failure. 
Furthermore, the relationships between cardiovascular disease and reduced leukocyte 
telomere length may represent an epiphenomenon attributed to the relationship between risk 
factors for cardiovascular disease and increased leukocyte telomere attrition. Hence, 
currently, the relative importance of risk factors for cardiovascular disease with regards to the 
relationship between telomere and heart failure is uncertain and requires further investigation. 
It is possible that reduced telomere length is independent of the pathophysiological processes 
of heart failure and is merely a consequence of the risk factors for heart failure.      
 
1.3.3 IS REDUCED TELOMERE LENGTH AN INDEPENDENT RISK FACTOR FOR HEART 
FAILURE?   
With regards to the cause and effect relationship between telomere length and heart 
failure, prospective data indicate that reduced leukocyte telomere length may be an 
independent risk factor for heart failure. In prospective and case-control studies, leukocyte 
telomere length was determined in clinically stable participants and cardiovascular outcomes 
were determined through follow up or hospital records (Brouilette et al., 2003; Fitzpatrick et 
al., 2007; Weischer et al., 2012; Zee et al., 2009). These studies found that individuals with 
reduced leukocyte telomere length had a greater risk for developing a myocardial infarction 
(Brouilette et al., 2003; Fitzpatrick et al., 2007; Weischer et al., 2012; Zee et al., 2009). 
Furthermore, these data demonstrate that reduced telomere length infers risk for developing 
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ischaemic heart disease and that a reduced telomere length is not merely an epiphenomenon 
attributed to the pathophysiological processes of heart failure.  
However, it has to be noted that in the case-control studies (Brouilette et al., 2003; 
Zee et al., 2009) the cases had a greater prevalence of risk factors for cardiovascular disease 
compared to the control groups. Even though these risk factors were adjusted for, in the 
respective multivariate regression analyses, it follows that individuals with a higher 
prevalence of risk factors for cardiovascular disease subsequently suffer cardiac events. 
Hence, these data  are insufficient to conclusively determine if reduced telomere length is a 
cause of heart failure and is independent of other risk factors for cardiovascular disease. 
Nevertheless, these data do indicate that reduced leukocyte telomere length is associated with 
an increased risk for ischaemic heart disease.   
 
1.3.4 IS TELOMERE LENGTH ASSOCIATED WITH NON-ISCHAEMIC FORMS OF HEART 
FAILURE?  
The association between reduced telomere length and increased risk for myocardial 
infarction raises the question of whether telomere length is also associated with non-
ischaemic forms of heart failure. Although reduced leukocyte telomere length has been found 
in patients in heart failure compared to healthy controls (Starr et al., 2007; van der Harst et 
al., 2007; Weischer et al., 2012), this data is primarily in ischaemic forms of heart failure. 
Van der Harst et al. (2007) did however demonstrated that leukocyte telomere length was 
reduced in patients with non-ischaemic heart disease. However, a high proportion of these 
patients with non-ischaemic heart disease had a history of stroke, peripheral arterial disease, 
angina pectoris, and the cause of heart failure in the remaining patients was not described 
(Van der Harst et al., 2007). Furthermore, Starr et al.(2007) demonstrated that reduced 
 INTRODUCTION Page 16 
telomere length was associated with ischaemic changes on electrocardiograms while the same 
associations were absent with non-ischaemic disease manifestations.  
There is currently no data available to suggest that reductions in telomere length are 
associated with non-ischaemic forms of heart failure. A possible explanation for the strong 
association between leukocyte telomere length and ischaemic forms of heart failure may be 
due to the confounding effects of risk factors that predispose individuals to ischaemic heart 
disease. In this regard, reduced telomere length has been associated with many risk factors for 
ischaemic heart disease, which include; increased intima-media thickness (O’Donnell et al., 
2008), hypertension (Fusteret al., 2007; Weischer et al., 2012), atherosclerosis (Huzen et al., 
2011; Samani et al., 2001), increased left ventricular mass (Kuznetsova et al., 2010; Vasan et 
al., 2009), type 2 diabetes mellitus (Salpea et al., 2010; Weischer et al., 2012), obesity 
(Valdes  et al., 2005; Weischer et al., 2012), smoking (Valdes  et al., 2005; Weischer et al., 
2012), increased total cholesterol, and decreased high-density lipoprotein cholesterol 
(Weischer et al., 2012). Hence, reduced leukocyte telomere length evident inischaemic heart 
disease may represent an epiphenomenon due to the presence of risk factors for 
cardiovascular disease. Therefore, it is important that non-ischaemic forms of heart failure are 
also investigated to determine if the relationship between telomere length and heart failure 
holds true for all types of heart failure. Furthermore, this will allow for the elucidation of 
whether the relationship between reduced leukocyte telomere length and heart failure is due 
to the associations between telomere length and risk factors for ischaemic heart disease or is 
an independent risk factor for heart failure.  
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1.3.5 THE IMPLICATIONS OF LONGITUDINAL LEUKOCYTE DATA ON TELOMERE LENGTH 
RESEARCH IN CARDIOVASCULAR DISEASE. 
A major assumption with regards to telomere research to date is that leukocyte 
telomere length decreases progressively with age. This notion is supported by all of the cross-
sectional studies cited previously, which demonstrate leukocyte telomere length is negatively 
associated with age. If this assumption holds true, then leukocyte telomere length could then 
be utilised, as marker of biological age representing the cumulative effects of stress on the 
body, to identify individuals with increased risk for future cardiac events. This hypothesis is 
supported by prospective data, which have demonstrated that reduced leukocyte telomere 
length is associated with an increased risk for ischaemic heart disease, namely myocardial 
infarction (Brouilette et al., 2003; Fitzpatrick et al., 2007; Weischer et al., 2012; Zee et al., 
2009).   
However, whether or not telomere length in an individual decreases in a predictable 
manner over time can only be determined using longitudinal data. In this regard, in a study 
consisting of 959 participants with a  follow up interval of approximately ten years, although 
most participants showed a decline in leukocyte telomere length (Nordfjäll et al., 2009), one 
third of this cohort showed either no change or increased leukocyte telomere length over 
time. Similarly, Aviv et al. (2009) found that, in 635 individuals with a mean follow up 
period of four and a half years, leukocyte telomere length either decreased or increased in 
individuals. These longitudinal data indicate that leukocyte telomere length is variable and 
may increase, remain the same or decrease in length over time. The high temporal variation 
in leukocyte telomere length (Aviv et al., 2009; Nordfjäll et al., 2009), suggests that the use 
of leukocyte telomere length as a possible predictor of risk for heart failure is unlikely as 
leukocyte telomere attrition may be specific to each individual (Aviv et al., 2009; Nordfjäll et 
al., 2009).  
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These data obtained from Nordfjället al.(2009) and Aviv et al. (2009) highlight the 
importance of investigating telomere length longitudinally. Currently, with regards to heart 
failure, there is no investigation that has assessed telomere length longitudinally.  
In addition to the high temporal variation in leukocyte telomere length, telomere 
length of leukocytes has been used as a surrogate marker of telomere length of cardiovascular 
tissues in all of the cross-sectional human studies investigating telomere length and 
cardiovascular disease to date. Support for the use of leukocyte telomere as surrogate marker 
of telomere length in other tissues emanates from a study conducted by Friedrich et al. 
(2000). This investigation found that leukocyte telomere length was correlated with telomere 
length in skin and synovial fluid samples. On the basis of these findings it was concluded that 
leukocyte telomere length could serve as a surrogate marker of telomere length in other 
tissues (Friedrich et al., 2000). The major limitation of this study relates to the small sample 
size (only nine participants). Furthermore, the age range of the participants was narrow (22 
years) and represented only an elderly cohort (individuals between the ages of 73 to 95 
years). The bias of this sample towards an elderly population and the small sample size raise 
doubts as to whether these relationships between leukocyte telomere length and telomere 
length in other tissues would be present in the general population. Moreover, with regards to 
the implications of research involving telomere length and heart failure, this study conducted 
by Friedrich et al. (2000) did not correlate leukocyte telomere length to any tissue type 
related to the cardiovascular system. This raises concerns for the validity of using leukocyte 
telomere length as a surrogate marker in epidemiological studies investigating telomere 
length and cardiovascular disease. 
Nevertheless, subsequent supporting evidence for the use of leukocyte telomere 
length as a surrogate marker of telomere length in cardiovascular tissue has been 
demonstrated. Wilson et al. (2008) showed that leukocyte telomere length was correlated 
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with telomere length in samples obtained from the abdominal aorta. However, as with the 
study conducted by Friedrich et al.(2000), this study is also hindered by a small sample size 
(n=32) and an older cohort with ages ranging from 56 to 78 years. However, despite the small 
sample size, a very strong positive association between leukocyte and aortic telomere length 
was found (r=0.62, p<0.001). Furthermore, Huzen et al. (2011) found a positive association 
between leukocyte telomere length and telomere length of carotid artery atherosclerotic 
plaques. The sample size of this study was large and therefore the issues of statistical power 
with previous studies were not a factor. However, an important finding from the study of 
Huzen et al. (2011) was that leukocyte telomere length and plaque telomere length were 
correlated with different aspects of plaque histology. Importantly, these findings highlight 
that leukocyte telomere length may correlate with telomere length in cardiovascular tissues 
but may not represent the overall diseased state of the tissue. Moreover, plaque telomere 
length was not correlated with age suggesting that plaque telomere length may not decrease at 
the same rate as leukocyte telomere length, which was associated with age in this study. 
Further evidence that telomere attrition may proceed at different rates over time in different 
cell types is demonstrated by O'Sullivan et al. (2006), who showed that telomere length in 
leukocytes decreased with age but the same association was absent in stromal cells of 
colonocytes. These data indicate that attrition of telomere length may proceed at different 
rates in different tissues.  
Hence, although there is significant evidence demonstrating that reduced leukocyte 
telomere length is associated with heart failure and some evidence that leukocyte telomere 
length is correlated with telomere length in tissues related to the cardiovascular system; 
leukocyte telomere length may not be representative of the diseased state of the tissue in 
question. The  measurement of leukocyte telomere length, or another easily accessible tissue, 
is however fundamental for future epidemiological studies investigating telomere length and 
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cardiovascular disease. Nevertheless, whether leukocyte telomere length can be used as a 
surrogate marker of telomere length in heart tissue in healthy or diseased states has yet to be 
established. 
 
1.3.6 OVERVIEW OF EVIDENCE INVESTIGATING TELOMERE LENGTH AND HEART FAILURE. 
The main findings with regards to telomere length and cardiovascular disease are as 
follows: reduced telomere length has been demonstrated in cardiomyocytes of failing hearts 
and is associated with cardiomyocyte apoptosis and senescence (Chimenti et al., 2003; Leri et 
al., 2003; Oh et al., 2003; Sheng et al., 2013). These data suggest that reduced telomere 
length may be associated with adverse cardiomyocyte changes in diseased hearts. These 
findings, have been supported by large cross-sectional studies in humans. In this regard, 
reduced leukocyte telomere length is associated with degenerative aortic valve stenosis (Kurz 
et al., 2006), increased risk for myocardial infarctions (Brouilette et al., 2003; Fitzpatrick et 
al., 2007; Weischer et al., 2012; Zee et al., 2009); and is reduced in patients with heart failure 
(Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 2012). Importantly, leukocyte 
telomere length is also associated with the severity of heart failure (van der Harst et al., 2007) 
and  indicates that telomere length may be associated with the pathophysiological processes 
that worsen heart failure. However, the major caveat with regards to the literature regarding 
telomere length and human heart failure is the inherit inability of cross-sectional data to 
elucidate cause and effect relationships. Nevertheless, there is significant data demonstrating 
that reduced telomere length is associated with cardiovascular disease and the sections to 
follow outline potential mechanisms that may explain the relationship between telomere 
length and heart failure specifically.  
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1.4 MECHANISMS LINKING TELOMERE LENGTH TO HEART FAILURE 
The following sections will discuss the potential biological mechanisms that provide 
explanations for the relationship between reduced telomere length and heart failure. These 
features include; oxidative stress, inflammation, apoptosis, and mitochondrial dysfunction.   
 
1.4.1 OXIDATIVE STRESS, HEART FAILURE AND TELOMERE LENGTH. 
Heart failure is associated with increased oxidative stress (Ahmed and  Tang, 2012; 
Giordano, 2005; Papaharalambus and Griendling, 2007; Singal et al., 1998), which is the 
result of an imbalance between the production of reactive oxygen species (ROS) and the 
body's ability to eliminate ROS, resulting in a net increase in ROS and oxidative stress. In 
heart failure, ROS production has been shown to be derived from NADPH oxidases, xanthine 
oxidase, and uncoupling of the mitochondrial respiratory chain (Ahmed and Tang, 2012; 
Papaharalambus and Griendling, 2007). The most prominent of the oxidases, in terms of ROS 
production during heart failure, is NADPH oxidase. In the myocardium of failing hearts, 
NADPH oxidase-derived ROS are increased (Maack et al., 2003). Moreover, NADPH 
oxidases have also been associated with increased angiotensin II, endothelin-1, oxidized low 
density lipoproteins, and adrenaline, which are all factors related to the pathophysiology of 
heart failure (Lassègue et al., 2001; Seddon et al., 2007; Wingler et al., 2001). Furthermore, 
animal studies have demonstrated that NADPH oxidase causes adverse changes in the heart 
including angiotensin II-induced cardiac hypertrophy, cardiac fibrosis (Johar et al., 2006), 
cardiomyocyte apoptosis, contractile dysfunction, andventricular remodelling (Bell et al., 
2005;  Looi et al., 2008).  
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Increases in oxidative stress are undoubtedly an important feature in the 
pathophysiology of heart failure (Ahmed and  Tang, 2012; Giordano, 2005; Papaharalambus 
and Griendling, 2007; Singal et al., 1998). Oxidative stress has also been found to have a 
negative influence on telomere length. Indeed, in vitro studies have demonstrated that 
oxidative stress results in increased telomere attrition (Harboa et al., 2012; von Zglinicki et 
al., 1995; von Zglinicki et al., 2000). Cross-sectional data in humans are consistent with in 
vitro findings, with negative associations found between leukocyte telomere length and 
markers of oxidative stress (Bekaert et al., 2007; Demissie et al., 2006; Masi et al., 2011; 
Watfa et al., 2011; Wolkowitz et al., 2011). In terms of in vivo data, Cattan et al. (2008) 
inhibited the production of glutathione (an important antioxidant) in mice and found that 
telomere length was reduced in some but not all tissues as a result of increased oxidative 
stress. In this regard, telomere length was reduced in the testes, brown fat, tail, white fat and 
skin (Cattan et al., 2008). Importantly however, telomere length of heart tissue in the 
experimental group was not significantly different to that of the control group (Cattan et al., 
2008). While in vitro studies have illustrated that increased oxidative stress is associated with 
a decrease in telomere length, the data from Cattan et al. (2008) provide evidence to suggest 
that tissues may differ in their susceptibility to telomere length attrition caused by oxidative 
stress. 
In terms of the mechanisms explaining oxidative stress induced telomere attrition, the 
predominant factor rendering telomeres susceptible to damage via oxidative stress is the high 
guanine content of telomeres (Houben et al., 2008). The guanine content of telomeres is high 
in both the telomeric sequence itself (5'-TTAGGG-3') and in the single stranded guanine 
overhang on the 3' end that forms the protective t-loop structure (Oikawa and Kawanishi, 
1999; Oikawa et al., 2001; Sitte et al., 1998). ROS interact with the guanine nucleotides to 
form 7,8-Dihydro-8-oxogaunine (8-oxodG) (Rhee et al., 2011). The presence of 8-oxodG in 
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telomeric DNA has been found to disrupt telomerase function (Szalai et al., 2002), which has 
a negative influence on the maintenance of telomere length. ROS have also been shown to 
promote the translocation of telomerase out of the nucleus and into the cytosol (Haendeler et 
al., 2003). Furthermore, ROS also result in single strand breaks in DNA, and telomeres are 
less efficient, compared to other regions of DNA, in the repair of these single strand breaks 
(Petersen et al., 1998). The inability of telomere regions to repair single strand breaks is 
possibly due to TRF2 inhibiting the access of DNA repair enzymes to telomeric regions 
(Ohki et al., 2004; Richter et al., 2007). Indeed, TRF2 has been implicated in impaired DNA 
repair responses (Fotiadou et al., 2004; Karlseder et al., 2004). 
Hence, together these data indicate that oxidative stress-induced reductions in 
telomere length may explain the associations between reduced leukocyte telomere length in 
heart failure.  
 
1.4.2 INFLAMMATION, HEART FAILURE AND TELOMERE LENGTH.  
It has been established that inflammation plays a key role in the pathophysiology of 
heart failure (Yndestad et al., 2006). Patients in heart failure have increased concentrations of 
inflammatory cytokines, such as tumour necrosis factor (TNF-α), interleukin-1β (IL-1β), and 
interleukin-6 (IL-6) (Adamopoulos et al., 2001; Aukrust et al., 1999; Levine et al., 1990; 
Testa et al., 1996; Yndestad et al., 2006). Moreover, increases in these cytokines have been 
correlated with the severity of heart failure (Aukrust et al., 1999; Testa et al., 1996) and 
worse clinical outcomes (Torre-Amione et al., 1996). The increase in concentrations of 
inflammatory cytokines in heart failure is possibly due to; mechanical stress in the heart 
(Shioi et al., 1997), ischaemia (Singal et al., 1998), toll-like receptor activation (Satoh et al., 
2005), and sustained white cell activation (Brooksbank
a 
et al., 2005; Brooksbank
b 
et al., 
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2005). The importance of inflammation as a possible causal factor of heart failure is 
highlighted by animal studies. In mice, the over expression of TNF-α resulted in heart failure, 
which was characterised by ventricular hypertrophy, dilatation and fibrosis (Kubota et al., 
1997). Similarly, in rats injected with TNF-α adverse left ventricular function and dilatation 
were noted (Bozkurt et al., 1998).   
In addition to heart failure, inflammation has also been associated with telomere 
length. Compared to healthy participants a reduced leukocyte telomere length has been 
associated with a number of inflammatory diseases (Houben et al., 2008) such as; 
atherosclerosis (Huzen et al., 2011; Samani et al., 2001), diabetes mellitus (Salpea et al., 
2010; Weischer et al., 2012), inflammatory bowel disease (Kinouchi et al., 1998), chronic 
hepatitis (Aikata et al., 2000), and obesity (Valdes et al., 2005). Furthermore, leukocyte 
telomere length has been negatively correlated with markers of inflammation including; IL-6 
(Carrero et al., 2008; Shiels et al., 2011; Wolkowitz et al., 2011), C-reactive protein (CRP) 
(Bekaert et al., 2007; Carrero et al., 2008; Masi et al., 2012), and fibrinogen (Bekaert et al., 
2007). Moreover, the probability of having shorter leukocyte telomere length was increased 
in patients with high concentrations of TNF-α and IL-6 (O’Donovan et al., 2011). In two 
large cross-sectional studies in adolescent and middle-aged participants that had no signs of 
cardiovascular disease it was found that telomere length was not associated with traditional 
risk factors for cardiovascular disease such as; dyslipidaemia, hypertension, insulin 
resistance, and obesity (Bekaert et al., 2007; Masi et al., 2012). However, there was a 
negative association between telomere length and markers of inflammation in these two 
studies. These data indicate that there is a strong negative relationship between telomere 
length and inflammation. This tenet is reinforced by animal studies where mice injected with 
Salmonella enterica bacteria had reduced leukocyte telomere length compared to their sham-
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injected siblings (Ilmonen et al., 2008). These data indicate that inflammation is capable of 
inducing telomere attrition.  
With regards to the cellular mechanisms of inflammatory induced telomere attrition, 
Beyne-Rauzy et al. (2004) showed that in leukaemic cells TNF-α resulted in a decreased 
telomere length and reduced expression of Tert. The same investigator (Beyne-Rauzy et al., 
2005), treated leukaemic cells and normal bone marrow CD34 hematopoietic progenitor cells 
with TNF-α and found that Tert expression was reduced in both cell types. These studies 
suggest that inflammation could reduce the expression of Tert, which would then result in a 
decreased ability to maintain telomere length. However, there are conflicting data with 
regards to the negative effects of TNF-α on telomere length. Akiyama et al. (2003) 
demonstrated that TNF-α mediates the nuclear translocation of Tert. The translocation of Tert 
into the nucleus could possibly have a positive effect on telomere length by increasing the 
availability of Tert for telomere elongation. The exact mechanisms behind TNF-α having 
both positive and negative effects on Tert are currently unknown. In this regard, the 
mechanisms behind inflammatory induced reductions in telomere length require further 
elucidation.    
Hence, these data indicate that inflammatory induced reductions in telomere length 
could provide an explanation for the associations between telomere length and heart failure.  
 
1.4.3 INFLAMMATION, OXIDATIVE STRESS, AND HEART FAILURE 
It is well established that oxidative stress (Giordano, 2005; Singal et al., 1998) and 
inflammation (Yndestad et al., 2006) are key features of both heart failure itself and risk 
factors for heart failure (Russel, 1999; Tardif, 2000). Furthermore, oxidative stress and 
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inflammation are known to occur concomitantly. In this regard, oxidative stress can illicit 
inflammation (Knuefermann et al., 2004; Frantz et al., 2000) and conversely inflammatory 
mediators can increase oxidative stress (Floyd et al., 1999; Jaiswal et al., 2000).  
As discussed in Sections 1.4.1 and 1.4.2 above, telomere attrition is increased by 
inflammation as well as oxidative stress (Houben et al., 2008). Hence, the relationship 
between oxidative stress, inflammation and heart failure has implications regarding 
investigations between telomere length and heart failure. Firstly, the mechanisms whereby 
oxidative stress and inflammation increase telomere length attrition are not mutually 
exclusive. Secondly, to determine independent relationships between telomere length and 
heart failure, inflammation and oxidative stress have to be measured in order to account for 
their influences on telomere length. Hence, in order to establish cause and effect relationships 
between telomere length and heart failure, measurements of inflammation and oxidative 
stress are required to determine whether changes in telomere length during heart failure are 
independent of inflammation and oxidative stress.  
 
1.4.4 APOPTOSIS, HEART FAILURE AND TELOMERE LENGTH 
There is significant evidence to suggest that apoptosis is associated with heart failure. 
In this regard, apoptotic death of cardiomyocytes has been found to be increased in patients 
with heart failure compared to healthy controls (Guerra et al., 1999; Olivetti et al., 1997; 
Saraste et al., 1999), with the incidence of apoptosis being between 0.08-0.25% in these 
patients. Moreover, animal models have illustrated that apoptosis itself is sufficient to herald 
the onset of heart failure. Wencker et al. (2003), using transgenic mice with a cardiac specific 
over expression of caspase enzymes, found that after several weeks these mice developed a 
dilated cardiomyopathy. Moreover, the rate of apoptosis was low (0.023%) and comparable 
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to levels seen in human studies. These data demonstrate that low levels of apoptosis are 
pathologically relevant and could be an important pathophysiological process in heart failure.  
With regards to the consequences of apoptosis in the heart, there has been research 
into adverse ventricular remodelling as a result of apoptosis (Abbate et al., 2002). Olivetti et 
al.(1990) showed that apoptosis potentially results in side-to-side slippage of cardiomyocytes, 
which then results in architectural rearrangements of the myocardium contributing towards 
ventricular dilatation. However, these findings were noted in a myocardial infarction model 
of heart failure in rats. In this regard, myocardial infarction results in acute changes in the 
heart, however these findings could still be applicable to other types of heart failure where the 
rate of cardiomyocyte apoptosis is reduced compared to acute myocardial infarction (Guerra 
et al., 1999; Olivetti et al., 1997; Saraste et al., 1999; Wencker et al., 2003), but is continuous 
over a number of years. In addition to architectural rearrangements of the myocardium, 
apoptosis may have an impact on intrinsic myocardial function. In this regard, intrinsic 
myocardial function is determined by the number of functional cardiomyocytes and their 
ability to contract. Therefore, a significant increase in apoptosis may result in the reduction of 
intrinsic myocardial function by decreasing the available number of functional 
cardiomyocytes.  
As discussed previously in Section 1.3, telomere length has been associated with 
apoptosis in cardiomyocytes in heart failure (Chimenti et al., 2003; Oh et al., 2003). 
Moreover, telomere length has a major role in the regulation of apoptosis (Section 1.2). 
Therefore, reductions in telomere length could potentially mediate the activation of apoptosis 
in heart failure resulting in adverse left ventricular remodelling and reduced intrinsic 
myocardial function.  
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1.4.5 MITOCHONDRIAL DYSFUNCTION, HEART FAILURE AND TELOMERE LENGTH. 
Mitochondrial dysfunction is another key feature of heart failure (Bayeva et al., 2012; 
Marin-Garcia and Goldenthal, 2008). The pathophysiological consequences of mitochondrial 
dysfunction in heart failure include; decreased energy production, ROS generation, apoptosis, 
and disruptions of Ca
2+
 transients with subsequent alterations in cardiac contractility (Marin-
Garcia and Goldenthal, 2008). Definitive evidence for the adverse effects of mitochondrial 
dysfunction on the heart are found with genetic mutations that effect mitochondrial function 
and produce cardiac dysfunction (Bayeva et al., 2012).   
In terms of the link between mitochondrial function and telomere length, Sahin et al. 
(2011) noted that telomere dysfunction in mice  (Tert and Terc knockout mice) resulted in 
suppression of pathways linked to peroxisome proliferator-activated receptor gamma (PPAR-
γ) coactivators 1 α and β. These PPAR-γ co-activators play a crucial role in the biogenesis 
and functioning of mitochondria. Hence, these mice displayed characteristics associated with 
abnormal mitochondrial functioning, which included; disruptions in oxidative 
phosphorylation, increased oxidative stress and reduced gluconeogenesis (Sahin et al., 2011). 
Furthermore, Sahin et al. (2011) showed in p53 knockout mice that the adverse effects caused 
by telomere induced mitochondrial dysfunction were ameliorated. These data suggest that the 
link between reduced telomere length and the suppression of PPAR-γ co-activators are 
directly associated with p53. This study demonstrated that when critically short telomeres 
activate p53, PPAR-γ coactivators 1 α and β are suppressed and these changes are associated 
with mitochondrial dysfunction.  
In terms of heart failure, these data suggest that reductions in telomere length could be 
an important factor causing mitochondrial dysfunction in heart failure. Therefore, telomere 
length attrition may have a role in mitochondrial-induced decreased energy production, ROS 
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generation, apoptosis, and disruptions of Ca
2+
 transients with subsequent alterations in 
cardiac contractility (Marin-Garcia and Goldenthal, 2008). Hence, telomere attrition may 
play a causal role in the development of heart failure.   
Although mechanism of inflammation, oxidative stress, and apoptosis were explored 
in my thesis, thorough investigations of the relationship between telomere length and 
mitochondrial function would have required me to conduct a multitude of additional assays 
(relating to metabolic function) which were outside the scope of my current thesis and hence 
were not done. Although it may well be interesting as part of a thesis on metabolic function.       
 
1.4.6 OVERVIEW OF POTENTIAL MECHANISMS LINKING TELOMERE LENGTH TO HEART 
FAILURE. 
The discussions in earlier sections provide the framework for a potential mechanistic 
links between reduced telomere length and heart failure (FIGURE 1.3). Currently a number of 
possibilities exist. Firstly, telomere length could be a causal factor in heart failure. In this 
regard, individuals with a higher prevalence of risk factors for heart failure have increased 
oxidative stress and inflammation (Russel, 1999; Tardif, 2000). Increases in oxidative stress 
and inflammation could precipitate an increase in telomere attrition (Beyne-Rauzy et al., 
2005; Houben et al., 2008) and when telomere length of cardiomyocytes reaches a threshold 
level, cellular senescence and apoptotic pathways are activated (Artandi andAttardi, 2005). 
Furthermore, critical telomere shortening is also associated with mitochondrial dysfunction 
(Sahin et al., 2011). Hence, reductions in cardiomyocyte telomere length could herald the 
activation of senescence (Chimenti et al., 2003), apoptosis (Chimenti et al., 2003; Oh et al., 
2003; Leri et al., 2003; Sheng et al., 2011), and mitochondrial dysfunction (Sahin et al., 
2011) and potentially result in the onset of heart failure (Leri et al., 2003). Alternatively, 
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telomere length may not be a causative factor but could mediate the changes in heart failure. 
In this regard, increased oxidative stress (Singal et al., 1998; Giordano, 2005) and 
inflammation (Yndestad et al., 2006) present in heart failure may cause a decrease in 
cardiomyocyte telomere length with the subsequent activation of apoptosis (Artandi and 
Attardi, 2005), senescence, and mitochondrial dysfunction (Sahin et al., 2011). The activation 
of these telomere regulated pathways may not be the underlying cause of heart failure, but 
could mediate the adverse changes in cardiac function and structure evident in heart failure 
(Abbate et al., 2002; Bayeva et al., 2012; Marin-Garcia and Goldenthal, 2008). Lastly, 
reduced telomere length may have no pathophysiological consequences in heart failure and 
may merely be an epiphenomenon due to the increased oxidative stress and inflammation 
caused by heart failure or risk factors associated with the development of heart failure. 
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FIGURE 1.3 Potential pathway of telomere-induced activation of cellular senescence, 
apoptosis, and mitochondrial dysfunction in heart failure. Red arrows indicate possible causal 
pathways and green arrows indicate possible consequential pathways linking decreased 
telomere length  and heart failure.   
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1.5 PROBLEM STATEMENTS AND AIMS 
There is a clear negative association between telomere length and heart failure. 
However, the cause and effect relationships between telomere length and heart failure are 
uncertain. In this regard, whether reduced telomere length plays a role in the 
pathophysiological processes of heart failure or if telomere length is reduced in heart failure 
merely due to the pathophysiological processes involving oxidative stress and inflammation 
is unknown. The caveats within the literature regarding the data investigating the relationship 
between telomere length and heart failure have been discussed in detail in previous sections. 
A summary of the problems are: the utilisation of leukocyte telomere length as a surrogate 
marker for cardiovascular telomere length; the relationship between telomere length and non-
ischaemic forms of heart failure have not been investigated (non-ischaemic forms of heart 
failure do not have atherosclerosis associated oxidative stress and inflammation); the 
relationship between telomere length and heart failure has not been investigated 
longitudinally; and associations between telomere length and cardiac geometry and function 
have not been adequately investigated.  
The main aim of this thesis was to therefore further investigate the relationship 
between telomere length and heart failure in light of the deficiencies within the literature. In 
this regard, I investigated the relationships between telomere length and a non-ischaemic 
form of heart failure, and between telomere length and measurements of cardiac remodelling 
and systolic function prior to the development of heart failure. The specific aims for each of 
my studies were as follows: 
 To investigate the association of telomere length with the severity and presence of a 
non-ischaemic form of heart failure (Chapter 2). 
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 To investigate whether telomere shortening is a cause of adverse left ventricular 
remodelling and systolic dysfunction in an animal model of dilated cardiomyopathy 
(chronic ethanol consumption) (Chapter 3).  
 To determine whether adverse left ventricular remodelling and systolic chamber 
dysfunction produced by chronic β-adrenergic receptor activation are associated with 
telomere shortening (Chapter 4) 
 To determine the impact of chronic inflammation on telomere length, left ventricular 
remodelling, and systolic dysfunction (Chapter 5). 
 To determine the relationships between telomere length and inflammation, left 
ventricular geomtery, and systolic function in a cross-sectional community study 
(Chapter 6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 2 - IDIOPATHIC DILATED 
CARDIOMYOPATHY AND TELOMERE 
LENGTH 
 
The data in this chapter has been published in the European Journal of Heart Failure: 
Raymond AR, Norton GR, Sareli P, Woodiwiss AJ, Brooksbank RL. Relationship between 
average leukocyte telomere length and the presence or severity of idiopathic dilated 
cardiomyopathy in black Africans. Eur J Heart Fail 2013; 15:56-60. 
 
 
 
 
 
 
 
 
 
IDC AND TELOMERE LENGTH Page 35 
2.1 ABSTRACT  
Aims: A reduced average leukocyte telomere length is associated with ischaemic 
heart disease. Whether this relationship represents a cause or consequence of heart failure or 
is attributed to associated risk factors and coronary artery disease is uncertain. We evaluated 
if average leukocyte telomere length is associated with idiopathic dilated cardiomyopathy 
(IDC) or its severity. Methods and Results: We compared average leukocyte telomere length 
in 223 patients with heart failure due to IDC and 227 healthy controls of black African 
ancestry. We also evaluated the relationship between average leukocyte telomere length and 
left ventricular (LV) ejection fraction (EF). LVEF was determined using echocardiography 
and radionuclide multiple-gated acquisition (MUGA) scans in patients with IDC. Relative 
leukocyte telomere length (T/S) was measured using a quantitative real-time polymerase 
chain reaction assay. Log T/S was negatively correlated with age in patients with IDC 
(p=0.0007) and in controls (p=0.030), and with alcohol consumption (p=0.032) and regular 
smoking (p=0.021) in patients with IDC. Log T/S did not differ between IDC and control 
groups either before (p=0.11) or after (IDC=0.071±0.19 vs. Control=0.071±0.19, p=0.99) 
adjustments for confounders. Log T/S was not associated with echocardiographic (p=0.47) or 
MUGA (p=0.99) LVEF or LV end diastolic diameter (LVEDD) (p=0.34) in patients with 
IDC. With adjustments for age, sex, alcohol consumption and smoking, log T/S was similarly 
not associated with echocardiographic (p=0.60) or MUGA (p=0.91) LVEF or LVEDD 
(p=0.53) in patients with IDC. Conclusions: Average relative leukocyte telomere length is 
not associated with IDC or its severity in groups of black African ancestry. 
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2.2 INTRODUCTION 
Recent evidence suggests that patients with chronic heart failure have a reduced 
average leukocyte telomere length (Starr et al., 2007; van der Harst et al., 2007; Weischer et 
al., 2012) and that telomere length is associated with the severity of heart failure (van der 
Harst et al., 2010). A decreased average leukocyte telomere length also predicts deaths and 
hospitalisations in patients with New York Heart Association (NYHA) functional class II-IV 
heart failure (van der Harstet al., 2010). Moreover, in the very elderly, a shorter leukocyte 
telomere length is related to a reduced left ventricular (LV) ejection fraction (EF) (Collerton 
et al., 2007). A number of possibilities may explain these relationships including 
cardiomyocyte apoptosis and premature senescence caused by telomere attrition (Chimenti et 
al., 2003; Leri et al., 2001; Leri et al., 2003; Oh et al., 2003), or repression of mitochondrial 
biogenesis and performance caused by telomere dysfunction (Sahin et al., 2011). In addition 
heart failure-induced chronic inflammation, oxidative stress or renal dysfunction may result 
in telomere attrition (Beyne-Rauzy et al., 2004; Houben et al., 2008; van der Harst et al., 
2008). Moreover, relationships between heart failure and a reduced average leukocyte 
telomere length (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 2012) may 
represent an epiphenomenon attributed to the relationship between telomere length and 
coronary artery disease (Brouilette et al., 2003; Ogami et al., 2004) or its risk factors 
(Fitzpatrick et al., 2007; Valdes et al., 2005). Currently, the relative importance of each of 
these potential explanations is uncertain. 
If the relationship between average telomere length and heart failure (Starr et al., 
2007; van der Harst et al., 2007; Weischer et al., 2012) or its outcomes (van der Harst et al., 
2010) are an index of the deleterious consequences of heart failure (Beyne-Rauzy et al., 
2004; Houben et al., 2008; van der Harst et al., 2008), then one would expect most forms of 
heart failure, depending on their severity, to be associated with telomere length. Similarly, if 
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a reduced average leukocyte telomere length reflects the impact of telomere attrition or 
dysfunction on heart failure through apoptosis (Chimenti et al., 2003; Leri et al., 2001; Leri 
et al., 2003; Oh et al., 2003), and/or repression of mitochondrial biogenesis and function 
(Sahinet al., 2011), then one would anticipate this relationship to exist in all forms of heart 
failure associated with excessive apoptosis or impaired mitochondrial biogenesis and 
function. In contrast, if the relationship between average leukocyte telomere length and heart 
failure (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 2012) reflects an 
association with coronary artery disease (Brouilette et al., 2003; Ogami et al., 2004) and/or 
its risk factors (Fitzpatrick et al., 2007; Valdes et al., 2005) then it is more likely that this 
relationship will be specific to ischaemic heart disease. In this regard, to-date only one study 
has reported on the relationship between average leukocyte telomere length and heart failure 
of non-ischaemic as opposed to ischaemic origins (van der Harst et al., 2007). Although both 
forms of heart failure were associated with a reduced average leukocyte telomere length, a 
high proportion of patients with non-ischaemic heart disease had a history of stroke, 
peripheral arterial disease and angina pectoris (van der Harst et al., 2007). Furthermore, the 
causes of heart failure in the remaining patients in this study were not described (van der 
Harst et al., 2007). Consequently, there is a need to establish whether average leukocyte 
telomere length is associated with non-ischaemic heart disease and its severity. In the present 
study we therefore evaluated the relationship between average relative leukocyte telomere 
length and either the presence or the severity of idiopathic dilated cardiomyopathy (IDC), a 
form of heart failure associated with excess inflammation (Brooksbank
a 
et al., 2005; 
Brooksbank
b 
et al., 2005; Sliwa et al., 1998), oxidative stress (Yücel et al., 1998), and 
cardiomyocyte apoptosis (Kostin et al., 2003).
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2.3 METHODOLOGY 
2.3.1 Study groups: The present study was conducted according to the principles 
outlined in the Helsinki declaration. The Committee for Research on Human Subjects of the 
University of the Witwatersrand approved the protocol (approval number: M951122). 
Participants provided informed, written consent. 223 patients of black African ancestry with 
IDC and 227controls randomly recruited from the same community and who had no history 
of cardiovascular disease, were normotensive (not taking medication and had a normal seated 
blood pressure) and had no diabetes mellitus (no glucose-lowering therapy and a random 
glucose<7.0mmol.l
-1
), participated in this study. 
A diagnosis of IDC was established by the presence of NYHA class II-IV heart failure 
despite stable medical therapy for at least 1 month before entry into the study and an 
LVEF<45% determined from echocardiography. Exclusion criteria have previously been 
reported on (Candy et al., 1999) and included previous cardiac ischaemic events, the use of 
nitrates, the presence of angina pectoris or peripheral arterial disease or a history of stroke. In 
addition, patients were excluded if they had wall motion abnormalities on echocardiography 
or pathologic Q waves on electrocardiography. Furthermore, patients with primary rheumatic 
valve disease, congenital heart disease, active myocarditis or a history of myocarditis, clinical 
and echocardiographic features consistent with an obstructive, hypertrophic, or restrictive 
cardiomyopathy, or pericardial disease were excluded. Moreover, patients with obvious 
hypertensive or alcohol-induced dilated cardiomyopathy, a history of hypertension, or 
systolic or diastolic blood pressure of greater than 170 and 105 mmHg respectively were 
excluded. Patients with liver and renal function changes that could only be attributed to 
primary hepatic and renal disease as opposed to changes that may occur subsequent to heart 
failure were also excluded. To avoid the impact of arrhythmias on systolic and diastolic left 
ventricular performance, patients with significant arrhythmias were similarly excluded. To 
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ensure that co-morbidities did not contribute toward cardiac performance, patients with 
significant pulmonary, neurologic, or endocrine disease were excluded. 
Coronary angiography was performed in 28 patients in whom, on history, a potential 
ischaemic contribution was uncertain. Angiography was not routinely performed in the rest of 
the cohort as we have previously shown that patients from this population labelled as IDC 
according to the above criteria, have a very low incidence of coronary artery pathology on 
angiography (Sliwa et al., 1998; Wisenbaugh et al., 1993). In all of the 28 patients who may 
have had ischaemic pathology the coronary anatomy was noted to be normal on angiography. 
2.3.2 Left ventricular performance: A multiple gated equilibrium cardiac blood pool 
scintigraphic (MUGA) technique was used to measure LVEF. This procedure was performed 
by an experienced cardiologist. The MUGA scans were performed using a Elscint Apex 
409M mobile scintillation camera equipped with a collimator (Elscint APC-3, Haifa, Israel). 
The scans were performed at rest, in participants who consented, after  a 2 ml intravenous 
injection of stannous pyrophosphate and an injection of 1,100 MBq (20 mCi) technetium-
99m 20 minutes later. In addition to MUGA scans, LVEF was determined using two-
dimensional echocardiography. Hewlett Packard 1000 or 2000 echocardiographs coupled to 
2.5- or 3.5-MHz transducers were used to determine LV dimensions (Hewlett Packard, 
Boeblingen, Germany). LV dimensions were measured according to the American Society of 
Echocardiography guidelines and LVEF was determined using a standard formula: LVEF = 
(LVEDD-LV end systolic diameter (ESD))/ LVEDD (Sahn et al., 1978). Moreover, left 
ventricular dilation was assessed using the LV internal dimensions during end diastole and 
systole.  
2.3.3 Average relative telomere length: Leukocyte DNA for each participant was 
extracted from whole blood samples using the salting out method of Higuchi et al.(1989) and 
samples were stored at -20°C until analysed. A quantitative real-time PCR (qRT-PCR) 
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method was used to determine relative telomere length of leukocyte DNA (Cawthon, 2002; 
Gil and Coetzer, 2004). This method determines the factor by which telomere repeat copy 
number (T) differs from the copy number of a single copy gene (S). The single copy gene 
used in this protocol was the 36B4 gene located on chromosome 12, which codes for acidic 
ribosomal phosphoprotein PO. Samples were amplified in duplicate in two different PCR 
amplifications; one to determine telomere repeat copy number and the other to determine 
36B4 copy number. The PCR reactions were carried out using LightCycler FastStart DNA 
Master SYBR I Green kits (Roche Diagnostics GmbH, Mannheim, Germany) as per 
manufacturer’s instructions. Each reaction mix contained FastStart Taq Polymerase, reaction 
buffer, MgCl2, SYBR Green I dye, dNTP mix, and the appropriate primers for either the 
telomere or 36B4 reaction (TABLE 2.1).  
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TABLE 2.1 The primer sequences and LightCycler thermal profiles for the telomere and 36B4 
PCR amplifications. 
 
 All temperature transition rates were 20°C per second, except for the telomere annealing 
transition rate, which was 4°C per second. 
 
Telomere PCR primers and thermal profile 
Telomere forward primer: 5'-3' CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT 
Telomere reverse primer: 5'-3' GCC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT 
Thermal profile: Number of cycles Temperature Duration 
Activation 1 95°C 10 min 
Amplification 20 95, 56, 72°C 5, 10, 60 sec 
Cooling 1 30°C 30 sec 
    
36B4 PCR primers and thermal profile 
 
36B4 forward  primer: 5'-3' CAG CAA GTG GGA AGG TGT AAT CC 
36B4 reverse  primer: 5'-3' CCC ATT CTA TCA TCA ACG GGT ACA A 
Thermal profile: Number of cycles Temperature Duration 
Activation 1 95°C 10 min 
Amplification 30 95, 58, 72°C 5, 10, 40 sec 
Cooling 1 30°C 30 sec 
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The telomere primers in this method were designed to ensure that in the first PCR 
cycle the forward and reverse telomere primers hybridized to the telomere sequence, but with 
a mismatch in the last six base pairs at the 5' prime end. This mismatching ensures that the 
primers favour hybridization to the products formed at the end of the first PCR cycle over 
binding to the DNA template in subsequent cycles, thus the amount of telomere product at the 
end of the PCR is proportional to the product produced after the first PCR cycle. The amount 
of product produced after the first round of PCR cycle is determined by telomere length. 
Hence, the amount of telomere product produced in this method is directly proportional to 
telomere length.  
PCR amplifications and their analysis were carried out using a Roche LightCycler 
v1.5 and LightCycler software v1.4 respectively (Roche Diagnostics GmbH, Mannheim, 
Germany). The qRT-PCR method used in this study, includes a SYBR
®
 Green I dye, which is 
a double stranded DNA intercalating dye that only fluoresces when binding to double 
stranded DNA. As the number of PCR cycles increases, the amount of double-stranded DNA 
increases and consequently the amount of fluorescence eventually reaches a threshold value 
(Ct), which is the point where fluorescence levels are statistically significant. Hence, Ct is the 
number of PCR cycles required to reach threshold levels of fluorescence. Hence, the greater 
the amount of starting template there is, the less number of PCR cycles are required to reach 
Ct. In regards to telomere length, the telomere Ct is proportional to telomere length, with a 
smaller Ct representing a greater telomere length. The telomere Ct of each sample was 
compared to its respective 36B4 Ct. 36B4 has only one copy per genome and allows for the 
correction of different sample DNA concentrations, thus allowing for inter-individual 
comparisons. The relative telomere length of each sample was calculated using the following 
formula: 
T/S ratio = 2
-(ΔCt(sample) -ΔCt(standard)) where ΔCt = Ct (telomere) - Ct (36B4).  
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DNA from a single individual was used as the calibrator in this study to standardise 
all of the T/S ratios. Standard curves were generated for both telomere and 36B4 reactions 
(FIGURE 2.1) from the calibrator that was serially diluted to produce a range of DNA 
quantities from 200ng to 5ng. The reaction efficiencies of 2.1 and 1.9, and the tube-to-tube 
variations of 0.09 and 0.001 for the 36B4 and telomere standard curves, respectively, were 
well within accepted limits (Gil and Coetzer, 2004). For the telomere and 36B4 standard 
curves, the slopes of the fitted regressions were –3.18±0.3 and –3.75±0.3 (p<0.001, FIGURE 
2.1), respectively. The regression coefficients were 0.998 and 1.00 for the telomere and 36B4 
standard curves, respectively. The standard curves showed that there was a strong negative 
linear relationship between DNA concentration and Ct. Moreover, melting curve analysis 
were performed on the 36B4 reaction to ensure that the method was producing a single 
product (FIGURE 2.2). As the telomere reaction generates a range of product sizes, this 
approach would not be appropriate for demonstrating the specificity of the telomere reaction. 
Furthermore, the calibrator was included in each amplification run and was used to determine 
coefficients of variation of the S and T assays, which were 3.12% and 3.46% respectively. 
Samples that fell outside the linear concentration range of the standard curves were diluted 
and re-run in order to ensure they fell within the linear range of the standard curves. This 
real-time quantitative PCR method has been validated and shown to give a measure of 
relative telomere length, which is proportional to mean telomere length as determined by 
Southern blotting (Cawthon, 2002; Gil and Coetzer, 2004).  
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FIGURE 2.1 Figures on the left show the amplification curves generated from the Lightcycler 
software for the telomere and 36B4 standard curves respectively. The quantity of DNA used 
to generate the curves ranged from 200ng to 5ng. The amplification curve on the far left 
corresponds to 200ng and the curve on the far right corresponds to 5ng of DNA in the 
telomere and 36B4 amplification curves respectively. Figures on the right are a plot of Ct 
versus log concentration for the telomere and 36B4 dilution series respectively. These figures 
indicate that there is a strong linear relationship between DNA concentration and the PCR 
cycles required to reach threshold levels of fluorescence (Ct). 
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FIGURE 2.2 Melting curves and peaks for the 36B4 PCR reaction. 
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2.3.4 Statistical analysis: All tests were carried out on log-transformed T/S crossing 
point ratios, as they were not normally distributed. A Student’s unpaired t-test was used for 
unadjusted comparisons and bivariate relationships were identified from a Pearson’s 
correlation. Multivariate regression analysis was performed to assess independent 
relationships. Statistical analysis was conducted using SAS software, version 9.1 (SAS 
Institute Inc., Cary, NC, USA). Data are represented as mean±standard deviation (SD). 
 
2.4 RESULTS 
2.4.1 Participant characteristics: TABLE 2.2 shows the characteristics of the IDC and 
control groups. The control group was younger than the IDC group. The proportion of 
females, the proportion that smoked regularly and the proportion that consumed alcohol was 
greater in the control group as compared to the IDC group. The mean BMI and blood 
pressures were similar between the groups.  
2.4.2 Relationships between average relative leukocyte telomere length and 
participant characteristics: There was a negative bivariate relationship between T/S ratio and 
age in both the IDC and control groups (TABLE 2.3). Although the T/S ratio was not affected 
by smoking or alcohol consumption in control participants, the T/S ratio was decreased in 
patients with IDC who regularly smoked or consumed alcohol. No relationships between the 
T/S ratio and sex, BMI, or blood pressure were noted. 
2.4.3 Relationships between average relative leukocyte telomere length and IDC: 
The median (interquartile range) for the non log-transformed T/S ratios were 1.18 (0.95 to 
1.50) for the control group and 1.12 (0.89 to 1.40) for the IDC group. TABLE 2.4 shows the 
unadjusted and multivariate adjusted average relative leukocyte telomere lengths in 
participants with IDC as compared to controls. The mean T/S ratio in the IDC group did not 
differ from that of the control group either before or after adjustments. 
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TABLE 2.2 Characteristics of patients with idiopathic dilated cardiomyopathy (IDC) and 
control participants. 
 Controls (n=227) IDC (n=223) p value 
Age (years) 39.9 ± 15.4  51.1 ± 11.3 <0.0001* 
% Female 49 37 0.007* 
Regular alcohol consumption (%) 35 14 <0.0001* 
Regular smoking (%) 32 17 <0.0001* 
Body mass index (kg.m
-
²) 24.3±4.9 25.0±4.4 0.13 
Systolic blood pressure (mm Hg) 121±15 118±20 0.17 
Diastolic blood pressure (mm Hg) 78±8 77±13 0.28 
LVEF (echocardiography) (%) - 24.8±7.5  
LVEF (MUGA) (%) - 26.1±10.6 (n = 219)  
LVEDD (mm) - 66.7±7.1   
 
LVEF, left ventricular ejection fraction determined using echocardiography or multiple gated 
equilibrium cardiac blood pool scintigraphic techniques (MUGA); LVEDD, left ventricular 
end-diastolic diameter. Values are represented as mean±SD or percentage; *p<0.05 versus 
IDC and control groups. 
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TABLE 2.3 Relationship between relative leukocyte telomere length (log T/S) and risk factors for cardiovascular disease in control participants 
and in patients with idiopathic dilated cardiomyopathy. 
 
r, correlation coefficient; CI, confidence interval; M, male; F, female. *p<0.05;** Student’s t-test. 
 Controls (n=227)  Idiopathic dilated cardiomyopathy (n=223) 
 Pearson's r 95% CI p value  Pearson's r 95% CI p value 
Age  -0.14 -0.27 to -0.01 0.03*  -0.23 -0.35 to -0.10 0.0007* 
Body mass index -0.06 -0.19 to 0.08 0.41  -0.03 -0.18 to 0.12 0.71 
Systolic blood pressure -0.08 -0.20 to 0.06 0.26  -0.11 -0.23 to 0.03 0.11 
Diastolic blood pressure -0.06 -0.19 to 0.08 0.41  -0.07 -0.20 to 0.06 0.29 
        
      Mean±SD  log T/S p value**       Mean±SD  log T/S p value** 
Gender M= 0.074±0.196     F= 0.093±0.173 0.43  M= 0.043±0.158     F= 0.083±0.165     0.07 
Regular alcohol Yes= 0.079±0.211  No= 0.086±0.173 0.82  Yes= 0.005±0.139 No= 0.068±0.164 0.032* 
Regular smoking  Yes= 0.085±0.187  No= 0.083±0.185 0.93  Yes=-0.014±0.131  No= 0.066±0.163     0.021* 
IDC AND TELOMERE LENGTH Page 49 
TABLE 2.4 Comparison of unadjusted and multivariate adjusted average relative leukocyte 
telomere length (log T/S, mean±SD) between patients with idiopathic dilated cardiomyopathy 
and control participants. 
 
* regular alcohol consumption and regular smoking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Controls (n=227) IDC (n=223) p value 
Unadjusted 0.084±0.173 0.058±0.173 0.11 
Age- and sex-adjusted 0.070±0.179 0.071±0.179 0.95 
Age-, sex- and risk factor*-adjusted   0.071±0.187 0.071±0.187 0.99 
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2.4.4 Relationships between average relative leukocyte telomere length and the 
severity of IDC: FIGURE 2.3 shows the bivariate relations between T/S ratios and LV 
dimensions or pump function. TABLE 2.5 gives the multivariate adjusted correlation 
coefficients between T/S ratios and LVEDD (echocardiography) and LVEF 
(echocardiography and MUGA) in the IDC group. There was no association between T/S and 
indices of LV dilatation or pump dysfunction in patients with IDC and heart failure. 
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FIGURE 2.3 Bivariate relationships between average relative leukocyte telomere length (log 
T/S) and left ventricular end-diastolic diameter (LVEDD) (lower panel) or left ventricular 
ejection fraction (LVEF) (echocardiography (ECHO) (upper left panel) and multiple gated 
acquisition scan (MUGA) (upper right panel)) in patients with idiopathic dilated 
cardiomyopathy. 
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TABLE 2.5 Multivariate adjusted relations between average relative leukocyte telomere length 
(log T/S) and left ventricular (LV) end diastolic diameter and ejection fraction (EF) in 
patients with idiopathic dilated cardiomyopathy (n=223). Bivariate relationships are shown in 
FIGURE 2.3. 
 
r, correlation coefficient; CI, confidence interval; Multiple gated equilibrium cardiac blood 
pool scintigraphic scan (MUGA), left ventricular ejection fraction (LVEF).*regular alcohol 
consumption and regular smoking. 
 
 
 
 
Log T/S versus Partial r 95% CI p value  
LV end diastolic diameter:       
Age- and sex-adjusted 0.052 -0.084 to 0.185 0.46 
Age-, sex- and risk factor*-adjusted 0.043 -0.093 to 0.178 0.53 
    
LVEF (echocardiography):    
Age- and sex-adjusted -0.048 -0.182 to 0.087 0.49 
Age-, sex- and risk factor*-adjusted -0.036 -0.171 to 0.099 0.60 
    
LVEF (MUGA): (n=219)    
Age- and sex-adjusted 0.010 -0.123 to 0.143 0.88 
Age-, sex- and risk factor*-adjusted -0.008 -0.141 to 0.126 0.91 
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2.5 DISCUSSION  
The main findings of this chapter of my thesis are as follows: In a group of black 
African ancestry, IDC is not associated with average relative leukocyte telomere length. 
Furthermore, average telomere length is not related to the severity of pump dysfunction 
(MUGA and echocardiographic EF) and chamber dilatation (LVEDD) in patients with 
mainly NYHA functional class II-III heart failure (86.5%) and IDC. 
Whilst prior studies have largely been conducted in ischaemic heart disease (Starr et 
al., 2007; van der Harst et al., 2007; Weischer et al., 2012), the present study is the first to 
assess the relationship between average leukocyte telomere length and IDC or the severity of  
pump dysfunction and chamber dilatation in patients with IDC and heart failure. In this 
regard, the usual risk factors for atheroma formation, which may themselves be causally 
related to telomere shortening (Fitzpatrick et al., 2007; Valdes et al., 2005), and are 
associated with ischaemic heart disease, are not characteristic of IDC. Hence, by studying 
relationships between average telomere length and IDC or its severity, the impact of these 
risk factors on average telomere length can be separated from alternative potential 
determinants of telomere length and heart failure. As the present study indicates that average 
telomere shortening, at least in leukocytes, is not associated with IDC or its severity, these 
data therefore suggest that previously described associations between average leukocyte 
telomere length and ischaemic heart disease, its severity and its outcomes (Starr et al., 2007; 
van der Harst et al., 2007; van der Harst et al., 2010; Weischer et al., 2012), may be by virtue 
of associations with coronary artery disease (Brouilette et al., 2003; Ogami et al., 2004) or its 
risk factors (Fitzpatrick et al., 2007; Valdes et al., 2005). 
Although a prior study has demonstrated a relationship between average leukocyte 
telomere length and non-ischaemic heart disease, in that study 22% of the non-ischaemic 
group of patients had advanced atheromatous disease as indexed by a history of stroke, 
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peripheral arterial disease or angina pectoris (van der Harst et al., 2007). In that study 
telomere length was strongly associated with atherosclerotic disease (van der Harst et al., 
2007). Furthermore, the causes of heart failure in the remaining non-ischaemic patients were 
not stated (van der Harst et al., 2007). In contrast, in the present study I evaluated 
relationships between average leukocyte telomere length and IDC, a specific cause of heart 
failure, where patients with co-morbid conditions consistent with advanced atheroma were 
excluded. It is therefore possible that inconsistencies between this prior study (van der Harst 
et al., 2007), and the present study may be attributed to differences in the disease profiles of 
the patient groups. Importantly, a similar proportion of patients with NYHA functional class 
II-III heart failure of non-ischaemic aetiology was evaluated in the present (86.5%) as 
compared to this prior (99%) (van der Harst et al., 2007) study. Thus, it is unlikely that 
differences in the severity of heart failure contributed toward the discrepant outcomes 
between the present and this prior study (van der Harst et al., 2007). Nevertheless, the present 
study was conducted in participants of black African ancestry, whilst the prior study was 
conducted in Caucasians (van der Harst et al., 2007). In this regard, telomere length has a 
high inter-individual variability; and hence a cross-sectional determination of telomere length 
at one specific time point may not accurately reflect long-term telomere length dynamics in 
individuals (Nordfjäll et al., 2009). It is possible that in groups of African ancestry a greater 
inter-individual variability of telomere length exists thus reducing the chances of 
demonstrating relationships in cross-sectional studies. Whether the results of the present 
study can be reproduced in alternative population samples therefore warrants further 
investigation. 
The results of this chapter do not discount an important contribution of cardiomyocyte 
telomere attrition or dysfunction to the pathogenesis of heart failure. In this regard, leukocyte 
telomere length may not closely represent the extent of telomere attrition that occurs in 
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cardiomyocytes. Indeed, cardiomyocyte telomere attrition or dysfunction is associated with 
cardiomyocyte apoptosis, cell death and premature senescence in human heart failure 
(Chimenti et al., 2003; Oh et al., 2003) and with repression of mitochondrial biogenesis and 
performance (Sahin et al., 2011). Importantly, genetic knockout of the telomerase enzyme in 
mice is associated with telomere attrition and the development of overt heart failure in 
subsequent generations (Leri  et al., 2003). Moreover, the length of the shortest telomere in a 
particular population of cells rather than average telomere length of a population of 
leukocytes, as studied in the present and in prior (Starr et al., 2007; van der Harst et al., 2007; 
Weischer et al., 2012)studies, determines cellular function (Hemann et al., 2001). Thus, 
average relative telomere length may not closely reflect the impact of telomeres on cellular 
performance. 
The previously described relationships between average leukocyte telomere length 
and ischaemic heart disease (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 
2012) may also be attributed to the impact of heart failure on oxidative stress and 
inflammation, both of which are associated with shortened telomeres (Houben et al., 2008; 
Beyne-Rauzy et al., 2004). Although in the present study I did not assess relationships 
between leukocyte telomere length and either oxidative stress or inflammation, IDC has 
previously been shown to be associated with both of these pathophysiological processes 
(Sliwa et al., 1998; Yücel et al., 1998). Thus, I assume that in the present study, these two 
mechanisms for progressive heart failure are likely to play a role. The lack of relationship 
between average leukocyte telomere length and either IDC or its severity in the present study 
therefore suggests that the previously described relationships between average leukocyte 
telomere length and heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer et 
al., 2012) are unlikely to be explained by an impact of oxidative stress and inflammation on 
telomere length. However, the possibility that the duration of heart failure in the patients in 
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the present study was too short for either of these mechanisms to cause significant telomere 
attrition should also be considered. Prospective intervention studies evaluating the impact of 
therapy in heart failure over a prolonged period are required to address this question. 
In terms of study limitations, firstly, this is a cross-sectional study which does not 
allow for the elucidation of conclusions regarding cause and effect. In addition, the cross-
sectional design may in-part explain the inability to show relationships between average 
leukocyte telomere length and left ventricular function and dimensions. In this regard, left 
ventricular function and dimensions were evaluated at different times in the development of 
the disease. Moreover, as highlighted in the aforementioned discussion, telomere length has a 
high inter-individual variability; and hence a cross-sectional determination of telomere length 
at one specific time point does not accurately reflect long-term telomere length dynamics of 
individuals (Nordfjäll et al., 2009). These arguments nevertheless do not detract from the fact 
that if average leukocyte telomere length did herald a pathophysiological change that causes 
IDC, we should have been able to show a decreased average leukocyte telomere length in 
patients with IDC irrespective of the point in the progression of the disease at the time of 
recruitment. Second, it may be argued that the point at which a diagnosis of heart failure in 
IDC is made is the end-stage of the disease and hence the range of LV diameters or EF values 
would be too narrow to show relations between telomere length and LV function or 
dimensions. However, examination of the bivariate relations shown in the figure indicates 
that a wide range of LV dimensions and EF values were obtained. Third, as highlighted in the 
aforementioned discussion, we did not assess the relationships between average leukocyte 
telomere length and indexes of oxidative stress or inflammation. Hence, it is possible that 
leukocyte telomere length could be related to these parameters in heart failure, but that this 
does not translate into relationships with the severity of LV dysfunction or dilatation. Last, as 
also indicated in the aforementioned discussion we assessed the relationship between average 
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leukocyte telomere length and IDC in one ethnic group only (black African). Hence, further 
studies are required to determine whether a lack of relationship exists between average 
leukocyte telomere length and IDC in other ethnic groups. 
In conclusion, the present study shows that average relative leukocyte telomere length 
is not associated with IDC or the severity of IDC in groups of black African ancestry. Thus, 
previously described relationships between average leukocyte telomere length and largely 
ischaemic heart disease (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 2012), 
may represent an epiphenomenon attributed to the co-existence of coronary artery disease and 
its risk factors (Brouilette et al., 2003; Fitzpatrick et al., 2007; Ogami et al., 2004; Valdes et 
al., 2005), which themselves are related to telomere attrition. Further prospective studies in 
IDC are required to validate the results of the present cross-sectional study. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
CHAPTER 3 - CARDIAC REMODELLING, 
SYSTOLIC DYSFUNCTION, AND TELOMERE 
LENGTH 
 
Data from this chapter have been submitted for review in: International Journal of 
Cardiology. 
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3.1 ABSTRACT 
Aims: In order to further explore whether telomere shortening is a cause of cardiac 
remodelling and systolic dysfunction, the relationships between telomere length and an 
animal model of alcoholic cardiomyopathy (a form of dilated cardiomyopathy) were 
investigated. Methods and Results: Sprague-Dawley (SD) rats received either drinking water 
with (ethanol: n=19) or without (control: n=19) 5% (v/v) ethanol ad libitum, for four months. 
Echocardiography was performed to determine LV dimensions and function in vivo and 
isolated perfused heart preparations (ethanol: n=10; control: n=10) were performed to obtain 
ex vivo load independent measurements of LV chamber geometry and function. Ethanol 
consumption resulted in LV dilatation (LVEDD: ethanol=8.20±0.14mm vs. 
control=7.56±0.11mm, p=0.0014; the volume intercept at 0 mmHg (V0) of the left ventricular 
end diastolic pressure-volume relationship: ethanol=0.40±0.03ml vs. control=0.31±0.02ml, 
p=0.020), and a reduced LV relative wall thickness (ethanol=0.50±0.08mm vs. 
control=0.60±0.092mm, p=0.0011). However, there were no changes in systolic chamber 
function as indexed by endocardial fractional shortening (FSend) or the slope of the LV 
systolic pressure-volume relation (end systolic elastance-Ees). Ethanol administration resulted 
in a marked increase in cardiomyocyte apoptosis (ethanol=0.85±0.13% vs. 
control=0.36±0.06%, p=0.0021). Furthermore, % apoptosis was correlated with LVEDD 
(r=0.39, n=38, p=0.021) and V0 (r=0.44, n=19, p=0.046). However, no significant differences 
in leukocyte, cardiac, liver, or kidney telomere length were noted between ethanol and 
control groups. In addition, cardiac telomere length was not associated with indices of LV 
dilatation (LVEDD and V0) or apoptosis. Conclusions: In conclusion, chronic alcohol-
induced cardiac remodelling and apoptosis in the absence of systolic dysfunction are 
independent of changes in telomere length. 
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3.2 INTRODUCTION  
Having shown that average relative leukocyte telomere length was not associated with 
the presence or severity of a non-ischaemic cardiomyopathy (Raymond et al., 2013), there is 
a need to establish the cause and effect relationships between reduced telomere length and 
heart failure. In this regard, in order to further explore whether telomere shortening is a cause 
of cardiac remodelling and systolic dysfunction, I investigated the relationships between 
telomere length and cardiac remodelling and systolic dysfunction in an animal model of 
alcoholic cardiomyopathy. 
Chronic, excessive alcohol consumption is a leading cause of non-ischaemic, dilated 
cardiomyopathy (Piano, 2002). Ninety grams of ethanol per day for approximately five years 
is known to result in a alcoholic cardiomyopathy, which is characterised by LV dilatation, 
hypertrophy, myocardial wall thinning, and ventricular dysfunction (Capasso et al., 1991; 
Capasso et al., 1992; Doser et al., 2009; Piano, 2002; Ren and Brown, 2000; Urbano-
Marquez et al., 1989; Zhang et al., 2010). Importantly, all of these changes are produced in 
the absence of coronary artery disease (Piano, 2002). An alcoholic cardiomyopathy is 
characterised by two stages, the asymptomatic stage where LV dilatation, hypertrophy, and 
diastolic dysfunction are common features, which eventually lead to systolic dysfunction and 
heart failure in the symptomatic stage (Piano, 2002). Chronic alcohol consumption may 
produce reduced systolic function as a consequence of intracellular organelle dysfunction, 
alterations in contractile proteins, disruption of calcium homeostasis, and cardiomyocyte loss 
(George and Figueredo, 2011; Laonigro et al., 2009). Importantly, with respect to 
cardiomyocyte loss, there is significant evidence demonstrating that cardiomyocyte apoptosis 
may be a fundamental change with chronic alcohol consumption (Fernández-Solà et al., 
2006; Guan et al., 2004; Hajnóczky et al., 2005; Jing et al., 2012). Furthermore, an alcoholic 
cardiomyopathy is associated with mitochondrial dysfunction (Hajnóczky et al., 2005) and 
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oxidative stress (Guo and Ren, 2010; Jing et al., 2012; Kalaz et al., 2012). Thus, chronic 
ethanol consumption is associated with prominent features of telomere attrition such as 
oxidative stress (Houben et al., 2008), mitochondrial dysfunction (Sahin et al., 2011), and 
apoptosis (Artandi and Attardi, 2005). Hence, telomere attrition may be associated with the 
pathophysiological processes present in an alcoholic cardiomyopathy. Therefore, in the 
present study I investigated the relationship between telomere length and adverse LV 
remodelling in a animal model of chronic alcohol consumption.  
 
3.3 METHODS 
3.3.1 Animal model: This study was approved by the Animal Ethics Screening 
Committee of the University of the Witwatersrand (ethics number: 2011/18/05). Thirty eight 
male Sprague-Dawley (SD) rats at 3 months of age were studied. The experimental group 
(n=19) received drinking water with 5% (v/v) ethanol, whilst the control group (n=19) 
received normal water for a 4 month period. No pair-feeding was performed and no micro or 
macronutrient supplementation was provided as a previous study has demonstrated that 5% 
v/v ethanol in drinking water has no effect on food or fluid intake (Segel et al., 1975), but is 
still capable of producing changes in the myocardium. Indeed, in the present study, as 
assessed over a 7 day period, neither food intake (ethanol group=24.6g.day
-1
  vs. 
control=23.9g.day
-1
) nor fluid intake (ethanol group= 39.1ml.day
-1
 vs. control= 42.8ml.day
-1
) 
differed between the groups. Importantly, in the present study the experimental rats 
consumed on average 2.4±0.3g ethanol.kg body weight
-1
.day
-1
. This is approximately the 
average ethanol intake known to produce an alcoholic cardiomyopathy in humans (>90g 
ethanol per day, or assuming an average body weight of 70 kg, 1.29 g ethanol.kg body 
weight
-1
.day
-1
) (Piano, 2002). 
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3.3.2 Echocardiography: To determine in vivo LV internal dimensions and function, 
echocardiography measurements were performed on all of the rats from the experimental and 
control groups (Woodiwiss et al., 2001). Fifteen minutes after intraperitoneal injections of 
ketamine (75 mg.kg
-1
) and xylazine (15mg.kg
-1
) to anaesthetise animals, the chest area was 
shaved. A high resolution 7.5-MHz linear array transducer attached to an Acuson Cyprus 
echocardiograph machine (Siemens AG, Munich, Germany) was used to obtain two-
dimensional guided M-mode images (FIGURE 3.1) of the left ventricle at the level of the 
papillary muscles. Measurements were taken from three consecutive beats. All left 
ventricular dimensions were determined using the American Society for Echocardiography’s 
leading edge method (Sahn et al., 1978). All echocardiographic measurements were 
performed by the same experienced investigator who was blinded to the designation of 
animals to experimental or control groups.   
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FIGURE 3.1 Accuson Cyprus echocardiograph machine and the high resolution 7.5-MHz 
linear array transducer (upper panel) employed to obtain echocardiography measurements 
from rats. A representative 2D M-mode image of the left ventricle obtained via 
echocardiography (lower panel). LVESD, left ventricular end systolic diameter; LVEDD, left 
ventricular end diastolic diameter; PWTES, posterior wall thickness at end-systole; PWTED, 
posterior wall thickness at end-diastole. 
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With respect to adverse cardiac remodelling, LV internal dimensions at end diastole 
were used as an index of LV dilatation. Moreover, relative wall thickness (RWT) was also 
calculated, which is an index of wall thinning where left ventricular wall thickness is 
expressed relative to internal chamber dimensions, and was calculated using the following 
formula: 
RWT = (PWTED x 2)/ LVEDD 
LVEDD, left ventricular end diastolic diameter; PWTED, posterior wall thickness at end-
diastole 
With respect to systolic LV function, midwall fractional shortening (FSmid) and 
endocardial fractional shortening (FSend) are load-dependant indices of left ventricular 
intrinsic myocardial function and chamber function respectively. FSend is analogous to 
ejection fraction in that it represents the change in diameter in the left ventricle during a 
single heartbeat, thus representing the ability of the left ventricle to pump and hence chamber 
function. FSmid is a measure of intrinsic myocardial function and differs from chamber 
function in that it refers specifically to the ability of cardiomyocytes to contract. FSmid and 
FSend, were calculated using the following formulae: 
FSmid = ((LVEDD + PWTED) - (LVESD +PWTES))/ (LVEDD + PWTED) *100 
FSend = (LVEDD-LVESD)/ LVEDD *100 
LVESD, left ventricular end systolic diameter; LVEDD, left ventricular end diastolic 
diameter; PWTES, posterior wall thickness in end systole; PWTED, posterior wall thickness 
in end diastole. 
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3.3.3 Isolated, perfused heart preparations: Ten rats each from the experimental and 
control groups had ex vivo analysis of cardiac remodeling and function performed using 
Langendorff isolated, perfused heart preparations (Weber et al., 1988; Woodiwiss et al., 
2001). Langendorff preparations always took place after echocardiography. Hearts were 
removed via thoracotomy and rinsed in ice cold physiological solution (118.0mM NaCl, 4.7 
mM KCl, 2.5 mM CaCl2, 25 mM NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 10.0 mM 
glucose). The hearts were then immediately mounted onto a perfusion apparatus (FIGURE 3.2) 
and retrogradely perfused through the aorta at a constant rate with the same physiological 
solution, which was warmed to 37 °C and was saturated with 95% O2 and 5% CO2. The flow 
rate was determined volumetrically over thirty seconds and was adjusted to achieve a flow 
rate of 12ml.min
-1
.g heart weight
-1
. Platinum wire electrodes were placed on the right atrium 
and at the apex of the heart and were paced at a constant rate of 330 beats per minute.  
Left ventricular developed pressure and diastolic pressures were determined using a 
water-filled balloon-tipped cannula coupled to a Gould P50 pressure transducer that was 
inserted into the left ventricular cavity via the left atrium. The volume of the balloon was 
known, was kept constant throughout each study, and was corrected for when determining 
pressure-volume relationships. The left ventricular pressures were recorded using a Hellige 
polygraph. A micromanipulator was used to increase the volume of the water-filled balloon 
and thus left ventricular volumes until there were no further increases in left ventricular 
developed pressures (difference between systolic and diastolic pressures). This technique was 
performed to determine cardiac function under controlled heart rates, loading conditions, and 
without any interference of anaesthetic drugs. All Langendorff heart preparations were 
performed by the same experienced investigator throughout, who was blinded to the 
designation of animals to experimental and control groups.     
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FIGURE 3.2 The perfusion apparatus used for all the Langendorff heart preparations (left 
panel). The water jacket, fed from the water bath, was used to warm the physiological 
solution to 37 °C. The bubble trap ensured that no air bubbles reached the coronary 
circulation. The peristaltic pump was use to perfuse the heart with the physiological solution. 
The figure in the right panel is a close up viewillustrating the heart; platinum electrodes that 
kept heart rates constant, the water-filled balloon tipped cannula, the micro-manipulator used 
to steadily increase the volume of the balloon, and the pressure transducer used to record 
pressures in the left ventricle. 
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Left ventricular remodelling was assessed from the LV diastolic pressure-volume (P-
V) relationships, using the volume intercept at zero mmHg (V0) for comparative purposes. A 
dilated ventricle requires a greater volume of blood to fill the ventricle and cause a 
subsequent increase in LV pressure during diastole. Thus, a greater V0 is an index of a larger 
chamber cavity and by inference left ventricular dilatation. The V0 value for each animal was 
determined from the Hellige polygraph data at the point of first increase in diastolic pressure 
as the volume of the water-filled balloon (left ventricular volume) was increased.  
LV systolic chamber performance was determined from the left ventricular (LV) 
developed pressure-volume (dP-V) relationships. The LV dP-V relationship was determined 
using the Hellige polygraph data, where systolic and diastolic pressures for every increment 
in volume were measured. A load independent measure of LV systolic chamber function was 
determined from the slope of the linear portion of the LV systolic dP-V relationship (LV end 
systolic elastance-Ees). In addition, a load independent measure of intrinsic myocardial 
systolic function was assessed by constructing LV developed stress-strain relationships and 
comparing the slopes (LV systolic myocardial elastance-Een) of these relationships (Weber et 
al., 1988). LV developed stress and strain were calculated using the following equations: 
 
Stress = (1.36 P Vm)/((V + Vm)
2/3
-V
2/3
) 
 
Strain = ((V
1/3
 + (V + Vm)
1/3
)/(V0
1/3
 + (V0 + Vm)
1/3
)) - 1 
 
P, pressure; Vm, left ventricular muscle weight; V0, systolic volume intercept at zero mmHg 
(Weber et al., 1988). 
 
3.3.4 Blood sampling: Blood samples for DNA extraction were collected from the tail 
vein at monthly intervals. In order to collect blood samples, rats were placed in restrainers 
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and their tails were cleaned with a disinfectant alcohol spray. A 24 gauge JELCO intra-
venous catheter (Smith's Medical, London, United Kingdom) was used to collect blood from 
the tail vein of the rats. 200 µl of blood was collected from the open end of the catheter and 
transferred to Eppendorf tubes containing 10 µl of heparin. The Eppendorf tubes were then 
centrifuged at 8 000xg for 10 minutes to collect plasma samples. Care was taken to ensure 
that no white or red blood cells were collected with the plasma samples.  
Blood samples were also collected in heparinised tubes at the termination of the 
animals. These tubes were subsequently centrifuged in order to obtain plasma samples. All 
blood and plasma samples were stored at -80 °C until analysed. In addition, fasting blood 
samples were also collected in sodium fluoride tubes for the determination of fasting blood 
glucose concentrations using a glucose oxidase based assay, which was conducted by an 
external laboratory accredited for good laboratory procedures.  
3.3.5 Urine collection: Urine samples were collected in the morning prior to each 
monthly collection of blood samples. The collection of urine and blood samples took place on 
the same day to ensure the variables measured in each of these respective body fluids were 
temporally matched. Metabolic chambers (FIGURE3.3) were employed for the collection of 
urine. These chambers are designed for the separation and collection of urine and faeces 
respectively. 
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FIGURE 3.3 Metabolic chamber used to collect urine samples from animals. 
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Urine samples were also collected at termination. After a thoracotomy was performed 
to remove the heart, the incision for the thoracotomy was continued down the length of the 
abdomen until the bladder was exposed. Urine samples were collected directly from the 
bladder using a syringe. 
0.05% (v/v) butylated hydroxytoluene (BHT) in ethanol was added to all urine 
samples collected. BHT is an organic anti-oxidant, which prevented oxidation of urine 
samples during storage. All urine samples were stored at -80C until analysed. 
3.3.6 DNA isolation: Genomic DNA from stored whole blood was extracted using 
NucleoSpin
®
 Blood QuickPure kits (Macherey-Nagel, Dueren, Germany) as per 
manufacturer's instructions. DNA was released from leukocytes by incubating samples at 70 
°C for one hour in the lysis and Proteinase K solutions provided in the kit. Ethanol was then 
added to each sample, which alters the binding conditions and allows DNA to bind to the 
silica membrane present in the NucleoSpin
®
columns. The columns were then centrifuged at 
11 000xg for one minute to discard protein in the samples. The columns were then washed 
twice using the wash buffers provided in the kit. During the wash stages any protein that was 
present on the silica membrane was removed. The NucleoSpin
® 
columns were then placed 
into sterile 1.5 ml Eppendorf tubes, elution buffer (warmed to 70 °C) was added to each 
column, samples were incubated at room temperature for three minutes and the tubes were 
then centrifuged at 11 000xg for one minute. The elution buffer modified the binding 
conditions of the DNA in the silica membrane and ensured that the pure DNA present in the 
NucleoSpin
® 
columns was transferred to the Eppendorf tubes. 
Genomic DNA from cardiac, liver and kidney tissue samples were extracted using 
NucleoSpin
®
 Tissue kits (Macherey-Nagel, Dueren, Germany), as per manufacturer's 
instructions. Twenty five milligrams of tissue sample was homogenised using a TissueRuptor 
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homogeniser (Qiagen, Hilden, Germany) in phosphate buffered saline (PBS) (NaCL 137mM, 
KCl 2.7 mM, Na2HPO4 10mM, KH2PO4 1.8mM). Once the samples were homogenised, 
DNA was released from cells by incubating samples at 56 °C overnight in the lysis and 
Proteinase Ksolutions provided in the kit. The following day, the samples were vortexed and 
the samples were further lysed with another incubation in the lysis solution. Ethanol was then 
added to each sample to alter the binding conditions of the DNA. The samples were then 
loaded into the NucleoSpin
®
columns, which contain a silica membrane that DNA binds to. 
The columns were centrifuged at 11 000xg and all of the protein that was not bound to the 
silica membrane was discarded. The columns were then washed twice using the wash buffers 
provided in the kit to ensure that no protein was bound to the silica membrane. The 
NucleoSpin
® 
columns were then placed into sterile 1.5 ml Eppendorf tubes, and the elution 
buffer (warmed to 70°C) provided in the kit was added to each column, samples were 
incubated at room temperature for three minutes and the NucleoSpin
® 
columns were then 
centrifuged at 11 000xg for one minute. The elution buffer modified the binding conditions of 
the DNA in the silica membrane and ensured that the pure DNA present in the NucleoSpin
® 
columns were transferred to the Eppendorf tubes.  
3.3.7 Blood pressure measurement: Blood pressure in rats was determined one week 
prior to termination using a CODA non-invasive tail-cuff blood pressure system designed for 
laboratory animals (Kent Scientific Corporation, Connecticut, USA.) (FIGURE 3.4). This 
system usesvolume pressure recording (VPR). An occlusion cuff (O-cuff) inflates and 
restricts blood flow to the tail and then steadily deflates while the VPR cuff measures the 
changes in blood flow in the tail. The pressure of the O-cuff at the first instance of blood 
return to the tail corresponds to systolic blood pressure. The point at which the increase in 
blood volume to the tail ceases is the point at which diastolic blood pressure is defined. 
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FIGURE 3.4 CODA (Kent Scientific Corporation, Connecticut, USA.)non-invasive blood 
pressure system employed to record blood pressure in rats. 
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An hour prior to blood pressure measurements, a heating pad was switched on and rat 
restrainers were placed on the pad in order to ensure they were at the correct temperatures for 
blood pressure measurements. The temperature in the animal's tails required for recordings 
was approximately 30°C. Once the restrainers and room were at the appropriate temperature, 
the rats were placed into the restrainers and the O-cuff was placed as close to the base of the 
tail as possible followed by the VPR cuff. The animals were then allowed to acclimatise to 
the restrainers and cuffs for 15 minutes prior to blood pressure measurements. A cloth was 
placed over the animals to reduce stress and ensure that the temperatures remained constant. 
It was not necessary to acclimatise the animals to the restrainers prior to blood pressure 
measurements as these animals were already acclimatised to the restrainers due to the blood 
sampling that took place once a month (see Section 3.3.4). Each animal had 20 blood 
pressure measurements recorded over 10 minutes. The first 10 recordings were 
acclimatisation recordings and were not included in the data analyses.                      
3.3.8 Telomere length measurement: Relative telomere length in leukocytes, and in 
the DNA of the LV lateral wall of the myocardium, liver, and kidney tissue was determined. 
The qRT-PCR methodology employed to determine average relative telomerelength in the 
IDC study was used to determine relative telomere length in this study (see Section 2.3.3), 
with the only modification being in the single copy gene employed. The single copy gene 
used for rat DNA was pyruvate kinase, as this gene has been used as a single copy gene in 
other studies conducted in rat DNA (Walters et al., 2009; Ross-Inta et al., 2009). The PCR 
reactions were carried out using LightCycler FastStart DNA Master SYBR I Green kits. The 
thermal profile and reaction mixes were the same described for 36B4 (see Section 2.3.3) 
except for the primer sequences for pyruvate kinase (Walters et al., 2009), which were:  
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Pyruvate kinase forward primer: 5'-tgtgggtgatctggtgattgtggt-3' 
Pyruvate kinase reverse primer: 5'-aggcatttcaggatacgctcagca-3' 
 
As with the IDC study, standard curves were generated for both telomere and 
pyruvate kinase reactions (FIGURE 3.5) from a single calibrator that was serially diluted to 
produce a range of DNA quantities from 200 ng to 5 ng of DNA. The regression coefficients 
were 0.989 and 0.996 for the telomere and pyruvate kinase standard curves, respectively, and 
the coefficients of variation of the S and T assays were 0.86% and 2.09%, respectively. 
Similar to the IDC study, the standard curves for the animal studies illustrate that there was a 
strong negative linear relationship between DNA concentration and crossing point. Samples 
that fell outside the linear concentration range of the standard curves were diluted and re-run 
in order to ensure they fell within the linear range of the standard curves. 
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FIGURE 3.5 A plot of crossing point (Ct) versus log concentration for the pyruvate kinase 
(upper panel) and telomere (lower panel) standard curves respectively. The DNA dilution 
series was from 200ng to 5 ng of DNA. 
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3.3.9 Assay for C-reactive protein concentration: Plasma CRP concentrations were 
determined using a commercially available rat-specific CRP enzyme linked immuno-
adsorbent assay (ELISA) as per manufacturer's instructions (eBioscience, San Diego, USA.). 
Samples were diluted 1:10 000 prior to loading in the pre-coated 96 microwell plate and 
incubated at room temperature for two hours. The CRP present in the rat plasma samples was 
bound to the walls of the microwell plate during this incubation period. The plate was washed 
using a Thermo Labsystems original wellwash 4 (Agilent Technologies Inc., Santa Clara, 
USA) ELISA plate washer during which all substrates not bound to the microwell plate were 
removed. A rat CRP antibody that was conjugated to horseradish peroxidase was added to 
each well and incubated for a further hour. During this incubation period the rat CRP 
antibody bound to the CRP present in the wells. The plate was then washed again, allowing 
for the removal all unbound rat CRP antibody, and a 3,3’,5,5’-tetramethylbenzidine substrate 
solution was added. The tetramethylbenzidine solution reacts with the horseradish 
peroxidase, that is conjugated to the rat CRP antibody, to produce a blue colour. The intensity 
of the colour produced via thehorseradish peroxidase and tetramethylbenzidine interactions 
was proportional to the amount of CRP present in each well. This reaction was allowed to 
proceed for five to ten minutes before a stop solution provided in the kit was added. 
Absorbance readings were recorded using a Thermo Labsystems Multiskan Ascent ELISA 
plate reader (Agilent Technologies Inc., Santa Clara, USA) set at a wavelength of 570 nm. 
CRP concentrations were then determined from a standard curve, which was plotted from 
standard calibrators (66 ng.ml
-1 
to 2 ng.ml
-1
 of CRP), which were supplied with the kit. 
3.3.10 Assay to assess oxidative stress: All urine samples were purified using a solid 
phase extraction (SPE) protocol previously described (Dahl and van Breemen, 2010).Urine 
samples were thawed, vortexed, and centrifuged for 3 min at 3500xg to separate particulates 
that may be present in the urine. Three and a half millilitres of 50 mMTris–HCl buffer (pH 
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6.00, using 50 mMTris base) was added to each 0.5 ml urine sample. Then, Strata X-AW (60 
mg, 3 ml) (Phenomenex, Torrance, USA.) SPE cartridges were placed onto a vacuum 
manifold (FIGURE 3.6) and preconditioned with 2 ml of 2% formic acid in methanol followed 
by 2 ml of water. Urine samples were then added to the SPE columns, and the cartridges were 
washed sequentially with, 2 ml of water, 4 ml of 25% methanol in water, and 2 ml of 100% 
acetonitrile. After the washing sequence, the cartridges were dried under vacuum and samples 
were then eluted with three elutions of 100% methanol each of 1ml, with 15 seconds of 
vacuum drying between each elution. The methanol was then completely evaporated using 
nitrogen and 8-isoprostanes were reconstituted in Tris buffer ((HOCH2)3CNH2). 
Oxidative stress was then assessed by the measurement of 8-isoprostanes from urine 
samples using STAT-8-Isoprostane EIA kits (Cayman Chemicals, Ann Arbor, USA.) as per 
manufacturer’s instructions. This assay is based on the competition between 8-iosprostane 
and 8-isoprostane-alkaline phosphatase conjugate (tracer) for 8-isoprostane specific binding 
sites on rabbit antiserum. The concentration of the tracer remains constant in each well while 
the concentration of 8-isoprostane in the sample varies. Therefore the greater the 
concentration of 8-isoprostane contained in the sample the greater the competition for binding 
sites on rabbit antiserum. Thus the concentration of tracer that is bound to the rabbit 
antiserum is inversely proportional to 8-isoprostane concentration that is contained in the 
sample. 
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FIGURE 3.6 Vacuum manifold attached to a pump that allowed fluids to be drawn through the 
Strata X-AW (60 mg, 3 ml) solid phase extraction cartridges. 
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The 8-isoprostane calibrators provided with the kit were prepared to produce 
standards ranging from 3000 pg.ml
-1
 to 23.4 pg.ml
-1
. The 96 microwell plate was then loaded 
following the manufacturer's protocol. After all the samples and reagents were loaded, the 
plate was covered with a plastic film and incubated at room temperature for one hour on an 
orbital shaker. The plate was then washed five times using a Thermo Labsystems original 
wellwash 4 (Agilent Technologies Inc., Santa Clara, USA) ELISA plate washer and p-
nitrophenol phosphate solution provided in the kit was added to each well and produced a 
yellow colour. The plate was subsequently covered with a plastic film and incubated at room 
temperature for an additional hour. The plate was periodically checked and when the 
absorbance values of the maximum binding wells were in the range of 0.3-1.0, the plate was 
read in a Thermo Labsystems Multiskan Ascent ELISA plate reader (Agilent Technologies 
Inc., Santa Clara, USA) at a wavelength of 417nm.  
3.3.11 Determination of cardiomyocyte apoptosis: After termination of rats, LV 
tissue was stored in 10% phosphate buffered formaldehyde. Myocardial tissue samples were 
then embedded in paraffin wax and five µm tissue sections were subsequently cut and fixed 
to microscope slides. Apoptotic cell death was determined in LV sections prepared for light 
microscopy using a non-radioactive in situ apoptotic cell death detection kit (DeadEndTM 
Colorimetric TUNEL system, Promega, Madison,WI, USA). This assay labels the ends of 
fragmented DNA in apoptotic nuclei using terminal deoxynucleotidyl transferase (rTdT) 
mediated dUTP Nick-End Labeling (TUNEL). Biotinylated nucleotides are incorporated at 
the 3'-OH ends of DNA using the TdT enzyme. Horseradish peroxidase labeled streptavidin 
is then bound to these biotinylated nucleotides, which are visualised using peroxidase 
substrate, hydrogen peroxide and diaminobenzidine. 
Briefly, the TUNEL staining procedure was as follows: slides were deparaffinised 
with two five minute incubations in 100% xylene. The tissue sections were then rehydrated 
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with immersion in graded ethanol of (100%-50%) for three minutes each. Tissue sections 
were then incubated in PBS (137 mM NaCl, 2.68 mM KCl, 1.47 mM KH2PO4, 8.1 mM 
Na2HPO4, pH = 7.4) for five minutes and then fixed to microscope slidesby immersion in 4% 
paraformaldehyde for 15 minutes. A 20 µg.ml
-1
 solution of Proteinase K was then added to 
the tissue sections and incubated for 30 minutes at room temperature in order to break down 
cell walls. The sections were then washed in PBS for five minutes and refixed to slides in 4% 
paraformaldehyde for an additional five minutes. Subsequently, the tissue sections were 
washed again in PBS for five minutes and the sections were covered with an equilibration 
buffer and incubated for 10 minutes. The rTdT reaction mix was then added and the sections 
were covered with a plastic film and incubated at 37ºC for an hour inside a humidified 
chamber to allow for labeling of fragmented DNA to occur. Labeling was stopped with a 15 
minute incubation in saline-sodium citrate (3 M NaCl,  300 mM Na3C6H5O7). The sections 
were then washed twice in PBS for 5 minutes and endogenous peroxidases were blocked with 
0.3% hydrogen peroxide for five minutes followed by another wash in PBS for five minutes. 
Horseradish-peroxidase-labeled streptavidin was then added to the sections and incubated for 
30 minutes. The sections were subsequently washed in PBS for five minutes and hydrogen 
peroxide and diaminobenzidine solutions were added to each section and developed until 
there was a light brown background in the tissue section. The slides were then rinsed in 
deionised water several times and dehydrated in graded ethanol (50%-100%). The sections 
were then incubated twice in 100% xylene for five minutes, covered in distrene 
xylene/dibutylphthalate xylene (DPX) fixative and coverslips were then placed over the 
tissue sections. Apoptotic nuclei were stained brown and visible under a microscope after 
TUNEL staining (FIGURE 3.7). Positive (DNase treated) and negative (no addition of rTdT 
enzyme) control sections were incorporated in each assay.  
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The number of apoptotic cardiomyocyte nuclei and total cardiomyocyte nuclei were 
then determined using a computer-based image acquisition system (Axiovision 3, Carl Zeiss, 
Gottingen, Germany). The total number of cardiomyocyte nuclei, visualised using 
haematoxylin and eosin staining (FIGURE 3.7), present in each slide were counted on ten 
evenly spaced fields from the apex to base using acomputer based image acquisition and 
analysis system (Osadchii et al., 2007). The degree of apoptosis was then expressed as a 
percentage of total cardiomyocyte nuclei. All data were obtained by the same investigator 
who was blinded to the designation of histology slides to experimental and control groups. 
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FIGURE 3.7 A representative image of an apoptotic nuclei stained using TUNEL staining 
(white arrow) (upper panel) and cardiomyocyte nuclei stained using haematoxylin and eosin 
staining (black arrows) (lower panel). 
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3.3.12 Statistical analysis: All statistical analyses were performed on log transformed 
T/S ratios. All analyses were conducted using a Student's paired and unpaired t-test where 
appropriate. All associations between variables were conducted using Pearson’s correlation 
coefficients. A p<0.05 was considered to be statistically significant. Data are represented as 
mean±SD or mean±SEM where indicated. 
 
3.4 RESULTS 
3.4.1 Heart weight, blood pressure, and blood parameters: TABLE 3.1 shows body 
and heart weights, blood pressures and blood parameters of rats receiving ethanol-containing 
or normal drinking water. There were no differences in body weight, whole heart weight, and 
LV weight between the rats receiving ethanol versus controls (TABLE 3.1). Similarly, no 
differences in systolic and diastolic blood pressures, plasma CRP concentrations, and fasting 
blood glucose concentrations were noted between the groups receiving ethanol versus 
controls (TABLE 3.1). 
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TABLE 3.1 The effects of 4 months of ethanol consumption on body weight, heart weight, 
blood pressure, plasma C-reactive protein concentrations, and fasting blood glucose 
concentrations in rats. 
 
 Ethanol (n=19) Control (n=19) p value 
Body weight (g) 645.6±52.4 658.5±51.2 0.45 
Whole heart weight (g) 1.56±0.19 1.62±0.20 0.34 
Left ventricular weight (g) 1.28±0.16 1.34±0.16 0.24 
Systolic blood pressure (mmHg) 130±11 137±14 0.17 
Diastolic blood pressure (mmHg) 101±12 97±10 0.23 
Plasma C-reactive protein (ng.ml
-1
) 451.7±138.1 443.7±110.2 0.85 
Fasting blood glucose (mmol.l
-1
) 13.9±1.7 13.8±2.0 0.91 
 
Values are represented as mean±SD.  
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3.4.2 Telomere length: The T/S ratios of leukocyte DNA were greater, which 
indicates longer leukocyte telomere length, in blood samples obtained at 4 months as 
compared to 1 month of the study (TABLE 3.2). This relationship was present in both the rats 
receiving ethanol and those receiving water for 4 months (TABLE 3.2). However, no 
significant differences in the T/S ratios were noted between the rats receiving ethanol or 
normal water when assessed at either the first month, or at 4 months of the study (TABLE 3.2). 
Furthermore, there was no significant difference in the change in telomere length from the 
first to the fourth month of the study between the experimental and control groups (TABLE 
3.2). Moreover, the T/S ratios in cardiac, kidney, and liver tissues, were not significantly 
different between the ethanol and control groups (TABLE 3.2). Leukocyte telomere length at 
termination (4 months) was correlated with telomere length in cardiac (Pearson's r=0.49, 
r
2
=0.24, p=0.0021), and kidney (Pearson's r=0.52, r
2
=0.27, p=0.0017), but not with telomere 
length in liver tissue (Pearson's r=0.032, r
2
=0.0010, p=0.87). Furthermore, neither indices of 
LV dilatation (LVEDD, V0), LV systolic chamber function (FSend, LV Ees) nor inflammation 
(CRP) were correlated with cardiac T/S ratios (TABLE 3.3). 
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TABLE 3.2 The effects of 4 months of ethanol consumption on relative telomere length, as 
indexed by log T/S, in leukocyte, cardiac, liver, and kidney tissues in rats. 
 
 Ethanol (n=19) Control (n=19) p value 
Leukocyte T/S month 1  -0.76±0.58 -0.79±0.51 0.87 
Leukocyte T/S month 4 -0.22±0.11* -0.19±0.10* 0.33 
Δ Leukocyte T/S from month 1 -0.38±0.85 -0.62±0.49 0.38 
Cardiac T/S -0.19±0.10 -0.15±0.089 0.29 
Liver T/S -0.21±0.11 -0.20±0.13 0.86 
Kidney T/S 
 
-0.20±0.20 -0.18±0.20 0.78 
 
Δ, percentage change in leukocyte telomere length from one month to four months. Values 
are represented as mean±SD; *p<0.05, month 4 versus month 1 leukocyte T/S.   
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TABLE 3.3 Correlations between cardiac telomere length and indices of left ventricular (LV) dilatation (the volume intercept at 0 mmHg (V0) in 
the left ventricular (LV) diastolic pressure-volume relations and LV end diastolic diameter (LVEDD)), systolic chamber function (slope of the 
systolic pressure-volume relations (LV Ees) and endocardial fractional shortening (FSend)), intrinsic myocardial function (slope of the systolic 
stress-strain relations (Een) and midwall fractional shortening (FSmid)) and inflammation (C-reactive protein (CRP)). 
 
 
 
  
 
 
 
 
 
 
r, correlation coefficient; CI, confidence interval
 
V0 LVEDD LV Ees FSend LV Een FSmid CRP (month 4) 
Ethanol 
(n=119) 
 
 
  
  
 Pearson's r -0.11 0.041 0.11 -0.35 -0.076 -0.34 -0.26 
95% CI -0.75 to 0.66 -0.43 to 0.50 -0.64 to 0.76 -0.70 to 0.13 -0.70 to 0.62 -0.71 to 0.17 -0.68 to 0.29 
p value 0.80 0.78 0.79 0.15 0.85 0.18 0.35 
  
 
  
  
 Control 
 
 
  
  
 Pearson's r 0.16 -0.0056 -0.25 -0.36 0.098 -0.52 0.015 
95% CI -0.72 to 0.52 -0.46 to 0.45 -0.76 to 0.45 -0.70 to 0.12 -0.61 to 0.72 -0.70 to 0.07 -0.48 to 0.50 
p value 0.66 0.98 0.48 0.14 0.80 0.26 0.95 
  
 
  
  
 Combined 
 
 
  
  
 Pearson's r -0.20 -0.098 -0.13 
-- 
-0.31 
-0 
0.044 -0.27 -0.011 
95% CI -0.61 to 0.32 -0.41 to 0.24 -0.57 to 0.35 -0.57 to 0.01 -0.43 to 0.50 -0.54 to 0.053 -0.35 to 0.33 
p value 0.45 0.57 0.59 0.065 0.86 0.10 0.95 
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3.4.3 LV remodelling: FIGURE 3.8 and TABLE 3.4 show the effect of chronic ethanol 
administration on indices of adverse LV remodelling. Chronic ethanol administration resulted 
in LV dilatation as illustrated by increases in LV end diastolic (FIGURE 3.8) and systolic 
diameters (TABLE 3.4), a right shift in the LV diastolic P-V relationship (FIGURE 3.8), and an 
increase in the LV V0 (FIGURE 3.8) in rats receiving ethanol as compared to the control 
group. Furthermore, chronic ethanol administration resulted in LV wall thinning as indexed 
by a decrease in LV posterior wall thickness at end-diastole and a reduction in LV relative 
wall thickness in the group receiving ethanol (TABLE3.4). 
3.4.4 LV systolic function: FIGURES 3.9 and 3.10 show the effect of chronic ethanol 
administration on LV systolic chamber (FIGURE 3.9) and intrinsic myocardial (FIGURE 3.10) 
function. Chronic ethanol administration failed to modify systolic LV chamber function as 
indexed by either the load and heart rate-dependent measure, FSend, or the load- and heart 
rate-independent measure, Ees (slope of the linear portion of the LV systolic P-V relationship) 
(FIGURE 3.9). Moreover, chronic ethanol administration failed to modify LV intrinsic 
myocardial systolic function as indexed by either the load and heart rate-dependent measure, 
FSmid, or the load- and heart rate-independent measure, En (slope of the LV systolic stress-
strain relationship) (FIGURE 3.10). 
3.4.5 Cardiomyocyte apoptosis: FIGURE 3.11 shows the effect of chronic ethanol 
administration on cardiomyocyte apoptosis as assessed using TUNEL staining and the relationships 
between cardiomyocyte apoptosis and indices of LV dilatation. Chronic ethanol administration 
resulted in an increase in the percentage of apoptotic nuclei present in cardiomyocytes (FIGURE 3.11). 
Furthermore, the percentage apoptosis was associated with both ex vivo (LV V0) and invivo (LVEDD) 
indices of LV dilatation in the groups combined (FIGURE 3.11). Pearson's correlation coefficient 
between indices of LV dilatation and apoptosis was greater in the experimental group (r=0.42) 
compared to the control group (r=0.29). Importantly, neither leukocyte, cardiac, kidney, or liver 
telomere length was associated with percentage apoptosis (TABLE 3.5).  
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FIGURE 3.8 Effect of 4-months of ethanol consumption in rats on left ventricular (LV) chamber 
dimensions or volumes as indexed by LV end diastolic diameter (LVEDD) (lower left panel), LV 
diastolic pressure-volume relations (upper panel) and the volume intercept at 0 mmHg (V0) (lower 
right panel) LV diastolic pressure. Data are represented as mean±SEM; *p<0.05 versus control. 
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TABLE 3.4 The effects of 4 months of ethanol consumption in rats on left ventricular (LV) 
dimensions. 
 
 
 
 
 
 
LVESD, left ventricular end systolic diameter; EDPWT, end diastolic posterior wall thickness; 
ESPWT, end-systolic PWT; RWT, relative wall thickness. Values are represented as 
mean±SD;*p<0.05 versus ethanol and control groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethanol (n=19) Control (n=19) p value 
LVESD (mm) 4.6±0.8 4.2±0.4 0.034* 
ESPWT (mm) 2.9±0.4 3.0±0.3 0.51 
EDPWT (mm) 2.0±0.3 2.3±0.2 0.012* 
RWT (mm) 0.5±0.08 0.6±0.09 0.0014* 
 
 
CARDIAC REMODELLING, SYSTOLIC DYSFUNCTION, AND TELOMERE LENGTH Page 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.9 Effect of 4 months of ethanol consumption in rats on left ventricular (LV) 
systolic chamber function as indexed by LV endocardial fractional shortening (FSend) (lower 
left panel), LV systolic pressure-volume relations (upper panel), and the slope of the systolic 
pressure-volume relations (LV Ees) (lower right panel). Data are represented as mean±SEM. 
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FIGURE 3.10 Effect of 4-months of ethanol consumption in rats on left ventricular (LV) 
intrinsic myocardial systolic function as indexed by LV midwall fractional shortening (FSmid) 
(lower left panel), LV systolic stress-strain relations (upper panel), and the slope of the 
systolic stress-strain relations (LV En) (lower right panel). Data are represented as 
mean±SEM. 
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FIGURE 3.11 Effect of 4-months of ethanol consumption on the mean percentage apoptotic-
to-total cardiomyocyte nuclei (% apoptosis) determined in the left ventricle (LV) (upper 
panel) and relationships between % LV apoptosis and indices of LV dilatation, namely the 
volume intercept at 0 mm Hg of the LV diastolic pressure-volume relationship (V0) (lower 
left panel) and LV end diastolic diameter (LVEDD) (lower right panel). Data are represented 
as mean±SEM; *p<0.005 versus ethanol and control groups. 
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TABLE 3.5 The relationships between leukocyte, cardiac, kidney, and liver telomere length to cardiomyocyte apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
r, correlation coefficient; CI, confidence interval 
 
 
Leukocyte Cardiac Kidney Liver 
Ethanol 
 
 
  Pearson's r -0.081 0.021 -0.19 0.42 
95% CI -0.51 to 0.39 -0.45 to 0.48 -0.61 to 0.32 -0.070 to 0.75 
p value 0.74 0.93 0.47 0.089 
  
 
  Control 
 
 
  Pearson's r 0.099 0.25 0.23 -0.048 
95% CI -0.46 to 0.60 -0.28 to 0.66 -0.34 to 0.68 -0.58 to 0.52 
p value 0.73 0.35 0.43 0.88 
  
 
  Combined 
 
 
  Pearson's r -0.068 -0.13 -0.065 0.22 
95% CI -0.39 to 0.27 -0.45 to 0.22 -0.41 to 0.30 -0.15 to 0.53 
p value 0.70 0.46 0.73 0.25 
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3.4.6 Oxidative stress: TABLE 3.6 demonstrates the 8-isoprostane concentrations 
obtained using STAT-8-Isoprostane EIA kits (Cayman Chemicals, Ann Arbor, USA) as per 
manufacturer’s instructions. Each sample was measured in duplicate at different dilutions. 
After the assay was performed and after correction for dilution factors the percentage 
difference between the samples should have been within 20%. However, after several 
attempts and after purification of all urine samples using the solid phase extraction 
purification protocol described above, the percentage difference of the samples obtained were 
not consistently within acceptable limits. The differences ranged from 280 to 0.4 % (TABLE 
3.6) versus the acceptable limits of 20 % as per manufacturers guidelines. The same technical 
issues were experienced in subsequent animal studies (Chapters 4 and 5) and hence the 
measurement of urinary 8-isoprostane concentration as a marker of oxidative stress was 
abandoned.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CARDIAC REMODELLING, SYSTOLIC DYSFUNCTION, AND TELOMERE LENGTH Page 96 
TABLE 3.6 8-isoprostane absolute and corrected concentrations determined using STAT-8-
Isoprostane EIA kits (Cayman Chemicals, Ann Arbor, USA). 
 
Sample no. Dilution 1 
Corrected concentration for 
dilution 1 (pg.ml
-1
) Dilution 2 
Corrected concentration for 
dilution 2 (pg.ml
-1
) % Difference 
1 1163.3 1163.3 2007.5 4015.0 -245.14 
2 333.5 333.5 293.1 586.2 -75.77 
3 1246.8 1246.8 2368.8 4737.6 -279.98 
4 2087.9 2087.9 3089 6178.0 -195.90 
5 655.9 655.9 331.9 663.8 -1.20 
6 346.2 346.2 175.8 351.6 -1.56 
7 1134.5 1134.5 604.5 1209.0 -6.57 
8 901.2 901.2 338.2 676.4 24.94 
9 297.1 297.1 207 414.0 -39.35 
10 955 955 648.2 1296.4 -35.75 
11 434.6 434.6 259.3 518.6 -19.33 
12 1225 1225 615 1230.0 -0.41 
13 863.9 863.9 228.6 457.2 47.08 
14 1735.7 1735.7 287.8 575.6 66.84 
15 2.6 2.6 3.2 6.4 -146.15 
16 1463.1 1463.1 1143.9 2287.8 -56.37 
17 1328.6 1328.6 1080.2 2160.4 -62.61 
18 611.5 611.5 327.3 654.6 -7.05 
19 671.8 671.8 208 416.0 38.08 
20 801.7 801.7 297.1 594.2 25.88 
21 625.8 625.8 205.2 410.4 34.42 
22 829.1 829.1 266.4 532.8 35.74 
23 291.8 291.8 220.5 441.0 -51.13 
24 512.5 512.5 233.8 467.6 8.76 
25 407.5 407.5 213.7 427.4 -4.88 
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3.5 DISCUSSION 
The main findings of the present study are as follows: Chronic (4 months) ethanol 
administration (5% v/v in the drinking water) to rats failed to reduce either leukocyte, 
cardiac, liver or kidney relative telomere length. However, ethanol induced LV dilatation as 
indexed by increases in LV end diastolic diameter (LVEDD) and an increased volume 
intercept of the LV diastolic P-V relationship (LV V0), without associated changes in LV 
systolic intrinsic myocardial (FSmid and LV Een) or chamber (FSend and LV Ees) function. 
Moreover, ethanol-induced LV dilatation was associated with marked increases in 
cardiomyocyte apoptosis as determined from TUNEL positive nuclei, with strong 
correlations noted between the extent of apoptosis and indices of LV dilatation (LVEDD and 
LV V0). Cardiac telomere length was not correlated to indices of LV dilatation, systolic 
function or cardiomyocyte apoptosis. 
The present investigation is the first to assess the relationship between telomere length 
in an animal model of alcoholic cardiomyopathy. In the present investigation after four 
months of chronic ethanol intake no significant differences in leukocyte, cardiac, liver or 
kidney relative telomere length were noted between the ethanol and control groups. Hence, in 
a animal model of chronic ethanol intake, that produced changes similar to those seen in an 
asymptomatic human alcoholic cardiomyopathy, reduced telomere length was not associated 
with the pathophysiological processes involved in LV dilatation and cardiomyocyte 
apoptosis. These results suggest that telomere length does not have a causal role in an 
alcoholic cardiomyopathy and further demonstrate that reduced telomere length may not be 
associated with all types of cardiomyopathies. 
The failure of chronic ethanol consumption to produced changes in telomere length 
may be due to the absence of inflammatory processes in the current study. Inflammation is a 
prominent feature of heart failure (Yndestad et al., 2006) and is also known to increase 
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telomere attrition (Beyne-Rauzy et al., 2005; Houben et al., 2008). With respect to 
inflammation in this study, no significant differences in CRP concentrations were noted 
between the ethanol and control groups. Hence, the failure of chronic ethanol consumption to 
increase telomere attrition, despite producing marked LV dilatation and increased 
cardiomyocyte apoptosis, may be due to the absence of inflammatory processes.  
Consistent with the present findings, a number of prior studies have demonstrated LV 
dilatation (Kim et al., 2001 ; Kim et al., 2003; Law et al., 2012; Lazarević et al., 2000; 
Mathews et al., 1981) and cardiomyocyte apoptosis (Fernández-Solà et al., 2006; Guan et al., 
2004; Hajnóczky et al., 2005; Jing et al., 2012) following ethanol consumption. However, 
previous studies have not demonstrated that cardiomyocyte apoptosis is associated with 
indices of LV dilatation in a rat model of chronic ethanol intake. These data therefore suggest 
a possible causal role for cardiomyocyte apoptosis in the adverse chamber remodelling 
produced by chronic ethanol consumption. In this regard, ethanol consumption is known to 
result in increased oxidative stress (Guo and Ren, 2010; Jing et al., 2012; Kalaz et al., 2012) 
that is possibly responsible for ethanol-induced cardiomyocyte apoptosis (Jing et al., 2012). 
Ethanol consumption may precipitate increases in oxidative stress through the production of 
the metabolite, acetaldehyde, which results in the formation of free radicals and reduced 
efficacy of the anti-oxidant defence system (Guo and Ren, 2010). Ethanol-induced oxidative 
stress may activate cardiomyocyte apoptosis through adverse actions on mitochondria (Guan 
et al., 2004; Hajnóczky et al., 2005). The increased apoptosis, oxidative stress and 
mitochondrial dysfunction produced by ethanol consumption may have an important causal 
role in initiating adverse LV remodelling present in the early stages of an alcoholic 
cardiomyopathy. Importantly, neither percent apoptosis nor indices of LV dilatation were 
associated with relative telomere length in any tissue type. These data indicate that 
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cardiomyocyte apoptosis possibly has a causal role in the LV dilatation produced by chronic 
ethanol intake, but that these changes are independent of telomere attrition.   
An observation that requires further discussion is that leukocyte telomere length 
increased from one to four months in both experimental and control groups in this study. 
These findings have, however, been demonstrated previously. In this regard, longitudinal data 
in human and animal studies, noted that leukocyte telomere length is variable and may 
increase, remain the same, or decrease in length over time (Aviv et al., 2009; Ilmonen et al., 
2008; Nordfjäll et al., 2009). Moreover, it has been noted that telomere attrition was highly 
associated with baseline telomere length (Aviv et al., 2009). Thus, a major factor with respect 
to the maintenance of telomere length may be initial telomere length itself (Aviv et al., 2009). 
In this regard, there was no significant difference in leukocyte telomere length at 1 month 
between the ethanol and control groups and subsequently both groups had an increase in 
leukocyte telomere length from 1 month to 4 months after their respective treatments. Hence, 
one can conclude that chronic ethanol intake did not increase leukocyte telomere attrition, but 
more importantly that ethanol did not alter normal leukocyte telomere length maintenance in 
the ethanol group when compared to the control group.       
The results of the present study do not exclude a contribution of cardiomyocyte 
telomere dysfunction to the pathogenesis of ethanol-induced LV dilatation. In this regard, the 
length of the shortest telomere in a particular population of cells rather than average telomere 
length, as evaluated in this study, determines cellular function (Hemann et al., 2001). Thus, 
average relative telomere length may not closely reflect the impact of telomeres on cellular 
performance. Further studies are required to evaluate whether ethanol reduces the length of 
the shortest telomere. 
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In terms of study limitations, firstly, cardiac telomere length may not have been 
reduced in the ethanol compared to the water group due to the fact that, at this four month 
time point, all of the cardiomyocytes with critically short telomere length may have already 
undergone apoptosis. However, there is evidence demonstrating that average cardiomyocyte 
telomere length is reduced in diseased heart tissue even where there is an increase in 
cardiomyocyte apoptosis (Chimenti et al., 2003). Hence, the inability of ethanol to decrease 
telomere length in cardiac tissue is not due to the fact that all of the cardiomyocytes with 
critically short telomere length had already undergone apoptosis. Secondly, no measurements 
of myocardial oxidative stress were available and as such it is not known if the dose of 
ethanol employed in this study was sufficient to cause an increase in oxidative stress. In this 
regard, it remains uncertain whether the absence of a relationship between reduced telomere 
length,ethanol-induced dilatation and cardiomyocyte apoptosis in this model of alcoholic 
cardiomyopathy is independent of increased oxidative stress. Thirdly, TUNEL staining was 
employed to determine cardiomyocyte apoptosis and this approach has well recognised 
caveats (Kang and Izumo, 2000). In this regard, an increase in TUNEL stained nuclei may 
reflect either apoptotic cell death or DNA repair. However, either change would reflect 
excessive cardiomyocyte tissue damage produced by alcohol administration and hence 
indicates a pathological change. Fourthly, no markers for oxidative stress were measured. 
However, if oxidative stress was assumed to be increased in the present study, based on 
previous findings in an alcoholic cardiomyopathy (Jing et al., 2012; Kalaz et al., 2012; Guo 
and Ren, 2010), then one could argue that oxidative stress did not increase telomere attrition 
in leukocyte, cardiac, liver, and kidney tissues in a rat model of chronic ethanol excess. This 
possibility is supported by previous findings demonstrating that increased oxidative stress did 
not increase telomere attrition in heart, liver and kidney tissues (Cattan et al., 2008). Hence, 
the failure of ethanol-induced oxidative stress to increase telomere attrition may be due to the 
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fact that not all tissue types are susceptible to oxidative stress-induced telomere attrition. 
Importantly, the inability to measure oxidative stress does not discount the findings that 
reduced telomere length is not associated with ethanol-induced LV dilatation and 
cardiomyocyte apoptosis. 
In conclusion, ethanol intake in rats in amounts (2.4±0.3g ethanol.kg body weight
-
1
.day
-1
) that correspond with the minimum daily intake known to produce an alcoholic 
cardiomyopathy (>90g.day
-1
 or >1.29 g.kg
-1
 body weight per day assuming an average 70 kg 
male) (Piano, 2002) resulted in LV dilatation and cardiomyocyte damage that was 
independent of changes in telomere length. Importantly, the extent of cardiomyocyte 
apoptosis was correlated with indices of LV dilatation but neither apoptosis nor LV dilatation 
were associated with telomere length. Hence, cardiomyocyte apoptosis may play a causal role 
in the ethanol-induced LV dilatation, but these changes are independent of changes in cardiac 
telomere length. Furthermore, these data provide further evidence to demonstrate that 
reduced telomere length may not be associated with all forms of heart failure, including an 
ethanol-induced cardiomyopathy.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 4 - CHRONIC β-ADRENERGIC 
RECEPTOR ACTIVATION AND TELOMERE 
LENGTH 
 
The data in this chapter has been accepted for publication in the European Journal of Applied 
Physiology: Raymond AR, Hodson B, Woodiwiss AJ, Norton GR,Brooksbank RL. Telomere 
Length and Adrenergic-Induced Left Ventricular Dilatation and Systolic Chamber 
Decompensation in Rats. Eur J Appl Physiol 2013 (publication in press). 
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4.1ABSTRACT 
Aims: The mechanisms responsible for telomere shortening in chronic heart failure, 
are uncertain. We evaluated whether left ventricular (LV) dilatation and systolic chamber 
decompensation produced by chronic β-adrenergic receptor (β-AR) stimulation is associated 
with leukocyte or cardiac telomere shortening. Methods and Results: Following 6 months of 
daily injections of the β-AR agonist, isoproterenol (0.02 mg.kg-1.day-1) (n=16), or the saline 
vehicle (n=15) to SD rats, the extent of LV dilatation and LV systolic chamber 
decompensation were determined using echocardiography and isolated perfused heart 
procedures, and relative telomere length of leukocyte and cardiac  DNA was determined 
using a quantitative real-time polymerase chain reaction assay. Chronic β-AR stimulation 
resulted in LV dilatation as indexed by an increased LV diastolic diameter (9.2±0.6mm vs. 
8.4±0.9mm, p=0.01), and an increased volume intercept at zero pressure of the LV diastolic 
pressure-volume relationship (isolated, perfused heart preparation) (0.40±0.06ml vs. 
0.37±0.08ml, p=0.03). Moreover, chronic β-AR stimulation resulted in LV systolic chamber 
decompensation as indexed by reductions in LV endocardial fractional shortening (0.40±0.05 
vs. 0.60±0.06, p=0.01) and the slope of the LV systolic pressure-volume relation (609±176 
vs. 901±230, p=0.01). Although leukocyte telomere length (log T/S) decreased with age in 
rats receiving either the β-AR agonist or the saline vehicle (p<0.05), neither cardiac (-
0.10±0.14 vs. -0.15±0.12, p=0.3) nor leukocyte telomere length (-0.11±0.19 vs. -0.15±0.18, 
p=0.5) were modified by chronic β-ARstimulation. Conclusions: In conclusion, chronic β-
AR stimulation, sufficient to produce LV dilatation and systolic chamber decompensation, is 
not associated with alterations in leukocyte or cardiac telomere length. Telomere shortening 
in chronic heart failure is unlikely to be attributed to chronic β-AR stimulation. 
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4.2 INTRODUCTION 
Studies have demonstrated that reduced average leukocyte telomere length is 
associated with chronic heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer 
et al., 2012). However, the cause and effect relationships between telomere length and heart 
failure are uncertain. In this regard, whether reduced telomere length plays a role in the 
pathophysiological processes of heart failure or if telomere length is reduced in heart failure 
merely due the pathophysiological processes involving oxidative stress and inflammation is 
unknown. Hence, the relationship between telomere length and prominent features of heart 
failure need to be further investigated in order to elucidate that cause and effect relationships 
between reduced telomere length and heart failure.  
An important pathophysiological feature of progressive heart failure is stimulation of 
adrenergic receptors via activation of the sympathetic nervous system (neurohumoral 
activation) (Triposkiadis et al., 2009), a change which results in oxidative stress (Xu et al., 
2011), and inflammation (Kumar et al., 2009), and activates a cellular pathway (p53) (Zhou 
et al., 2006) that is known to mediate apoptosis associated with short telomeres (Artandi and 
Attardi, 2005; Aubert and Lansdorp, 2008). Thus, it is possible that in heart failure, chronic 
adrenergic receptor stimulation contributes toward telomere attrition. In order to test this 
hypothesis, I investigated whether left ventricular dilatation and systolic chamber 
decompensation induced by chronic adrenergic receptor stimulation in rats (Woodiwiss et al., 
2001) is associated with cardiac and/or leukocyte telomere shortening. 
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4.3 METHODS 
4.3.1 Animal model: This study was approved by the Animal Ethics Screening 
Committee of the University of the Witwatersrand (clearance number: 2010/25/04). Thirty 
one male SD rats at three months of age were assigned to receive either subcutaneous 
injections of 0.02 mg.kg
-1
 of isoproterenol (n=16), or a 0.9% saline vehicle of 0.2 ml volume 
(n=15) daily for 6 months. In an attempt to reduce animal deaths as a result of initial 
excessive adrenergic stimulation, animals received incremental doses of isoproterenol. 
During the first week rats received a 0.005 mg.kg
-1
 dose of isoproterenol in the morning and 
again in the evening. During the second week the rats received a single 0.01 mg.kg
-1
 daily 
dose of isoproterenol. During the third week rats received a 0.01 mg.kg
-1
 dose of 
isoproterenol in the morning and again in the evening. For the subsequent five months rats 
received once off daily injections of isoproterenol at a dose of 0.02 mg.kg
-1
. This protocol 
utilising a chronic low dose of isoproterenol is a well established model that is considered to 
accurately replicate the pathogenesis of human heart failure (Carll et al., 2011). 
4.3.2 Echocardiography: Echocardiography was performed as previously described 
(see Section 3.3.2) just prior to termination to determine LV chamber dimensions and 
posterior wall thickness at end-diastole and end-systole.Furthermore,load-dependant indices 
ofintrinsic myocardial function (FSmid) andleft ventricular systolic chamber function (FSend) 
were determined using echocardiography. Rats were evaluated 24 hours after receiving the 
last dose of isoproterenol. Echocardiography measurements were performed by the same 
experienced investigator who was blinded to the designation of animals to experimental and 
control groups. Immediately after echocardiography a carotid catheter was inserted to 
measure carotid pressures (Norton et al., 2002) and LV end-systolic wall stress was 
determined, assuming spherical LV geometry, from the formula: 
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LV end-systolic wall stress = LV end-systolic pressure x ((ESD + ESPWT)/ESPWT) x (1-
(ESPWT/(2x(ESD + ESPWT))) - 0.5), where end-systolic pressure was assessed from the 
carotid incisura and where ESD is end-systolic diameter and ESPWT is end-systolic posterior 
wall thickness (Norton et al., 2002; Shimizu et al., 1991). The carotid incisura was 
sufficiently obvious to identify end-systolic pressure in five out of six rats in the group 
receiving isoproterenol and four out of five rats in the group receiving the vehicle.   
4.3.3 Isolated, perfused heart preparations: Eight rats each from the experimental 
and control groups had LV dimension and function measurements determined using isolated, 
perfused heart preparations as previously described (see Section 3.3.3). Left ventricular 
diastolic remodelling was assessed from the LV diastolic pressure-volume relationships, 
using the volume intercept at zero pressure (V0) for comparative purposes, with an increased 
V0 representative of an increased LV chamber size in diastole. Left ventricular systolic 
chamber performance was determined from the slope of the linear portion of the left 
ventricular developed pressure-volume relationships (end systolic elastance-Ees). In addition, 
a load-independent measure of intrinsic myocardial systolic function was assessed by 
constructing LV developed stress-strain relations and comparing the slopes (LV end systolic 
myocardial elastance-En) of these relationships.  
4.3.4 Telomere length: DNA was extracted from leukocytes, LV lateral wall of the 
myocardium and kidney tissue using NucleoSpin
®
 Blood and Tissue kits (Macherey-Nagel, 
Dueren, Germany) respectively, as per manufacturer's instructions(see Section 3.3.6). Kidney 
telomere length was determined to evaluate whether changes in the myocardium were 
replicated in other tissues. The methodology employed to determine relative telomere length 
in leukocyte and tissue DNA was as described previously (see Sections 2.3.3 and 3.3.8). A 
standard sample was included in each amplification run and was used to standardise the entire 
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sample T/S ratios as well as to determine coefficients of variation. The coefficients of 
variation of the S and T assays were 2.10% and 4.1%, respectively.  
4.3.5 C-reactive protein concentrations: Blood samples were obtained at 1 and 6 
months of the study. CRP concentrations were determined, as previously described (see 
Section 3.3.9), using a commercially available rat-specific CRP enzyme-linked, 
immunoabsorbant kit (eBioscience, San Diego, USA.). This assay was performed without 
any modifications to manufacturer's instructions.   
4.3.6 Statistical analysis: All statistical analyses performed on telomere length were 
conducted on log transformed T/S ratios. Student's unpaired and paired t-tests were used to 
determine differences between and within groups receiving isoproterenol and saline where 
appropriate. All associations between variables were carried out using Pearson's correlation 
coefficients. A p value of less than 0.05 was considered statistically significant. All data are 
represented as mean±SD and mean±SEM where indicated. 
 
4.4 RESULTS 
4.4.1 Body and heart weight: No significant differences in body weight, whole heart 
weight, or left ventricular weight were noted between the groups receiving isoproterenol and 
saline for 6 months (TABLE 4.1). Rats receiving daily isoproterenol had an increased left 
ventricular end systolic wall stress (TABLE 4.1).  
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TABLE 4.1 Effect of 6 months of isoproterenol (ISO) versus vehicle (Control) administration 
on body weight, heart weight, and echocardiographically determined left ventricular 
dimensions in rats. 
 
LV, left ventricular; ESD, end-systolic diameter; EDPWT, end-diastolic posterior wall 
thickness; ESPWT, end-systolic posterior wall thickness; RWT, relative wall thickness; ESS, 
end-systolic wall stress. Values are represented as mean±SD; *p<0.05 versus ISO andControl 
group.  
 
 
 
 
 
 
 
 
 
  ISO (n=16) Control (n=15) p value 
Body weight (g) 628.6±48.2 676.7±111.1 =0.16 
Left ventricular weight (g) 1.24±0.40 1.2±0.1 =0.46 
Whole heart weight (g) 1.53±0.44 1.4±0.2 =0.49 
LVESD (mm) 5.5±0.8 4.7±0.9 =0.0079* 
LVESPWT (mm) 2.9±0.4 3.0±0.3 =0.36 
LVEDPWT (mm) 2.8±0.4 2.7±0.5 =0.61 
LVRWT (mm) 0.6±0.1 0.6±0.1 =0.40 
LVESS (g.cm
-2
) 135±14 (n=5) 98±24(n=4) =0.023* 
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4.4.2 Left ventricular remodelling: As assessed in vivo, chronic isoproterenol administration 
resulted in LV dilatation as indexed by increases in LV end diastolic (FIGURE 4.1) and 
systolic diameters (TABLE 4.1). There were no significant differences in the LV posterior wall 
thickness during either end-diastole or systole between the groups (TABLE 4.1). However, the 
increase in LVEDD and lack of wall thinning did not translate into decreases in RWT (TABLE 
4.1). Furthermore, as assessed ex vivo at the same heart rate, afterload and at comparable 
coronary flow rates, a right shift in the LV diastolic P-V relationship and an increase in the 
mean V0 in rats receiving chronic isoproterenol administration as compared to the saline-
treated group were noted (FIGURE 4.1).  
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FIGURE 4.1 Effect of 6 months of isoproterenol (ISO) versus vehicle (Control) as indexed by 
LV end diastolic diameter (LVEDD) (lower left panel), LV diastolic pressure-volume 
relations (upper panel) and the volume intercept at 0 mm Hg (V0) (lower right panel) LV 
diastolic pressure. Data are represented as mean±SEM; *p<0.05 versus ISO and Control 
groups. 
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4.4.3 Left ventricular systolic chamber and myocardial function: As assessed in 
vivo, the group receiving isoproterenol had a reduced systolic chamber function as indexed by 
a reduced FSend (FIGURE 4.2) compared to the control group, while there were no differences 
in the FSmid (FIGURE 4.3) between the groups. Consistent with in vivo findings, ex vivo data at 
the same heart rate, afterload and at comparable coronary flow rates, illustrated the LV 
developed P-V relationship was right shifted and mean Ees was reduced in rats receiving 
isoproterenol for 6 months as compared to control rats (FIGURE 4.2), while there were no 
shifts in LV developed stress-strain relations and mean Een (FIGURE 4.3). 
4.4.4 Telomere length: The leukocyte T/S ratios were reduced, which indicates 
shorter leukocyte telomere length, in blood samples obtained at 6 months as compared to 1 
month of the study (TABLE 4.2). This relationship was present in both the rats receiving 
isoproterenol and those receiving saline for 6 months (TABLE 4.2). However, no significant 
differences in the T/S ratios were noted between the rats receiving isoproterenol or saline 
when assessed at either the first month, or at 6 months of the study (TABLE 4.2). Furthermore, 
there was no significant difference in the percentage change in telomere length from the first 
to the sixth month of the study between groups receiving daily isoproterenol or saline (TABLE 
4.2). The T/S ratios in heart and kidney tissues, were not significantly different between 
groups receiving isoproterenol and saline groups (TABLE 4.2). Leukocyte telomere length at 
termination was not correlated with telomere length in cardiac (Pearson's r=0.21, r
2
=0.044, 
p=0.30) or kidney tissue (Pearson's r=0.21, r
2
=0.043, p=0.31). Furthermore, neither indices of 
LV dilatation (LVEDD and V0), chamber function (FSend, and Ees), nor inflammation (CRP) 
were correlated with cardiac telomere length (TABLE 4.3). 
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FIGURE 4.2 Effect of 6 months of isoproterenol (ISO) versus vehicle (Control) administration 
on left ventricular (LV) systolic chamber function as indexed by LV endocardial fractional 
shortening (FSend) (lower left panel), LV systolic pressure-volume relations (upper panel), 
and the slope of the systolic pressure-volume relations (LV Ees) (lower right panel). Data are 
represented as mean±SEM; *p<0.05 versus ISO andControl groups. 
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FIGURE 4.3 Effect of 6 months of isoproterenol (ISO) versus vehicle (Control) administration 
on left ventricular (LV) intrinsic myocardial systolic function as indexed by LV midwall 
fractional shortening (FSmid) (lower left panel), LV systolic stress-strain relations (upper 
panel), and the slope of the systolic stress-strain relations (LV En) (lower right panel). Data 
are represented as mean±SEM. 
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TABLE 4.2 Effect of 6 months of isoproterenol (ISO) versus vehicle (Control) administration 
on relative telomere length as indexed by log T/S±SD in leukocytes, myocardium and 
kidneys in rats. 
 ISO (n=16) Control (n=15) p value 
Leukocyte T/S month 1 0.15±0.010 0.11±0.12 =0.47 
Leukocyte T/S month 6 -0.11±0.19 * -0.15±0.18 * =0.50 
Δ Leukocyte T/S from month 1 -1.54±1.69 -1.74±1.49 =0.78 
Cardiac T/S -0.10±0.14 -0.15±0.12 =0.32 
Kidney T/S -0.11±0.11 -0.12±0.15 =0.83 
 
∆, percentage change in leukocyte telomere length from 1 month to 6 months. Values are 
represented as mean±SD; *p<0.05 versus month 1leukocyte T/S.  
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TABLE 4.3 Correlations between cardiac telomere length and indices of left ventricular (LV) dilatation (the volume intercept at 0 mm Hg (V0) in 
the left ventricular (LV) diastolic pressure-volume relations and LV end diastolic diameter (LVEDD)), systolic chamber function (slope of the 
systolic pressure-volume relations (LV Ees) and endocardial fractional shortening (FSend)), intrinsic myocardial function (slope of the systolic 
stress-strain relations (Een) and midwall fractional shortening (FSmid)) and inflammation (C-reactive protein (CRP)). 
 
r, correlation coefficient; CI, confidence interval 
 
V0 LVEDD LV Ees FSend Een FSmid CRP (6 months)  
Isoproterenol 
 
     
 Pearson's r -0.29 0.14 
-0.3 
-0.70 -0.32 -0.58 -0.059 
 
0.0048 
95% CI -0.83 to 0.52 -0.38 to 0.60 -0.94 to 0.01 -0.71 to 0.24 -0.91 to 0.20 -0.54 to 0.45 -0.51 to 0.52 
p value 0.49 0.60 0.054 0.25 0.13 0.93 0.98 
  
     
 Control 
 
     
 Pearson's r -0.09 
 
0.43 
- 
-0.12 -0.31 
-0.75 to 0.3 
0.28 0.27 
 
-0.26 
95% CI -0.75 to 0.66 -0.13 to 0.78 -0.76 to 0.64 -0.75 to 0.32 -0.69 to 0.89 -0.30 to 0.70 -0.69 to 0.32 
p value 0.83 0.13 0.78 0.32 0.59 0.34 0.38 
  
     
 Combined 
 
     
 Pearson's r -0.15 0.35 
- 
-0.38 -0.29 
0.70 to -+ 
-0.37 0.058 
 
-0.11 
-0.4 
95% CI -0.63 to 0.41 
0.6 
-0.01 to 0.63 
 
-0.75 to 0.17 
 
-0.60 to 0.10 -0.76 to 0.20 -0.31 to 0.41 -0.46 to 0.27 
p value 0.60 0.06 0.16 0.14 0.19 0.76 0.57 
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4.4.5 C-reactive protein: Plasma CRP concentrations were greater at 6 months as 
compared to at 1 month of the study in groups receiving either daily isoproterenol  or saline 
(FIGURE 4.4). However, no significant differences in CRP concentrations between groups 
receiving isoproterenol and saline at either the first month or at termination were noted. 
Moreover, there was no difference in the percentage change in CRP concentrations from the 
first to the sixth month of the study between rats receiving daily isoproterenol and saline 
(p=0.28). The plasma CRP concentrations at either time point for both groups receiving 
isoproterenol or saline were within normal ranges for rats. 
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FIGURE 4.4 Effect of 6 months of isoproterenol (ISO) versus vehicle (Control) administration 
on plasma C-reactive protein (CRP) concentrations from 1 month to 6 months. Values are 
represented as mean±SD; *p<0.001 versus 1 month in ISO and Control groups. 
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4.5 DISCUSSION 
Chronic (6 months) β-adrenergic receptor stimulation in rats, produced by daily 
administration of isoproterenol, despite producing LV dilatation (an increased LVEDD and 
LV V0), and LV systolic chamber dysfunction (a reduced FSend and Ees), did not increase 
either myocardial or leukocyte telomere attrition. Furthermore, no relationships between 
cardiac telomere length and indices of LV dilatation and function were noted.   
 To the best of my knowledge the results of the present study are the first to evaluate 
whether chronic β-adrenergic receptor stimulation, sufficient to produce structural and 
functional changes in the LV congruent with advanced cardiac pathology (LV systolic 
chamber dysfunction and chamber dilatation), promotes telomere shortening in either 
leukocyte or cardiac DNA. In this regard, chronic adrenergic stimulation is a well recognised 
change responsible for progressive heart failure (Triposkiadis et al., 2009), and is associated 
with an increased oxidative stress (Xu et al., 2011), and inflammation (Kumar et al., 2009) in 
cardiomyopathies, and activates a cellular pathway (p53) (Zhou et al., 2006) that is known to 
mediate apoptosis associated with short telomeres (Artandi and Attardi, 2005; Aubert and 
Lansdorp, 2008). The results of the present study therefore suggest that telomere shortening 
is not a sensitive biomarker of the adverse effects of adrenergic stimulation in heart failure. 
 The inability of chronic adrenergic stimulation to promote telomere shortening despite 
producing LV dilatation and systolic dysfunction may have several explanations. 
Inflammation may be caused by heart failure (Yndestad et al., 2006) and inflammatory 
processes may be responsible for telomere shortening in heart failure (Beyne-Rauzy et al., 
2005; Houben et al., 2008). In this regard, in the present study I was unable to show 
increased plasma CRP concentrations in rats receiving the β-adrenergic receptor stimulant 
compared to the control group. This may be explained by the absence of clinical features of 
heart failure, despite the presence of structural and functional changes in the heart. This may 
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be attributed to the dose of isoproterenol employed in this study. Previous studies have 
demonstrated that much higher doses of isoproterenol (5 mg.kg
-1
) than that employed in the 
present study (0.02 mg.kg
-1
) resulted in increased circulating concentrations of TNF-α and 
IL1-β (Kumar et al., 2009). Hence, it is possible that with a higher dose of isoproterenol, 
telomere shortening may have occurred. Importantly, however, the dose of isoproterenol 
employed in the present study produced striking changes in cardiac structure and function 
after 6 months of administration as demonstrated by indices of LV dilatation and systolic 
dysfunction. Thus, an inability of the dose of isoproterenol to promote inflammatory changes 
in the present study does not preclude me from drawing a conclusion that telomere length is 
an insensitive biomarker of adrenergic-induced LV dilatation and systolic dysfunction. 
 Telomere attrition may also occur as a consequence of oxidative stress (Houben et al., 
2008) and adrenergic-induced cardiomyopathies are associated with increases in oxidative 
stress (Xu et al., 2011). In this regard, an alternative explanation for the inability of chronic 
adrenergic stimulation to promote telomere length changes in the present study, may be due 
to the fact that the dose of isoproterenol may have been insufficient to induce oxidative stress. 
In this regard, a limitation of the present study is that we did not measure myocardial 
oxidative stress. However, in the present study, LV wall end systolic wall stress was 
increased, and this could translate into increases in myocardial oxidative stress (Giordano, 
2005). If oxidative stress was assumed to be increased in the present study, then one could 
argue that oxidative stress did not promote telomere attrition in leukocyte, cardiac, and 
kidney tissues in a rat model of chronic β-adrenergic receptor stimulation. This possibility is 
supported by previous findings demonstrating that increased oxidative stress does not 
increase telomere attrition in heart and kidney tissue (Cattan et al., 2008). Hence, the failure 
of adrenergic induced oxidative stress to increase telomere attrition may be due to the fact 
that not all tissue types are susceptible to oxidative stress-induced telomere attrition. 
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Therefore, my inability to measure myocardial oxidative stress does not preclude me from 
drawing a conclusion that telomere length is an insensitive biomarker of adrenergic-induced 
LV dilatation and systolic dysfunction.  
 The results of the present study have implications with respect to current evidence 
demonstrating telomere attrition in heart failure. In this regard, although a prior study (van 
der Harst et al., 2007) has demonstrated a relationship between reduced leukocyte telomere 
length and both ischaemic and non-ischaemic heart disease, in that study (van der Harst et al., 
2007) 22% of the non-ischaemic group of patients had advanced atheromatous disease as 
indexed by a history of stroke, peripheral arterial disease or angina pectoris. Moreover, in that 
study telomere length was strongly associated with atherosclerotic disease (van der Harst et 
al., 2007). Furthermore, the causes of heart failure in the remaining non-ischaemic patients 
were not stated (van der Harst et al., 2007). In contrast, as described in Chapter 2 of this 
thesis, I have failed to demonstrate similar relationships between average leukocyte telomere 
length and idiopathic dilated cardiomyopathy, a non-ischaemic cause of heart failure  
(Raymond et al., 2013). Moreover, Starr et al. (2007) demonstrated that reduced telomere 
length was associated with ischaemic changes on electrocardiograms, while the same 
associations were absent with non-ischaemic disease manifestations. Hence, the relationship 
between reduced leukocyte telomere length and ischaemic heart disease and the absence of 
this relationship between non-ischaemic heart disease, may be attributed to differences in the 
disease profiles of the patient groups rather than cause and effect relationships. In this regard, 
this study extends these previous studies, and suggests at least that neurohumoral activation 
(sympathetic nervous system activation), a major cause of progressive heart failure 
irrespective of the cause (Triposkiadis et al., 2009), may not be responsible for average 
telomere shortening in heart failure. 
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Importantly, the results of the present study do not discount an important contribution 
of cardiomyocyte telomere dysfunction to the pathogenesis of adrenergic-induced LV 
dysfunction and dilatation. In this regard, the length of the shortest telomere in a particular 
population of cells rather than average telomere length of a population of leukocytes, as 
evaluated in the present study, determines cellular function (Hemann et al., 2001). Thus, 
average relative telomere length may not closely reflect the impact of telomeres on cellular 
performance. Further studies are required to evaluate whether adrenergic stimulation reduces 
the length of the shortest telomere. 
In conclusion, the results of the present study show that chronic β-adrenergic receptor 
stimulation in rats, despite producing LV dilatation and LV systolic chamber dysfunction, 
failed to modify either cardiac or leukocyte telomere length. These results suggest that 
average telomere length is not a sensitive biomarker of LV systolic dysfunction and dilatation 
produced by chronic β-adrenergic receptor stimulation and that previously described 
relationships between average telomere length and heart failure (Starr et al., 2007; van der 
Harst et al., 2007; Weischer et al., 2012) are therefore unlikely to be attributed to chronic 
adrenergic stimulation. 
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5.1 ABSTRACT 
Aims: A prominent feature that is associated with both telomere attrition and chronic 
heart failure is inflammation. Hence, I evaluated the impact of chronic inflammation on 
telomere length and LV remodelling and systolic function in an animal model. Methods and 
Results: After 12 months of fortnightly intraperitoneal injections of 2.5x10
7 
Staphylococcus 
aureus cell walls (S. aureus: n=30) or saline vehicle (control: n=30) in SD rats, there were no 
differences in LV dimension (LVEDD, V0) or systolic chamber function (FSend, Ees) between 
the two groups. In the control group no significant differences in plasma C-reactive protein 
concentrations (marker of inflammation) were noted at 3 or 11 months compared to the 
baseline concentrations at 1 month. However, in the S. aureus group there was a significant 
increase in CRP concentrations at both 3 months (S. aureus=3 months: 435.4±90.00µl.ml
-1
 
vs. 1 month: 347.8±101.9µl.ml
-1
, p<0.0001) and 11 months (S. aureus=11 months: 
511.4±93.3µg.ml
-1
 vs. 1 month: 347.8±101.9µg.ml
-1
, p<0.0001) compared to the baseline 
CRP concentrations at 1 month. Furthermore, CRP concentrations were significantly 
increased in the S.aureus group compared to the control group at 11 months 
(511.4±93.3µg.ml
-1
 vs. 391.2±122.1µg.ml
-1
, p<0.01). Leukocyte log T/S was significantly 
reduced in the S.aureus compared to the control group at 11months (S.aureus: -0.21±0.15 
vs.control: -0.053±0.11, p=0.002). Furthermore, cardiac log T/S was significantly reduced in 
the S.aureus compared to the saline group (S. aureus: -0.20±0.10 vs. control: -0.11±0.084, 
p=0.0021). However cardiac log T/S was not associated with LVEDD, V0, FSend, Ees, FSmid, 
or Een. Conclusions: In conclusion, a chronic inflammatory stimulus that produced reductions 
in leukocyte and cardiac telomere length did not induce LV dilatation and a reduction in 
systolic chamber function. Hence, the negative association between telomere length and heart 
failure may be due to the impact of inflammatory processes on telomere length rather than 
signifying a cause of heart failure.
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5.2 INTRODUCTION 
Studies have demonstrated that reduced average leukocyte telomere length is 
associated with chronic heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer 
et al., 2012). From these association studies it is unclear whether telomere attrition is caused 
by increased inflammation.  
An important pathophysiological feature of heart failure that has been associated with 
reduced telomere length is inflammation (Beyne-Rauzy et al., 2005; Yndestad et al., 2006). 
Hence, it is possible that chronic inflammation may be responsible for the telomere attrition 
evident in heart failure. Indeed, leukocyte telomere length is inversely associated with 
markers of inflammation (Aikata et al., 2000;  Bekaert et al., 2007; Huzen et al., 2011; 
Ilmonen et al., 2008;  Kinouchi et al., 1998; Masi et al., 2012; Salpea et al., 2010; Samani et 
al., 2001; Valdes et al., 2005; Weischer et al., 2012) and patients in heart failure have 
increased concentrations of inflammatory cytokines (Adamopoulos et al., 2001; Aukrust et 
al., 1999; Levine et al., 1990; Testa et al., 1996; Yndestad  et al., 2006). In this regard, there 
is evidence demonstrating that inflammation alone is capable of heralding the onset of 
adverse cardiac remodelling (Bozkurt et al., 1998; Kubota et al., 1997).    
Nevertheless, it is unclear whether telomere attrition in heart failure is caused by 
inflammation. Hence, we developed an animal model of chronic inflammation in order to 
evaluate the relationship between telomere length and chronic inflammation. This 
investigation allowed for the determination of whether chronic inflammation affects telomere 
dynamics and if changes in telomere length could then precipitate adverse cardiac 
remodelling and systolic dysfunction.  
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5.3 METHODS 
5.3.1 Animal model: This study was approved by the Animal Ethics Screening 
Committee of the University of the Witwatersrand (ethics number: 2010/49/04). Sixty male 
SD rats at three months of age were used. The experimental group of rats (n=30) were 
injected intraperitoneally (i.p.) with 2.5 x10
7 
cell walls of Staphylococcus aureus (Pansorbin; 
Calbiochem, California, USA) fortnightly for a 12 month period. Previous studies have 
demonstrated that injection of 2.5 x10
9 
cell walls of S. aureus produced a febrile response in 
rats (Luker et al., 2000). In this current investigation, a sub-pyrogenic dose was desirable, 
thus a hundredth of the pyrogenic dose (Luker et al., 2000) was administered in the 
experimental group in an attempt to achieve this. Moreover, S. aureus was chosen for this 
study as there have been previous reports suggesting that animals do not develop diminished 
inflammatory responses after serial injections with gram positive bacterium (Goelst and 
Laburn, 1991). The control group (n=30) received 0.5ml of the saline vehicle every two 
weeks for the same 12 month treatment period. Great care was taken to avoid any possible 
contamination of the saline group with S. aureus. Such precautions included; housing of the  
S. aureus animals in a separate infectious area, handling of the saline rats was always 
conducted first on days requiring animal handling, and the S. aureus was not kept in the 
animal unit and was only brought into the animal unit on days of injection. 
5.3.2 Echocardiography: Echocardiography was performed as previously described 
(see Section 3.3.2) to determine LV chamber dimensions and posterior wall thickness at end-
diastole and end-systole in 15 rats each from the experimental and control groups. 
Furthermore, load-dependant indices of intrinsic myocardial function (FSmid) and left 
ventricular systolic chamber function (FSend) were also determined using echocardiography. 
Echocardiographic measurements were performed by a single experienced investigator who 
was blinded to the designation of animals to experimental and control groups.  
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5.3.3 Isolated, perfused heart preparations: 10 rats from each of the experimental 
and control groups had LV structural and functional measurements determined using isolated, 
perfused heart preparations as previously described (see Section 3.3.3). Left ventricular 
diastolic remodelling was assessed from the LV diastolic pressure-volume relationships, 
using the volume intercept at zero pressure (V0) for comparative purposes, with an increased 
V0 representative of an increased LV chamber size in diastole. Left ventricular systolic 
chamber performance was determined from the slope of the linear portion of the left 
ventricular developed pressure-volume relationships (Ees). In addition, a load-independent 
measure of intrinsic myocardial systolic function was assessed by constructing LV developed 
stress-strain relations and comparing the slopes (LV end systolic myocardial elastance-En) of 
these relationships. 
5.3.4 Telomere length: DNA was extracted from leukocytes and the LV lateral wall 
of the myocardium using NucleoSpin
®
 Blood and Tissue kits (Macherey-Nagel, Dueren, 
Germany) respectively, as per manufacturer's instructions (see Section 3.3.6). Leukocyte 
telomere length was determined at 1 month, 11 months, and at termination (13 months). The 
methodology employed to determine relative telomere length in leukocyte and tissue DNA is 
that described previously (see Sections 2.3.3 and 3.3.8). A standard sample was included in 
each amplification run and was used to standardise the entire sample T/S ratios as well as to 
determine coefficients of variation. The coefficients of variation of the S and T assays were 
1.23% and 1.93%, respectively. 
5.3.5 C-reactive protein: Plasma CRP concentrations at 1, 3 and 11 months were 
determined using a commercially available rat-specific CRP enzyme-linked, 
immunoabsorbant kit (eBioscience, San Diego, USA.). This assay was performed without 
any modifications to the manufacturer's instructions (see Section 3.3.9). 
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5.3.6 Blood pressure: Prior to termination, tail-cuff blood pressures were determined 
using a CODA (Kent Scientific Corporation, Connecticut, USA.) non-invasive blood pressure 
system specifically designed for use on laboratory animals (see Section 3.3.7). 
5.3.7 Running wheel activity: All of the animals in the experimental and control 
groups were housed in running wheel cages (FIGURE 5.1). The running wheels were equipped 
with bicycle ergometers and allowed for the measurement of voluntary activity. The activity 
levels were measured weekly, with a decrease in voluntary activity used as an indicator of 
illness-induced behavior (Grassi-Zucconi et al., 1995). The percentage change in running 
wheel activity in non-injected weeks compared to injection weeks was also calculated: Δ=                  
(non-injected weeks-injected weeks)/injected weeks).   
5.3.8 Blood collection: For the first month both the experimental and control animals 
were not given any interventions and had no procedures performed on them. Blood and 
plasma samples were collected at the end of month one which then served as the baseline 
measurement for all subsequent months. For the subsequent 12 months the experimental and 
control groups received their respective treatments and blood samples were collected as 
described previously (see Section 3.3.4). 
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FIGURE 5.1 Running wheel cage employed to measure voluntary activity in the S.aureus and 
saline groups. 
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5.3.9 Statistical analysis: All statistical analyses were performed on log transformed 
T/S ratios. All inter-group analyses were conducted using a Student's t-test. All intra-group 
analyses were conducted using a repeated measures ANOVA with a Dunnett's Multiple 
Comparison post-hoc test, using 1 month as the control measurement. All associations 
between variables were conducted using Pearson’s correlation coefficients. A p<0.05 was 
considered to be statistically significant. Data are represented as mean±SD and mean±SEM 
where indicated. 
 
5.4 RESULTS 
5.4.1 Animal deaths, weight data, and blood pressure: In total eight animals, four in 
the S. aureus and four the saline group respectively, died during the course of this 
investigation. The causes of death included; tooth malformations (n=2: 1 in the saline group 
and 1 in the S. aureus group), complications during i.p. injections (n=4: 3 in the saline group 
and 1 in the S. aureus group), growths (n=1), and one unknown cause (n=1). 
TABLE 5.1 demonstrates that the S. aureus group had a greater mean body weight 
compared to the saline group. However, there were no differences in whole heart weight, LV 
weight, SBP, or DBP noted between the experimental and control groups. In light of the fact 
that body weight was significantly different between the S. aureus and saline groups, whole 
heart weight and LV weight were adjusted to tibia length. Even after adjustment, no 
differences between whole heart and left ventricular weight were noted (TABLE 5.1). 
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TABLE 5.1 The effects of 12 months of S. aureus on body weight, heart weight, and blood 
pressure. 
 
  S.aureus (n=26) Saline (n=26) p value 
Body weight (g) 638.2±101.9 580.3±97.6 0.048* 
Whole heart weight (g) 1.53±0.11 1.49±0.18 0.43 
Whole heart weight/tibial length 0.33±0.028 0.33±0.041 0.49 
Left ventricle weight (g) 1.30±0.10 1.27±0.15 0.43 
Left ventricle weight/tibial length 0.28±0.025 0.28±0.035 0.52 
DBP (mmHg) 94±15 85±14 0.054 
SBP (mmHg) 133±18 128±15 0.34 
 
DBP, diastolic blood pressure; SBP, systolic blood pressure. Values are represented as 
mean±SD;*p<0.05 versus S.aureus  and saline groups.  
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5.4.2 LV remodelling: As assessed in vivo, chronic S.aureus  injections did not result 
in LV dilatation as indexed by increases in LVEDD (FIGURE 5.2) and ESD (TABLE 5.2). 
Moreover, there were no significant differences in the LVPWED or PWES between the 
groups and as a consequence, there were no reductions in LVRWT at end-diastole (TABLE 
5.2). As assessed ex vivo at the same heart rate, afterload and at comparable coronary flow 
rates, no right shift in the LV diastolic P-V relationship and no increase in mean V0 in rats 
receiving S. aureus as compared to the saline treated group were noted (FIGURE 5.2). 
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FIGURE 5.2 Effect of 12-months of S.aureus in rats on left ventricular (LV) chamber 
dimensions or volumes as indexed by LV end diastolic diameter (LVEDD) (lower right 
panel), LV diastolic pressure-volume relations (upper panel) and the volume intercept at 0 
mm Hg(V0) LV diastolic pressure (lower left panel). Data are represented as mean±SEM. 
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TABLE 5.2 The effects of 12 months of S.aureus injections in rats on echocardiography 
determined left ventricular dimensions. 
 
  S. aureus (n=26) Saline (n=26) p value 
LVESD (mm) 4.3±0.5 4.0±0.1 0.15 
PWED (mm) 2.2±0.2 2.0±0.2 0.53 
PWES (mm) 2.9±0.2 2.8±0.2 0.18 
RWT (mm) 0.6±0.1 0.6±0.1 0.66 
 
LV, left ventricle; ESD, end systolic diameter; PWES, LV end systolic posterior wall 
thickness; PWED, LV end diastolic posterior wall thickness; RWT,relative wall thickness. 
Values are represented as mean±SD.  
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5.4.3 LV systolic function: FIGURE 5.3 shows the effect of chronic inflammation on 
LV systolic chamber function. S.aureus produced no effects on systolic LV chamber function 
as indexed by either the in vivo load and heart rate-dependent measure, FSend, or the ex vivo 
load and heart rate independent measure, Ees (FIGURE 5.3). Furthermore, chronic S.aureus 
administration had no impact on intrinsic myocardial function as indexed by either the in vivo 
load and heart rate-dependent measure, FSmid, or the ex vivo load and heart rate independent 
measure, Een (FIGURE 5.4) 
5.4.4 C-reactive protein: FIGURE 5.5 demonstrates the effects of chronic inflammation 
on mean plasma CRP concentrations between the experimental and control groups over the 
12 month treatment protocol.  No significant differences in CRP concentrations at 3 and 11 
months compared to baseline measurements after 1 month of treatment were noted in the 
saline group. In contrast, the S. aureus group had a significant increase in CRP concentrations 
at both 3 and 11 months compared to the baseline CRP concentrations determined after 1 
month. In terms of inter-group analysis, the saline group had a greater mean CRP 
concentration at month 1 compared to the S.aureus group (FIGURE 5.5). After 3 months no 
differences between CRP concentrations between the experimental and control groups were 
noted (FIGURE 5.5). The S.aureus group had increased plasma CRP concentrations after 11 
months of treatment when compared to the saline group (FIGURE 5.5).  
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FIGURE 5.3 Effect of 12-months of S.aureus in rats on left ventricular (LV) systolic chamber 
function as indexed by LV endocardial fractional shortening (FSend) (lower right panel), LV 
systolic pressure-volume relations (upper panel), and the slope of the systolic pressure-
volume relations (LV Ees) (lower left panel). Data are represented as mean±SEM. 
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FIGURE 5.4 Effect of 12-months of S.aureus in rats on left ventricular (LV) intrinsic 
myocardial function as indexed by LV midwall fractional shortening (FSmid) (lower right 
panel), LV systolic stress-strain relations (upper panel), and the slope of the systolic stress-
strain relations (LV Een) (lower left panel). Data are represented as mean±SEM.  
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FIGURE 5.5 Mean plasma C-Reactive protein (CRP) concentrations for 1, 3, and 11 months in 
the S.aureus (n=20) and saline (n=17) groups respectively. Data are represented as mean±SD; 
*p<0.05 S.aureus versus saline group; 
†
p<0.05 versus month 1 in the S.aureus and saline 
groups respectively. 
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5.4.5 Running wheel: With regards to running wheel activity, only animals that had a 
mean weekly running distance of greater than 1km.week
-1
 in the S.aureus (n=20) and saline 
(n=17) groups were included for analysis. This was done as the possible impact of 
inflammation on voluntary activity can not be determined in animals that were sedentry prior 
to the initiation of treatment. FIGURE 5.6 shows the mean weekly running distance over the 12 
month treatment protocol in the S.aureus group was not significantly reduced compared to 
the saline group either in the injection or non-injection weeks. However intra-group analysis 
revealed that the experimental group had reduced weekly running distance on weeks that they 
were injected with S.aureus compared to weeks they received no injections. Importantly, this 
finding was not present in the control group when comparing weeks the animals were 
injected with saline compared to weeks they received no injections. These data indicate that 
the reduction in running wheel activity evident in the experimental group during injection 
weeks was due to S. aureus and not a result of the injections themselves.      
5.4.6 Telomere length: FIGURE 5.7 shows the changes in leukocyte T/S ratios over 
time in the experimental and control groups. In the S.aureus group, there was a decline in 
leukocyte telomere length at 11 months compared to after 1 month. However, there was a 
subsequent increase in the leukocyte telomere length at termination when compared to log 
T/S ratios determined after 1 month in the S.aureus group. With respect to the saline group, 
there was a significant increase in leukocyte telomere length at both 11 months and 
termination when compared to log T/S ratios at 1 month. In terms of inter group analysis, no 
significant differences between leukocyte telomere length at month 1 and termination were 
noted between the experimental and control groups. However, the mean leukocyte T/S ratio 
at month 11 was significantly reduced in the S.aureus compared to the saline group. With 
respect to the telomere length of cardiac tissue, FIGURE 5.8 demonstrates that cardiac 
telomere length was significantly reduced in the S.aureus compared to the saline group.      
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FIGURE 5.6 Effect of 12-months of S.aureus in rats on weekly running distance. Data are 
represented as mean±SD (upper panel) and percentage change (lower panel); *p<0.05 
injected versus non-injected weeks. 
 
 
* 
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FIGURE 5.7 Relative leukocyte telomere lengths (as indexed by T/S) at 1 month, 11 months, 
and at termination in the S.aureus and saline groups. Data are represented as mean±SD; 
*p<0.05 S.aureus versus saline groups; 
†
p<0.05 versus month 1 in the S. aureus and saline 
groups. 
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FIGURE 5.8 Effect of 12-months of S.aureus in rats on cardiac telomere length (as indexed by 
T/S). Data are represented as mean±SD; * p<0.05 versus saline group. 
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5.4.7 Telomere correlations: Neither indices of LV dilatation (LVEDD, V0), systolic 
chamber function (FSend, Ees), nor intrinsic myocardial function (FSmid, Een) were associated 
with cardiac telomere length in this study (TABLE 5.3). However, there was a significant 
negative association between leukocyte T/S ratio and CRP concentrations at month 11 but not 
month 1 in the combined groups (TABLE 5.3). Furthermore, there was a strong positive 
association between leukocyte telomere length at termination and cardiac telomere length 
(Pearson's r = 0.7, p< 0.0001, R
2 
= 0.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHRONIC INFLAMMATION AND TELOMERE LENGTH Page 143 
TABLE 5.3 Correlations between cardiac telomere length and indices of left ventricular (LV) dilatation (the volume intercept at 0 mm Hg (V0) in 
the left ventricular (LV) diastolic pressure-volume relations and LV end diastolic diameter (LVEDD)), systolic chamber function (slope of the 
systolic pressure-volume relations (LV Ees) and endocardial fractional shortening (FSend)), intrinsic myocardial function (slope of the systolic 
stress-strain relations (Een) and midwall fractional shortening (FSmid)), and correlations between leukocyte telomere length and inflammation (C-
reactive protein (CRP)). 
 
r, correlation coefficient; CI, confidence interval. *p<0.05  
 
V0 LVEDD LV Ees FSend LV Een FSmid CRP 1 month CRP 11 Months 
S. aureus 
 
 
  
  
  Pearson's r -0.13 -0.21 0.11 0.19 0.53 0.19 0.041 -0.30 
95 %CI -0.73 to 0.59 -0.67 to 0.36 -0.64 to 0.75 -0.38 to 0.66 -0.38 to 0.92 -0.38 to 0.66 -0.38 to 0.45 -0.68 to 0.21 
p value 0.74 0.46 0.79 0.51 0.22 0.51 0.86 0.24 
  
 
  
  
  Saline 
 
 
  
  
  Pearson's r 0.34 -0.39 0.30 0.064 0.31 
 
-0.028 0.014 -0.22 
95 %CI -0.42 to 0.82 -0.76 to 0.18 -0.46 to 0.80 -0.48 to 0.57 -0.50 to 0.83 -0.55 to 0.51 -0.43 to 0.45 -0.58 to 0.21 
p value 0.37 0.17 0.44 0.83 0.45 0.92 0.95 0.32 
  
 
  
  
  Combined 
 
 
  
  
  Pearson's r 0.054 -0.26 0.22 0.23 0.054 0.22 -0.020 -0.46 
95 %CI -0.42 to 0.51 -0.58 to 0.14 -0.30 to 0.63 -0.15 to 0.56 -0.54 to 0.61 -0.17 to 0.54 -0.32 to 0.28 -0.68 to -0.17 
p value 0.83 0.21 0.40 0.23 0.88 0.26 0.89 0.003* 
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5.5 DISCUSSION  
The main findings of this study are as follows: chronic (12 months) inflammatory 
stimulus with S.aureus bacterial cell walls produced a significant reduction in cardiac and 
leukocyte telomere length in rats. However, neither the increase in cardiac telomere attrition 
nor chronic inflammation heralded the onset of LV dilatation and systolic dysfunction in this 
study. Furthermore, no associations between cardiac telomere length and LV structure or 
function were noted. 
The main aim of the current investigation was to investigate whether inflammation 
causes telomere attrition which in turn results in cardiac remodelling and dysfunction. In this 
regard, there was clear evidence of immune activation following i.p. injections of S. aureus 
cell walls, demonstrated by plasma CRP concentrations that were both increased from 
baseline concentrations and were greater in the S. aureus animals compared to the control 
group after 11 months of treatment. Furthermore, the experimental group had reduced 
running wheel activity during weeks of S. aureus injections while this reduced activity was 
absent in the saline group. These data indicate a decrease in voluntary activity in the S. 
aureus group, which is an illness-induced behavioural response (Grassi-Zucconi et al., 1995). 
Collectively, these data indicate that fortnightly i.p. injections of 2.5x10
7 
S. aureus cell walls 
did illicit immune responses that coincided with increased CRP concentrations and illness-
induced behavioural responses and hence that this is a model of chronic inflammation.   
The results from this study demonstrate that chronic inflammation increases telomere 
attrition in leukocyte and cardiac tissue. This association between increased telomere attrition 
and inflammation is consistent with previous studies. Indeed, there is significant evidence 
demonstrating that leukocyte telomere length is negatively associated with markers of 
inflammation (Bekaert et al., 2007; Carrero et al., 2008; Masi et al., 2012; Shiels et al., 2011; 
Wolkowitz  et al., 2011). Furthermore, Ilmonen et al. (2008) infected mice with bacteria and 
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noted that after 7 months leukocyte telomere length was reduced in the infected animals 
whilst there was a corresponding increase in leukocyte telomere length in the control group. 
Ilmonen et al. (2008), on the basis of these findings concluded that immune activation could 
increase telomere attrition. These findings are consistent with the current investigation, as 
leukocyte telomere length was reduced after 11 months in S. aureus group, but with a 
corresponding increase in leukocyte telomere length in the saline group. However, in this 
study there was an additional time point two months later where it was found that leukocyte 
telomere length subsequently increased in the S. aureus group as well. Hence, both telomere 
attrition and elongation were observed in the S. aureus group during this study. These 
findings have been demonstrated previously, longitudinal data in humans have indicated that 
leukocyte telomere length is variable and may increase, remain the same, or decrease in 
length over time (Aviv et al., 2009; Nordfjäll et al., 2009). Moreover, these studies have 
noted that telomere attrition is associated with baseline telomere length (Aviv et al., 2009). 
Thus, a strong component of the rate of telomere attrition may be determined by initial 
telomere length itself. In this regard, there was no significant difference between leukocyte 
telomere length in the experimental and control groups after 1 month, thus one can still argue 
that inflammation increased leukocyte telomere attrition as leukocyte telomere decreased in 
the experimental group, but increased in the control group. However, when leukocyte 
telomere length reached a particular length in the S. aureus group telomerase (Nordfjället al., 
2009) and perhaps other factors involved in telomere length maintenance were activated to 
increase telomere length in the circulating population of leukocytes. Furthermore, it also 
possible that at any time point the circulating population of leukocytes had been replaced by 
new cells from bone marrow, with significantly different telomere lengths, and may also 
account for the fluctuations seen in leukocyte telomere length. This may explain the marked 
difference in telomere length measured over two months.      
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The results from this study provide insight into the cause and effect relationships 
between reduced telomere length evident in heart failure. In this regard, one of the possible 
explanations for reduced leukocyte telomere length in patients with chronic heart failure may 
be  due to inflammation (Beyne-Rauzy et al., 2005; Yndestad  et al., 2006). Indeed, the 
results from this investigation support this notion as both cardiac and leukocyte telomere 
lengths were reduced as a result of chronic inflammation. However, it is unknown if reduced 
cardiac telomere length has any pathophysiological consequences in the heart or if reduced 
telomere length represents an epiphenomenon due to the ongoing processes of heart failure. 
In this regard, this study demonstrated that marked reductions in cardiac telomere length, 
produced by 12 months of repeated S. aureus infections, did not herald the onset of any 
pathophysiological changes in the heart that are associated with heart failure measured in this 
study, namely LV dilatation and systolic dysfunction. Thus, previous studies demonstrating 
that reduced telomere length is associated with heart failure (Starr et al., 2007; van der Harst 
et al., 2007; Weischer et al., 2012) and risk factors for cardiovascular disease (Brouilette et 
al., 2003; Fitzpatrick et al., 2007; Ogami et al., 2004; Valdes et al., 2005; Zee et al., 2009) 
may represent an epiphenomenon due to ongoing inflammatory processes. Importantly, the 
results from this investigation indicate that increased cardiac telomere attrition as a 
consequence of chronic inflammation for 12 months in rats has no pathophysiological 
consequence on the heart in terms of LV structure and function. However, it has to be stated 
that if the animals received S. aureus infections for a longer period of time, whether or not 
these changes in cardiac telomere length coupled with continued inflammation would result 
in adverse cardiac remodelling and heart failure is uncertain. Nonetheless, these animals were 
16 months of age at termination, which represents a significant proportion of the lifespan of a 
Sprague-Dawley rat. 
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There is evidence to suggest that inflammation is sufficient to cause adverse cardiac 
remodelling (Bozkurt et al., 1998, 1998; Kubota et al., 1997). In this regard, previous studies 
have demonstrated that TNF-α produces ventricular hypertrophy, dilatation, and fibrosis in  
mice (Kubota et al., 1997) and rats (Bozkurt et al., 1998). However, in the present study, 
after repeated infection with S. aureus there was no evidence of LV dilatation or systolic 
dysfunction. A possible explanation for differences between the current study and previous 
reports in terms of cardiac remodelling and dysfunction after immune activation may be due 
to the concentrations of pro-inflammatory cytokines. In this regard, high concentrations of 
TNF-α  are known to produce septic shock (Meldrum, 1998). Moreover, septic shock has 
been demonstrated to produce LV dilatation and systolic dysfunction (Parker and Parrillo, 
1983; Parker et al., 1984; Parker et al., 1990). Hence, the previous studies demonstrating 
adverse cardiac remodelling with TNF-α (Bozkurt et al., 1998; Kubota et al., 1997) may have 
produced TNF-α concentrations sufficiently high enough to illicit septic shock, which then 
resulted in LV dilatation and dysfunction (Parker and Parrillo, 1983; Parker et al., 1984; 
Parker et al., 1990). In contrast, the dose of S. aureus used in this study was a hundredth of a 
known pyrogenic dose and was intended to provide enough stimulus to illicit a immune 
response and is unlikely to have produced septic shock. This is demonstrated by the fact that 
no differences in SBP or DBP blood pressures were noted between the experimental and 
control groups, as shock is characterised by hypotension (Celes et al., 2013). Moreover, there 
were no changes in cardiac function in the S. aureus group associated with septic shock 
(Celes et al., 2013). Hence, one can conclude that the dose of S. aureus utilised in this study 
did not produce septic shock.  Nonetheless, the dose of S. aureus was still sufficient to illicit 
both biological (increase CRP concentration) and behavioural (decreased voluntary activity) 
markers of immune activation. Thus, one could argue that a chronic infection with S. aureus 
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in rats, with concentrations of pro-inflammatory mediators that unequivocally did not result 
in septic shock, does not result in LV dilatation and systolic dysfunction.     
Previously I have made statements that the absence of telomere attrition did not 
exclude a contribution of cardiomyocyte telomere dysfunction to the pathogenesis of ethanol 
and chronic β-AR induced LV dilatation. In this regard, the length of the shortest telomere in 
a particular population of cells rather than average telomere length determines cellular 
function (Hemann et al., 2001). Thus, average relative telomere length may not closely 
reflect the impact of telomeres on cellular performance. However, the results of this study 
indicate that even a decrease in average cardiac telomere length was not sufficient to herald 
the onset of adverse cardiac remodelling and dysfunction in rats after 12 months of chronic S. 
aureusinfection. These results further support the findings that ethanol and chronic β-AR 
induced LV dilatation are independent of telomere attrition despite the fact that the average, 
and not the shortest, telomere length was measured.     
An observation of the current investigation that requires further explanation is that 
reduced leukocyte telomere length was not associated with plasma CRP concentrations 
determined at month 1, but was however correlated after 11 months. Telomere length is 
thought to represent the cumulative effects of inflammation throughout an individual's 
lifespan (Zglinicki and Martin-Ruiz, 2005), thus baseline measurements after 1 month in this 
study represented a time point early in the animal's life span where inflammation was 
possibly negligible. Hence, the lack of association between leukocyte telomere length and 
CRP at 1 month may be due to the absence of sufficient inflammation required to induce 
telomere attrition in the early lives in the experimental and control groups.  
In terms of study limitations, firstly, there were no markers of oxidative stress 
available in this study. Inflammation is known to result in an increase in oxidative stress 
(Frantz et al., 2000; Knuefermann et al., 2004), which could potentially increase telomere 
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attrition. Thus, the changes in leukocyte and cardiac telomere length that are attributed to 
oxidative stress in this study cannot be determined. Nonetheless, even if there was an increase 
in oxidative stress in this study, the reductions in cardiac telomere length had no pathological 
consequences on the heart. Secondly, body temperatures were not measured in the animals. In 
the current study a sub-pyrogenic dose was desired in an attempt to model individuals with 
chronic inflammatory disorders. Importantly, these individuals have chronic immune 
activation but without fever. In the present study there were biological and behavioural 
indicators of immune activation, but whether these changes occurred without fever is 
uncertain.    
In conclusion, chronic inflammation with S. aureus caused a decrease in cardiac 
telomere length but these changes in telomere length were not associated with adverse LV 
remodelling and systolic dysfunction. These data indicate that previous associations between 
reduced telomere length and heart failure and risk factors for heart failure may represent an 
epiphenomenon due to ongoing inflammatory processes. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 6 - IS TELOMERE LENGTH 
ASSOCIATED WITH INFLAMMATION, LEFT 
VENTRICULAR GEOMETRY AND 
FUNCTION, AND TELOMERE LENGTH IN A 
CROSS-SECTIONAL COMMUNITY STUDY? 
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6.1 ABSTRACT 
Aims: To determine, in a cross-sectional human study, whether inflammation and  
telomere attrition are associated with cardiac geometry and function. Methods and Results: 
Leukocyte telomere length (log T/S) was determined in 662 participants from a randomly 
selected community based cohort. There was a negative bivariate relationship between T/S 
ratio and age in the group (p<0.0001) and telomere length was reduced in participants who 
regularly consumed alcohol compared to those who did not (p=0.01). No relationships 
between log T/S and smoking, sex, BMI, diabetes mellitus, or blood pressure were noted. 
However, there was a negative relationship between leukocyte telomere length and C-reactive 
protein concentrations after multivariate adjustments (r=-0.11; p=0.0039; n=662). There were 
no associations between log T/S and echocardiographic indices of LV geometry (LVEDD) or 
systolic function (FSend, FSmid) in the participants. Conclusions: In conclusion, leukocyte 
telomere length is inversely associated with indices of inflammation. However, leukocyte 
telomere length is not associated with indices of LV geometry or function. Hence, 
inflammation may be an important determinant of leukocyte telomere attrition, but leukocyte 
telomere length is not a marker of alterations in cardiac geometry or function. 
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6.2 INTRODUCTION 
Studies have demonstrated that reduced average leukocyte telomere length is 
associated with chronic heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer 
et al., 2012). An important pathophysiological feature of heart failure that has been associated 
with reduced telomere length is inflammation (Beyne-Rauzy et al., 2005; Yndestad  et al., 
2006). In this regard, leukocyte telomere length has been demonstrated to be inversely 
associated with indices of inflammation (Aikata et al., 2000; Bekaert et al., 2007; Huzen et 
al., 2011; Ilmonen et al., 2008; Kinouchi et al., 1998; Masi et al., 2012; Salpea et al., 2010; 
Samani et al., 2001; Valdes et al., 2005; Weischer et al., 2012) and patients in heart failure 
have increased concentrations of inflammatory cytokines (Adamopoulos et al., 2001; Aukrust 
et al., 1999; Levine et al., 1990; Testa et al., 1996; Yndestad  et al., 2006). 
Hence, it is possible that inflammation may be responsible for the telomere attrition 
evident in heart failure. In this regard, I have demonstrated in an animal model that chronic 
inflammation decreased cardiac and leukocyte telomere length (see Chapter 5). However, 
these changes in telomere length were not associated with adverse LV remodelling and 
systolic dysfunction. These data indicate that previous associations between reduced telomere 
length and heart failure (Starr et al., 2007; van der Harst et al., 2007; Weischer et al., 2012) 
and risk factorsfor heart failure (Brouilette et al., 2007; Fuster et al., 2007; Huzen et al., 
2011; Ogami et al., 2004; Salpea et al., 2010; Samani et al., 2001;Valdes  et al., 2005; Valdes  
et al., 2005; Weischer et al., 2012) may represent an epiphenomenon due to ongoing 
inflammatory processes. 
In terms of human data that has investigated the associations between telomere length, 
cardiac geometry and function, Collerton et al. (2007) did show that leukocyte telomere 
length was negatively associated with left ventricular ejection fraction. However, an 
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important consideration is that this study consisted of individuals older than 85 years. Given 
the strong negative relationship between telomere length and age and between ejection 
fraction and age the association between telomere length and ejection fraction in this study is 
to be expected. In addition, Starr et al. (2007) demonstrated that reduced telomere length was 
associated with ischaemic changes on electrocardiograms. However, it is still unclear whether 
telomere attrition in humans has a pathophysiological role in heralding the onset of LV 
remodelling and systolic dysfunction in heart failure. Hence, in order to confirm my findings 
demonstrated in the animal model of chronic inflammation, a cross-sectional investigation to 
assess the relationship between leukocyte telomere length and LV cardiac geomtery and 
function in a community based population was conducted.    
 
6.3 METHODS 
6.3.1 Study group: The present study was conducted according to the principles 
outlined in the Helsinki declaration. The Committee for Research on Human Subjects of the 
University of the Witwatersrand approved the protocol (approval number: M02-04-72 and 
renewed as M07-04-69). Participants provided informed, written consent. All participants in 
this study were a part of a large scale community based study, which has been described 
previously (Norton et al., 2012). Families of black African descent, with siblings greater than 
16 years of age were randomly recruited from the South West Township of Johannesburg, 
South Africa. The sample size consisted of 1179 participants in whom leukocyte telomere 
length and CRP concentrations were assessed in 662 individuals.  
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6.3.2 Clinical, demographic, and anthropometric measurements: A standard 
questionnaire was used to obtain demographic, clinical, smoking, and drinking history of the 
participants (Norton et al., 2012). Height and weight, for the determination of BMI, were 
measured using standard methods, and participants were defined as obese if their BMI was 
greater than 30 kg.m
-2 
(Norton et al., 2012). Blood pressure measurements were obtained 
using a standard mercury sphygmomanometer (Norton et al., 2012). Hypertension was 
defined as a mean systolic blood pressure greater than 140 mmHg or diastolic pressure 
greater than 90 mmHg. Standard laboratory blood tests of percentage glycated haemoglobin 
were performed and diabetes mellitus was defined as a percentage glycated haemoglobin 
(HbA1c) value greater than 6.1% (Norton et al., 2012). CRP concentrations were determined 
using a immunoturbidimetric assay (Architect, Sentinel Diagnostics, USA) performed on 
Olympus OSR 6185 reagent (Olympus Diagnostics, Lismeehan, Ireland).   
6.3.3 LV dimensions and function: In 409 of the 662 participants, 2D, M-mode 
echocardiography was performed using a Hewlett-Packard Sonos 2500 system with a 2.5-
MHz transducer. LV internal dimensions were determined as previously described (Norton et 
al., 2012; see Section 2.5.3). 
6.3.4 Average telomere length: The methodology employed to determine relative 
telomere length in leukocyte and tissue DNA is that described previously (see Section 2.3.3). 
A standard sample was included in each amplification run and was used to standardise the 
entire sample T/S ratios as well as to determine coefficients of variation. The coefficients of 
variation of the S and T assays were 1.19% and 1.36%, respectively. 
6.3.5 Statistical analysis: All tests were carried out on log-transformed T/S crossing 
point ratios and CRP concentrations, as they were not normally distributed. Multivariate 
regression analysis was performed to assess independent relationships. Adjustments were 
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made for age and sex as these are strong determinants of telomere length. For the relationship 
between telomere length, CRP, LVEDD, FSend, and FSmid  adjustments for BMI, smoking, 
drinking, treatment for hypertension, and diabetes mellitus were also included as they may 
impact on CRP concentrations, cardiac function and geometry. Statistical analysis was 
conducted using SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA). Data are 
represented as mean±SD. 
 
6.4 RESULTS 
6.4.1 Participant characteristics: TABLE 6.1 shows the characteristics of the cross-
sectional community based cohort. This population consisted of primarily female participants 
with a high proportion of obesity and hypertension. However, there was a low proportion of 
other prominent risk factors for cardiovascular disease such as diabetes mellitus, regular 
smoking, and regular alcohol consumption in this cohort.  
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TABLE 6.1 Demographics and prevalence of risk factors for cardiovascular diseasein the 
participants.   
  
n  662 
Age (years) 44±19 
% Female 64 
Regular alcohol consumption (%) 22 
Regular smoking (%) 14 
% Diabetes mellitus (HbA1c>6.1) 24 
Body mass index (kg.m
-
²) 29.5±9.1 
% Obese  43 
Systolic blood pressure (mm Hg) 121±23 
Diastolic blood pressure (mm Hg) 84±13 
% Hypertensive  40 
 
Values are represented as mean±SD or percentage.  
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6.4.2 Relationships between average relative leukocyte telomere length and 
participant characteristics: There was a negative bivariate relationship between T/S ratio and 
age in the participants (FIGURE 6.1). The mean log T/S ratio of the participants who drank 
were reduced compared to those who did not regularly consume alcohol (TABLE 6.2). No 
relationships between T/S ratio and smoking, sex, BMI, diabetes mellitus, or blood pressure 
were noted (TABLE 6.2).  
6.4.3 Relationships between average relative leukocyte telomere length and CRP: 
FIGURE 6.2 shows the negative bivariate relationship between leukocyte telomere length and 
log CRP concentrations in this cohort. The relationship persisted after multivariate 
adjustment for age, BMI, sex, smoking, drinking, treatment for hypertension and diabetes 
mellitus (r=-0.11; p=0.0039; n=662).   
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FIGURE 6.1 Bivariate relationships between leukocyte telomere repeat number/single copy 
gene repeat number ratio (log T/S) and age (years) in a randomly selected community based 
cohort.  
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TABLE 6.2 Relationship between relative leukocyte telomere length (log T/S) and risk factors 
for cardiovascular disease in participants (n=662). 
 
r, correlation coefficient; CI, confidence interval; M, male; F, female. *p<0.05; 
ǂ 
age- and sex-
adjusted; ** Student’s t-test. 
 
 
Pearson's r 95% CI p value 
Body mass index
ǂ
 0.015 -0.060 to 0.089 0.70 
Systolic blood pressure
ǂ -0.024 -0.10 to 0.051 0.53 
Diastolic blood pressure
ǂ -0.060 -0.13 to 0.016 0.12 
 
Mean±SD  T/S pvalue** 
Gender M=1.191.07 (n=224)      F=1.312.9 (n=398) 0.77 
Diabetes mellitus Yes=1.08 (n=149)             No=1.33 (n=513) 0.48 
Regular alcohol Yes=1.030.62 (n=136)    No=1.332.7 (n=526) 0.012* 
Regular smoking Yes=1.31 (n=87)               No=1.26 (n=575) 0.43 
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FIGURE 6.2 Bivariate relationships between leukocyte telomere repeat number/single copy 
gene repeat number ratio (log T/S) and log transformed C-reactive protein (CRP) 
concentrations in a randomly selected community based cohort. 
 
 
r=-0.14 
p=0.00050 
n=662 
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6.4.4 Relationship between average relative leukocyte telomere length LV geometry 
and function: TABLE 6.3 gives the univariate and multivariate adjusted correlation 
coefficients between log T/S ratios and LVEDD, FSend, and FSmid in the participants. There 
were no association between log T/S ratios and indices of LV dilatation (LVEDD) or cardiac 
dysfunction (FSend, FSmid) in the participants.  
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TABLE 6.3 Multivariate adjusted relations between relative leukocyte telomere length (log 
T/S) and left ventricular end diastolic diameter (LVEDD), intrinsic myocardial function 
(FSmid), and ejection fraction (FSend) in participants. 
 
r, correlation coefficient; CI, confidence interval. *age, body mass index, sex, smoking, 
drinking, treatment for hypertension, diabetes mellitus, and CRP. 
 
 
 
 
Log T/S versus Partial r 95% CI p value  
LVEDD (n=409):       
Unadjusted 0.0013 -0.095 to 0.098 0.98 
Age- and sex-adjusted 0.000053 -0.097 to 0.097 0.99 
Age-, sex- and risk factor*- adjusted 0.019 -0.80 to 0.12 0.70 
FSend (n=409):    
Unadjusted -0.017 -0.11 to 0.08 0.73 
Age- and sex-adjusted -0.0054 -0.10 to 0.09 0.91 
Age-, sex- and risk factor*-adjusted -0.0013 -0.10 to 0.10 0.97 
FSmid (n=409):    
Unadjusted -0.05 -0.14 to 0.05 0.35 
Age- and sex-adjusted -0.03 -0.13 to 0.06 0.48 
Age-, sex- and risk factor*-adjusted -0.03 -0.13 to 0.07 0.50 
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6.5 DISCUSSION 
The main findings of this chapter in my thesis are that average leukocyte telomere 
length is inversely associated with CRP concentrations. However, leukocyte telomere length 
was not associated with indices of LV geometry (LVEDD) or systolic function (FSend, FSmid) 
in humans of black ancestry. 
The results of this study are in keeping with previous published reports investigating 
leukocyte telomere length and markers of inflammation. In this regard, CRP concentrations 
have been demonstrated to be inversely associated with relative leukocyte telomere length 
(Bekaert et al., 2007; Carrero et al., 2008; Masi et al., 2012). However, the results of this 
study extend previous findings by investigating the relationship between leukocyte and CRP 
over a wide age range (16-97 years of age). In this regard, previous large-scale cross-
sectional studies have been conducted in samples with relatively narrow age ranges such as 
adolescent (13-16 years of age) (Masi et al., 2012) and middle aged populations (35-55 years 
of age) (Bekaert et al., 2007). In addition to CRP, leukocyte telomere length has been 
negatively correlated with other markers of inflammation including; IL-6 (Carrero et al., 
2008; Shiels et al., 2011; Wolkowitz et al., 2011), and fibrinogen (Bekaert et al., 2007). 
Collectively these data indicate that inflammation could potentially increase telomere length 
attrition. Indeed, I have demonstrated that chronic inflammation with S. aureus resulted in a 
marked decrease in cardiac and leukocyte telomere length in rats and that leukocyte telomere 
length was inversely associated with CRP concentrations (see Chapter 5). 
Hence, it is possible that chronic inflammation could explain the reduced average 
leukocyte telomere length associated with chronic heart failure (Starr et al., 2007; van der 
Harst et al., 2007; Weischer et al., 2012). However, the relationships between leukocyte 
telomere length and cardiovascular disease have mainly been determined using outcome 
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based studies and not using measurements of cardiac function. However, Collerton et al. 
(2007) did show that leukocyte telomere length was negatively associated with left 
ventricular ejection fraction. However, an important consideration is that this study consisted 
of individuals older than 85 years. Moreover, Starr et al. (2007) demonstrated that reduced 
telomere length was associated with ischaemic changes on electrocardiograms. However, 
from this data it is not conclusive whether telomere attrition in humans has a 
pathophysiological role in heralding the onset of LV remodelling and systolic dysfunction in 
heart failure. Hence, telomere length may have no impact on cardiac structure and function 
and may merely be reduced as a consequence of the pathophysiological processes of 
cardiovascular diseases, such as inflammation. In this regard, the results of this study 
demonstrate that leukocyte telomere length was not associated with indices of LV geometry 
and systolic function, despite negative associations with CRP concentrations. The results of 
this study are consistent with previous findings in my thesis (see Chapter 5) demonstrating 
that marked reductions in cardiac and leukocyte telomere length, produced by 12 months of 
chronic S. aureus infections, did not herald the onset of any pathophysiological changes in 
the heart that are associated with heart failure. Hence, the results from this study support the 
associations between inflammation, telomere length, and cardiac geometry and function that I 
have demonstrated in rats (see Chapter 5). Collectively, these data indicate that previous 
associations between reduced leukocyte telomere length, heart failure (Starr et al., 2007; van 
der Harst et al., 2007; Weischer et al., 2012), and risk factors for cardiovascular disease 
(Brouilette et al., 2003; Fitzpatrick et al., 2007; Ogami et al., 2004; Valdes et al., 2005; Zee 
et al., 2009) may represent an epiphenomenon due to ongoing inflammatory processes and 
that reductions in telomere length may have no impact on cardiac geometry and function. 
In terms of study limitations, firstly, this is a cross-sectional study which does not 
allow for conclusions regarding cause and effect relationships. Nevertheless, the results of 
 
 
INFLAMMATION, LV REMODELLING, SYSTOLIC FUNCTION AND TELOMERE LENGTH  Page 165 
this study, in conjunction with the longitudinal chronic inflammation study in rats (see 
Chapter 5), support the notion that telomere length is merely reduced as an epiphenomenon 
due to ongoing inflammatory processes in heart failure or risk factors for heart failure. 
Secondly, as highlighted in the aforementioned discussions, telomere length has a high inter-
individual variability (Aviv et al., 2009; Nordfjäll et al., 2009); and hence a cross-sectional 
determination of telomere length at one specific time point does not accurately reflect long-
term telomere length dynamics of individuals. Hence, this could potentially explain the 
inability to demonstrate associations between leukocyte telomere length and cardiac 
geometry and function. Nevertheless, if leukocyte telomere length is associated with LV 
dimension and function, my inability to demonstrate this relationship in a large cross-
sectional study highlights that leukocyte telomere length may not be a sensitive marker of LV 
geometry and systolic function. Thirdly, this study only included particpants of African 
ancestry. Lastly, average leukocyte telomere length may not closely represent the extent of 
telomere attrition that occurs in cardiomyocytes. Indeed, cardiomyocyte telomere attrition or 
dysfunction has been associated with cardiomyocyte apoptosis, cell death and premature 
senescence in human heart failure (Chimenti et al., 2003; Oh et al., 2003) and with repression 
of mitochondrial biogenesis and performance (Sahin et al., 2011). However, I have 
demonstrated that  leukocyte telomere length is correlated with cardiac telomere length (see 
Chapters 3 and 5) in rats and hence leukocyte telomere may serve as a surrogate marker of 
cardiac telomere length. Furthermore, I have demonstrated that a decrease in average cardiac 
telomere length was not sufficient to herald the onset of adverse cardiac remodelling and 
dysfunction (see Chapter 5). 
In conclusion, leukocyte telomere length is inversely associated with inflammation. 
However, leukocyte telomere length is not associated with indices of LV geometry or systolic 
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dysfunction. Hence, inflammation is a strong determinant of leukocyte telomere attrition, but 
leukocyte telomere length is not a marker of changes in cardiac geometry or function.  
  
 
 
 
 
 
 
CHAPTER 7 - SUMMARY AND 
CONCLUSIONS 
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7.1 SUMMARY AND CONCLUSIONS 
The main aims of this thesis were to investigate: the association of telomere length 
with the severity and presence of a non-ischaemic form of heart failure; whether telomere 
shortening is a cause of adverse left ventricular remodelling and systolic dysfunction in an 
animal model of dilated cardiomyopathy; whether adverse left ventricular remodelling and 
systolic chamber dysfunction produced by chronic β-adrenergic receptor activation are 
associated with telomere shortening; the impact of chronic inflammation on telomere length, 
left ventricular remodelling, and systolic dysfunction; and to  the relationships between 
telomere length and inflammation, left ventricular geometry, and systolic function in a cross-
sectional community study.  
The main findings from my thesis are as follows (FIGURE 7.1); a reduced telomere 
length was not associated with a non-ischaemic form of heart disease nor with a model of 
alcoholic cardiomyopathy, which demonstrates that reduced telomere length may not be 
associated with all types of cardiomyopathy. Moreover, these data indicate that telomere 
length may not be a causal factor in heart failure. Although chronic β-AR activation and 
ethanol consumption induced cardiac remodelling and β-AR activation induced systolic 
dysfunction, cardiac telomere length was not altered. Moreover, in IDC, alcoholic 
cardiomyopathy, chronic β-AR stimulation, chronic inflammation, and in a random 
community based population study a reduced telomere length was not associated with 
pathological features of heart failure such as LV dilatation, systolic dysfunction, intrinsic 
myocardial function, and myocardial apoptosis. Furthermore, when the control groups of all 
the animal studies mentioned above were combined, I was still unable to show any 
associations between cardiac telomere length and indices of cardiac geometry and function 
(TABLE 7.1).  
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FIGURE 7.1 Diagram illustrating that reduced telomere length may be a consequence of 
increased inflammation in heart disease. Furthermore, telomere length is independent of 
adverse left ventricular remodelling, left ventricular systolic dysfunction, and β-adrenergic 
activity.   
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TABLE 7.1 Correlations between cardiac telomere length and indices of left ventricular (LV) dilatation (the volume intercept at 0 mm Hg (V0) in 
the left ventricular (LV) diastolic pressure-volume relations and LV end diastolic diameter (LVEDD)), systolic chamber function (slope of the 
systolic pressure-volume relations (LV Ees) and endocardial fractional shortening (FSend)), and intrinsic myocardial function (slope of the 
systolic stress-strain relations (Een) and midwall fractional shortening (FSmid)) in Sprague-Dawley rats (control groups from Chapters 3, 4, 5).  
 
 
 
 
 
 
 
r, correlation coefficient; CI, confidence interval 
 
V0 (n=27) LVEDD (n=47)  LV Ees (27) FSend (46) LV Een (n=26) FSmid (n=47) 
Pearson's r -0.15 0.047 0.068 -0.20 0.037 -0.023 
95% CI -0.50 to 0.24 -0.24 to 0.33 -0.32 to 0.43 -0.47 to 0.093 -0.36 to 0.47 -0.31 to 0.27 
p value 0.44 0.75 0.73 0.18 0.86 0.88 
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In terms of future research into telomere length, One potential animal model that 
could be utilised to further investigate the relationships between telomere length and heart 
failure may be the telomerase deficient mouse model (Terc knockout mice). In this regard, it 
has been demonstrated that the 5
th
 generation of Terc knockout mice present with cardiac 
characteristics similar to that of a dilated cardiomyopathy in humans (Leri et al., 2003). 
Hence, the Terc knockout model provides an animal model that includes the heritability of 
both telomere length and heart failure.  
The Terc knockout model provides a good model to further investigate the 
relationship between telomere length and heart failure using intervention studies. In this 
regard, based on the findings of thesis it would be of great interest to determine if animals on 
anti-inflammatory treatment would still progress to the heart failure phenotype demonstrated 
in the 5
th 
generation offspring of these mice. Furthermore, one could combine the p53 
deficient mice model utilised by Sahin et al. (2011) with the Terc knockout model. This 
would provide a model, whereby it is known that progressive telomere loss through several 
generation results in heart failure, but the mechanism (p53) through which telomere length 
regulates apoptosis and senescence would be inhibited. Such studies would provide valuable 
insight into the cause and effect relationship between telomere length and heart failure and 
also provide possible mechanisms that could explain this relationship. 
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One of the major caveats with human studies is the use of leukocyte telomere length as a 
surrogate marker of telomere length in cardiovascular tissues. In an attempt to address this issue I 
investigated if cardiac telomere length in the control groups of all the animal studies (Chapters 3, 4, 5) 
was correlated to leukocyte telomere length. These analyses demonstrated that both cardiac and 
kidney telomere length were strongly correlated to leukocyte telomere length in rats. Hence, leukocyte 
telomere length may serve as a potential surrogate marker of telomere length in cardiac tissue 
(FIGURE 7.2). Collectively, the data from the animal and human studies indicate that inflammation is 
potentially a major determinant of telomere attrition, but that telomere length is not a bio-marker of 
changes in cardiac dimension or function. 
In conclusion, the data emanating from my thesis indicate that telomere length may 
not be associated with all types of heart failure, specifically non-ischaemic forms of heart 
failure. Moreover, the pathophysiological processes of heart failure, namely LV dilatation 
and reduced systolic chamber function, may be independent of changes in telomere length. 
Hence in heart failure, telomere length may only be reduced as an epiphenomenon due to 
ongoing inflammatory processes associated with the presence of heart failure and associated 
risk factors.   
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FIGURE 7.2 Bivariate relationships between average relative leukocyte telomere length (log 
T/S), cardiac (upper panel) and kidney telomere length (lower panel). 
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